BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lee JS, Chu IS, Heo J, Calvisi DF, Sun Z, Roskams T, Durnez A, Demetris AJ, Thorgeirsson SS. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology. 2004;40:667-676. [PMID: 15349906 DOI: 10.1002/hep.20375] [Cited by in Crossref: 599] [Cited by in F6Publishing: 547] [Article Influence: 33.3] [Reference Citation Analysis]
Number Citing Articles
1 Jin A, Yang Y, Su X, Yang W, Liu T, Chen W, Li T, Ding L, Wang H, Wang B, Pan B, Zhou J, Fan J, Yang X, Guo W. High serum soluble CD155 level predicts poor prognosis and correlates with an immunosuppressive tumor microenvironment in hepatocellular carcinoma. Clinical Laboratory Analysis. [DOI: 10.1002/jcla.24259] [Reference Citation Analysis]
2 Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer. 2006;6:674-687. [PMID: 16929323 DOI: 10.1038/nrc1934] [Cited by in Crossref: 1337] [Cited by in F6Publishing: 1312] [Article Influence: 83.6] [Reference Citation Analysis]
3 Scheel JR, Kuo MD. Exploring the Human Genome in Cancer with Genomic Approaches. Journal of Vascular and Interventional Radiology 2006;17:1225-33. [DOI: 10.1097/01.rvi.0000232498.25928.a1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
4 Marzi L, Villa E. Prognostic signatures from hepatocellular carcinoma biopsy. Hepat Oncol 2017;4:65-8. [PMID: 30191054 DOI: 10.2217/hep-2017-0016] [Reference Citation Analysis]
5 Forner A, Díaz-gonzález Á, Liccioni A, Vilana R. Prognosis prediction and staging. Best Practice & Research Clinical Gastroenterology 2014;28:855-65. [DOI: 10.1016/j.bpg.2014.08.002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
6 Hu S, Chen S, Li X, Qin R, Mei Z. Antitumor effects of Chi-Shen extract from Salvia miltiorrhiza and Paeoniae radix on human hepatocellular carcinoma cells. Acta Pharmacologica Sinica 2007;28:1215-23. [DOI: 10.1111/j.1745-7254.2007.00606.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
7 Kalin TV, Wang IC, Ackerson TJ, Major ML, Detrisac CJ, Kalinichenko VV, Lyubimov A, Costa RH. Increased levels of the FoxM1 transcription factor accelerate development and progression of prostate carcinomas in both TRAMP and LADY transgenic mice. Cancer Res 2006;66:1712-20. [PMID: 16452231 DOI: 10.1158/0008-5472.CAN-05-3138] [Cited by in Crossref: 203] [Cited by in F6Publishing: 133] [Article Influence: 12.7] [Reference Citation Analysis]
8 Li B, Liu W, Wang L, Li M, Wang J, Huang L, Huang P, Yuan Y. CpG island methylator phenotype associated with tumor recurrence in tumor-node-metastasis stage I hepatocellular carcinoma. Ann Surg Oncol. 2010;17:1917-1926. [PMID: 20112070 DOI: 10.1245/s10434-010-0921-7] [Cited by in Crossref: 28] [Cited by in F6Publishing: 32] [Article Influence: 2.3] [Reference Citation Analysis]
9 Zhang J, Lu K, Xiang Y, Islam M, Kotian S, Kais Z, Lee C, Arora M, Liu HW, Parvin JD, Huang K. Weighted frequent gene co-expression network mining to identify genes involved in genome stability. PLoS Comput Biol 2012;8:e1002656. [PMID: 22956898 DOI: 10.1371/journal.pcbi.1002656] [Cited by in Crossref: 60] [Cited by in F6Publishing: 48] [Article Influence: 6.0] [Reference Citation Analysis]
10 Wu C, Lin J, Weng Y, Zeng DN, Xu J, Luo S, Xu L, Liu M, Hua Q, Liu CQ, Li JQ, Liao J, Sun C, Zhou J, Chen MS, Liu C, Guo Z, Zhuang SM, Huang JH, Zheng L. Myeloid signature reveals immune contexture and predicts the prognosis of hepatocellular carcinoma. J Clin Invest 2020;130:4679-93. [PMID: 32497024 DOI: 10.1172/JCI135048] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
11 Castven D, Becker D, Czauderna C, Wilhelm D, Andersen JB, Strand S, Hartmann M, Heilmann‐heimbach S, Roth W, Hartmann N, Straub BK, Mahn FL, Franck S, Pereira S, Haupts A, Vogel A, Wörns MA, Weinmann A, Heinrich S, Lang H, Thorgeirsson SS, Galle PR, Marquardt JU. Application of patient‐derived liver cancer cells for phenotypic characterization and therapeutic target identification. Int J Cancer 2019;144:2782-94. [DOI: 10.1002/ijc.32026] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
12 Li L, Chen J, Ge C, Zhao F, Chen T, Tian H, Li J, Li H. CD24 isoform a promotes cell proliferation, migration and invasion and is downregulated by EGR1 in hepatocellular carcinoma. Onco Targets Ther 2019;12:1705-16. [PMID: 30881025 DOI: 10.2147/OTT.S196506] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
13 Wada H, Nagano H, Yamamoto H, Yang Y, Kondo M, Ota H, Nakamura M, Yoshioka S, Kato H, Damdinsuren B, Tang D, Marubashi S, Miyamoto A, Takeda Y, Umeshita K, Nakamori S, Sakon M, Dono K, Wakasa K, Monden M. Expression pattern of angiogenic factors and prognosis after hepatic resection in hepatocellular carcinoma: importance of angiopoietin-2 and hypoxia-induced factor-1 alpha. Liver Int 2006;26:414-23. [PMID: 16629644 DOI: 10.1111/j.1478-3231.2006.01243.x] [Cited by in Crossref: 88] [Cited by in F6Publishing: 85] [Article Influence: 5.5] [Reference Citation Analysis]
14 Mohamed AA, Nada OH, El Desouky MA. Implication of protein kinase R gene quantification in hepatitis C virus genotype 4 induced hepatocarcinogenesis. Diagn Pathol 2012;7:103. [PMID: 22894766 DOI: 10.1186/1746-1596-7-103] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
15 Zhou Y, Tao J, Calvisi DF, Chen X. Role of Lipogenesis Rewiring in Hepatocellular Carcinoma. Semin Liver Dis 2021. [PMID: 34311471 DOI: 10.1055/s-0041-1731709] [Reference Citation Analysis]
16 Kim MY, Choi S, Lee SE, Kim JS, Son SH, Lim YS, Kim BJ, Ryu BY, Uversky VN, Lee YJ, Kim CG. Development of a MEL Cell-Derived Allograft Mouse Model for Cancer Research. Cancers (Basel) 2019;11:E1707. [PMID: 31683958 DOI: 10.3390/cancers11111707] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
17 Kramer MG, Hernandez-alcoceba R, Qian C, Prieto J. Evaluation of hepatocellular carcinoma models for preclinical studies. Drug Discovery Today: Disease Models 2005;2:41-9. [DOI: 10.1016/j.ddmod.2005.05.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
18 Furuta K, Sato S, Yamauchi T, Kakumu S. Changes in intrahepatic gene expression profiles from chronic hepatitis to hepatocellular carcinoma in patients with hepatitis C virus infection. Hepatology Research 2008;38:673-82. [DOI: 10.1111/j.1872-034x.2008.00328.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
19 Factor VM, Seo D, Ishikawa T, Kaposi-Novak P, Marquardt JU, Andersen JB, Conner EA, Thorgeirsson SS. Loss of c-Met disrupts gene expression program required for G2/M progression during liver regeneration in mice. PLoS One. 2010;5. [PMID: 20862286 DOI: 10.1371/journal.pone.0012739] [Cited by in Crossref: 45] [Cited by in F6Publishing: 48] [Article Influence: 3.8] [Reference Citation Analysis]
20 Lai JP, Thompson JR, Sandhu DS, Roberts LR. Heparin-degrading sulfatases in hepatocellular carcinoma: roles in pathogenesis and therapy targets. Future Oncol. 2008;4:803-814. [PMID: 19086847 DOI: 10.2217/14796694.4.6.803] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 2.6] [Reference Citation Analysis]
21 Lee JS, Leem SH, Lee SY, Kim SC, Park ES, Kim SB, Kim SK, Kim YJ, Kim WJ, Chu IS. Expression signature of E2F1 and its associated genes predict superficial to invasive progression of bladder tumors. J Clin Oncol 2010;28:2660-7. [PMID: 20421545 DOI: 10.1200/JCO.2009.25.0977] [Cited by in Crossref: 189] [Cited by in F6Publishing: 151] [Article Influence: 15.8] [Reference Citation Analysis]
22 Schulze K, Zucman-Rossi J. Current issues on genomic heterogeneity in hepatocellular carcinoma and its implication in clinical practice. Hepat Oncol 2015;2:291-302. [PMID: 30191009 DOI: 10.2217/hep.15.16] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
23 Protiva P, Gong J, Sreekumar B, Torres R, Zhang X, Belinsky GS, Cornwell M, Crawford SE, Iwakiri Y, Chung C. Pigment Epithelium-Derived Factor (PEDF) Inhibits Wnt/β-catenin Signaling in the Liver. Cell Mol Gastroenterol Hepatol 2015;1:535-549.e14. [PMID: 26473164 DOI: 10.1016/j.jcmgh.2015.06.006] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
24 Zhou Y, Huang T, Zhang J, Wong CC, Zhang B, Dong Y, Wu F, Tong JHM, Wu WKK, Cheng ASL, Yu J, Kang W, To KF. TEAD1/4 exerts oncogenic role and is negatively regulated by miR-4269 in gastric tumorigenesis. Oncogene 2017;36:6518-30. [PMID: 28759040 DOI: 10.1038/onc.2017.257] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 8.8] [Reference Citation Analysis]
25 Silva MF, Sherman M. Criteria for liver transplantation for HCC: what should the limits be? J Hepatol 2011;55:1137-47. [PMID: 21718672 DOI: 10.1016/j.jhep.2011.05.012] [Cited by in Crossref: 47] [Cited by in F6Publishing: 43] [Article Influence: 4.3] [Reference Citation Analysis]
26 Potikha T, Ella E, Cerliani JP, Mizrahi L, Pappo O, Rabinovich GA, Galun E, Goldenberg DS. Galectin-1 is essential for efficient liver regeneration following hepatectomy. Oncotarget. 2016;7:31738-31754. [PMID: 27166189 DOI: 10.18632/oncotarget.9194] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
27 Shimada S, Mogushi K, Akiyama Y, Furuyama T, Watanabe S, Ogura T, Ogawa K, Ono H, Mitsunori Y, Ban D, Kudo A, Arii S, Tanabe M, Wands JR, Tanaka S. Comprehensive molecular and immunological characterization of hepatocellular carcinoma. EBioMedicine. 2019;40:457-470. [PMID: 30598371 DOI: 10.1016/j.ebiom.2018.12.058] [Cited by in Crossref: 62] [Cited by in F6Publishing: 70] [Article Influence: 15.5] [Reference Citation Analysis]
28 Marquardt JU, Fischer K, Baus K, Kashyap A, Ma S, Krupp M, Linke M, Teufel A, Zechner U, Strand D, Thorgeirsson SS, Galle PR, Strand S. Sirtuin-6-dependent genetic and epigenetic alterations are associated with poor clinical outcome in hepatocellular carcinoma patients. Hepatology 2013;58:1054-64. [PMID: 23526469 DOI: 10.1002/hep.26413] [Cited by in Crossref: 94] [Cited by in F6Publishing: 91] [Article Influence: 10.4] [Reference Citation Analysis]
29 Shan YF, Huang YL, Xie YK, Tan YH, Chen BC, Zhou MT, Shi HQ, Yu ZP, Song QT, Zhang QY. Angiogenesis and clinicopathologic characteristics in different hepatocellular carcinoma subtypes defined by EpCAM and α-fetoprotein expression status. Med Oncol. 2011;28:1012-1016. [PMID: 20571936 DOI: 10.1007/s12032-010-9600-6] [Cited by in Crossref: 48] [Cited by in F6Publishing: 55] [Article Influence: 4.0] [Reference Citation Analysis]
30 Liu J, Ni W, Xiao M, Jiang F, Ni R. Decreased expression and prognostic role of mitogen-activated protein kinase phosphatase 4 in hepatocellular carcinoma. J Gastrointest Surg 2013;17:756-65. [PMID: 23325341 DOI: 10.1007/s11605-013-2138-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
31 Ogunwobi OO, Puszyk W, Dong HJ, Liu C. Epigenetic upregulation of HGF and c-Met drives metastasis in hepatocellular carcinoma. PLoS One. 2013;8:e63765. [PMID: 23723997 DOI: 10.1371/journal.pone.0063765] [Cited by in Crossref: 59] [Cited by in F6Publishing: 52] [Article Influence: 6.6] [Reference Citation Analysis]
32 Schneider C, Teufel A, Yevsa T, Staib F, Hohmeyer A, Walenda G, Zimmermann HW, Vucur M, Huss S, Gassler N, Wasmuth HE, Lira SA, Zender L, Luedde T, Trautwein C, Tacke F. Adaptive immunity suppresses formation and progression of diethylnitrosamine-induced liver cancer. Gut 2012;61:1733-43. [PMID: 22267597 DOI: 10.1136/gutjnl-2011-301116] [Cited by in Crossref: 107] [Cited by in F6Publishing: 108] [Article Influence: 10.7] [Reference Citation Analysis]
33 Mabrouk NMK, Elkaffash DM, Abdel-Hadi M, Abdelmoneim SE, Saad ElDeen S, Gewaifel G, Elella KA, Osman M, Baddour N. Identification of the possible therapeutic targets in the insulin-like growth factor 1 receptor pathway in a cohort of Egyptian hepatocellular carcinoma complicating chronic hepatitis C type 4. Drug Target Insights 2020;14:1-11. [PMID: 33132693 DOI: 10.33393/dti.2020.1548] [Reference Citation Analysis]
34 Lee DJ, Eun YG, Rho YS, Kim EH, Yim SY, Kang SH, Sohn BH, Kwon GH, Lee JS. Three distinct genomic subtypes of head and neck squamous cell carcinoma associated with clinical outcomes. Oral Oncol 2018;85:44-51. [PMID: 30220319 DOI: 10.1016/j.oraloncology.2018.08.009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
35 Wang XW, Thorgeirsson SS. Transcriptome analysis of liver cancer: ready for the clinic? J Hepatol 2009;50:1062-4. [PMID: 19328580 DOI: 10.1016/j.jhep.2009.02.007] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
36 Liu YF, Zha BS, Zhang HL, Zhu XJ, Li YH, Zhu J, Guan XH, Feng ZQ, Zhang JP. Characteristic gene expression profiles in the progression from liver cirrhosis to carcinoma induced by diethylnitrosamine in a rat model. J Exp Clin Cancer Res 2009;28:107. [PMID: 19638242 DOI: 10.1186/1756-9966-28-107] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 2.2] [Reference Citation Analysis]
37 Kim JH, Sohn BH, Lee HS, Kim SB, Yoo JE, Park YY, Jeong W, Lee SS, Park ES, Kaseb A. Genomic predictors for recurrence patterns of hepatocellular carcinoma: model derivation and validation. PLoS Med. 2014;11:e1001770. [PMID: 25536056 DOI: 10.1371/journal.pmed.1001770] [Cited by in Crossref: 58] [Cited by in F6Publishing: 61] [Article Influence: 7.3] [Reference Citation Analysis]
38 Ramesh V, Ganesan K. Integrative functional genomic delineation of the cascades of transcriptional changes involved in hepatocellular carcinoma progression. Int J Cancer 2016;139:1586-97. [PMID: 27194100 DOI: 10.1002/ijc.30195] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
39 Ye H, Sun M, Huang S, Xu F, Wang J, Liu H, Zhang L, Luo W, Guo W, Wu Z, Zhu J, Li H. Gene Network Analysis of Hepatocellular Carcinoma Identifies Modules Associated with Disease Progression, Survival, and Chemo Drug Resistance. Int J Gen Med 2021;14:9333-47. [PMID: 34898998 DOI: 10.2147/IJGM.S336729] [Reference Citation Analysis]
40 Stigliano R, Marelli L, Yu D, Davies N, Patch D, Burroughs AK. Seeding following percutaneous diagnostic and therapeutic approaches for hepatocellular carcinoma. What is the risk and the outcome? Seeding risk for percutaneous approach of HCC. Cancer Treat Rev. 2007;33:437-447. [PMID: 17512669 DOI: 10.1016/j.ctrv.2007.04.001] [Cited by in Crossref: 198] [Cited by in F6Publishing: 172] [Article Influence: 13.2] [Reference Citation Analysis]
41 Chew V, Tow C, Teo M, Wong HL, Chan J, Gehring A, Loh M, Bolze A, Quek R, Lee VK, Lee KH, Abastado JP, Toh HC, Nardin A. Inflammatory tumour microenvironment is associated with superior survival in hepatocellular carcinoma patients. J Hepatol. 2010;52:370-379. [PMID: 19720422 DOI: 10.1016/j.jhep.2009.07.013] [Cited by in Crossref: 144] [Cited by in F6Publishing: 154] [Article Influence: 11.1] [Reference Citation Analysis]
42 Kabashima A, Shimada S, Shimokawa M, Akiyama Y, Tanabe M, Tanaka S. Molecular and immunological paradigms of hepatocellular carcinoma: Special reference to therapeutic approaches. J Hepatobiliary Pancreat Sci 2021;28:62-75. [PMID: 33259135 DOI: 10.1002/jhbp.874] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
43 Lee SH, Yim SY, Shim J, Lee J. Molecular Subtypes and Genomic Signatures of Hepatocellular Carcinoma for Prognostication and Therapeutic Decision-Making. In: Hoshida Y, editor. Hepatocellular Carcinoma. Cham: Springer International Publishing; 2019. pp. 109-23. [DOI: 10.1007/978-3-030-21540-8_6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
44 Choi Y, Oh ST, Won M, Choi KM, Ko MJ, Seo D, Jeon T, Baik IH, Ye S, Park KU, Park I, Jang B, Seo J, Lee Y. Targeting ODC1 inhibits tumor growth through reduction of lipid metabolism in human hepatocellular carcinoma. Biochemical and Biophysical Research Communications 2016;478:1674-81. [DOI: 10.1016/j.bbrc.2016.09.002] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
45 Yang X, Wang Y, La K, Peng L, Song X, Shi X, Zhu X, Leung P, Ko C, Ye C. Inhibitory effects of cocoa tea (Camellia ptilophylla) in human hepatocellular carcinoma HepG2 in vitro and in vivo through apoptosis. The Journal of Nutritional Biochemistry 2012;23:1051-7. [DOI: 10.1016/j.jnutbio.2011.05.010] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
46 Chang Q, Chen J, Beezhold KJ, Castranova V, Shi X, Chen F. JNK1 activation predicts the prognostic outcome of the human hepatocellular carcinoma. Mol Cancer 2009;8:64. [PMID: 19686584 DOI: 10.1186/1476-4598-8-64] [Cited by in Crossref: 47] [Cited by in F6Publishing: 51] [Article Influence: 3.6] [Reference Citation Analysis]
47 Tischoff I, Tannapfel A. DNA methylation in hepatocellular carcinoma. World J Gastroenterol 2008; 14(11): 1741-1748 [PMID: 18350605 DOI: 10.3748/wjg.14.1741] [Cited by in CrossRef: 117] [Cited by in F6Publishing: 110] [Article Influence: 8.4] [Reference Citation Analysis]
48 Nicolau-Neto P, Da Costa NM, de Souza Santos PT, Gonzaga IM, Ferreira MA, Guaraldi S, Moreira MA, Seuánez HN, Brewer L, Bergmann A, Boroni M, Mencalha AL, Kruel CDP, Lima SCS, Esposito D, Simão TA, Pinto LFR. Esophageal squamous cell carcinoma transcriptome reveals the effect of FOXM1 on patient outcome through novel PIK3R3 mediated activation of PI3K signaling pathway. Oncotarget 2018;9:16634-47. [PMID: 29682174 DOI: 10.18632/oncotarget.24621] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
49 Befani C, Mylonis I, Gkotinakou IM, Georgoulias P, Hu CJ, Simos G, Liakos P. Cobalt stimulates HIF-1-dependent but inhibits HIF-2-dependent gene expression in liver cancer cells. Int J Biochem Cell Biol 2013;45:2359-68. [PMID: 23958427 DOI: 10.1016/j.biocel.2013.07.025] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 3.9] [Reference Citation Analysis]
50 Hung MH, Wang XW. Molecular Alterations and Heterogeneity in Hepatocellular Carcinoma. In: Hoshida Y, editor. Hepatocellular Carcinoma. Cham: Springer International Publishing; 2019. pp. 293-316. [DOI: 10.1007/978-3-030-21540-8_14] [Reference Citation Analysis]
51 Teufel A, Marquardt JU, Staib F, Galle PR. Snapshot liver transcriptome in hepatocellular carcinoma. Journal of Hepatology 2012;56:990-2. [DOI: 10.1016/j.jhep.2011.08.024] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
52 Kwee SA, Tiirikainen M, Sato MM, Acoba JD, Wei R, Jia W, Le Marchand L, Wong LL. Transcriptomics Associates Molecular Features with 18F-Fluorocholine PET/CT Imaging Phenotype and Its Potential Relationship to Survival in Hepatocellular Carcinoma. Cancer Res 2019;79:1696-704. [PMID: 30760520 DOI: 10.1158/0008-5472.CAN-18-3837] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
53 Dahmani R, Just PA, Perret C. The Wnt/β-catenin pathway as a therapeutic target in human hepatocellular carcinoma. Clin Res Hepatol Gastroenterol. 2011;35:709-713. [PMID: 21778132 DOI: 10.1016/j.clinre.2011.05.010] [Cited by in Crossref: 58] [Cited by in F6Publishing: 59] [Article Influence: 5.3] [Reference Citation Analysis]
54 Cillo U, Giuliani T, Polacco M, Herrero Manley LM, Crivellari G, Vitale A. Prediction of hepatocellular carcinoma biological behavior in patient selection for liver transplantation. World J Gastroenterol 2016; 22(1): 232-252 [PMID: 26755873 DOI: 10.3748/wjg.v22.i1.232] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 24] [Article Influence: 4.2] [Reference Citation Analysis]
55 Tornesello ML, Buonaguro L, Izzo F, Buonaguro FM. Molecular alterations in hepatocellular carcinoma associated with hepatitis B and hepatitis C infections. Oncotarget. 2016;7:25087-25102. [PMID: 26943571 DOI: 10.18632/oncotarget.7837] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 9.5] [Reference Citation Analysis]
56 McKillop IH, Moran DM, Jin X, Koniaris LG. Molecular pathogenesis of hepatocellular carcinoma. J Surg Res. 2006;136:125-135. [PMID: 17023002 DOI: 10.1016/j.jss.2006.04.013] [Cited by in Crossref: 76] [Cited by in F6Publishing: 67] [Article Influence: 4.8] [Reference Citation Analysis]
57 Eun YG, Lee D, Lee YC, Sohn BH, Kim EH, Yim SY, Kwon KH, Lee JS. Clinical significance of YAP1 activation in head and neck squamous cell carcinoma. Oncotarget 2017;8:111130-43. [PMID: 29340043 DOI: 10.18632/oncotarget.22666] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
58 Jaganathan R, Ravinayagam V, Panchanadham S, Palanivelu S. Potential therapeutic role of Tridham in human hepatocellular carcinoma cell line through induction of p53 independent apoptosis. BMC Complement Altern Med 2013;13:323. [PMID: 24256980 DOI: 10.1186/1472-6882-13-323] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
59 Vásquez-Garzón VR, Beltrán-Ramírez O, Salcido-Neyoy ME, Cervante-Anaya N, Villa-Treviño S. Analysis of gene expression profiles as a tool to uncover tumor markers of liver cancer progression in a rat model. Biomed Rep 2015;3:167-72. [PMID: 25798242 DOI: 10.3892/br.2014.411] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
60 Blum HE. Hepatocellular carcinoma: therapy and prevention. World J Gastroenterol. 2005;11:7391-7400. [PMID: 16437707 DOI: 10.3748/wjg.v11.i47.7391] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 94] [Article Influence: 2.3] [Reference Citation Analysis]
61 Cornellà H, Alsinet C, Villanueva A. Molecular pathogenesis of hepatocellular carcinoma. Alcohol Clin Exp Res. 2011;35:821-825. [PMID: 21303380 DOI: 10.1111/j.1530-0277.2010.01406.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 3.3] [Reference Citation Analysis]
62 Varnholt H, Drebber U, Schulze F, Wedemeyer I, Schirmacher P, Dienes HP, Odenthal M. MicroRNA gene expression profile of hepatitis C virus-associated hepatocellular carcinoma. Hepatology. 2008;47:1223-1232. [PMID: 18307259 DOI: 10.1002/hep.22158] [Cited by in Crossref: 312] [Cited by in F6Publishing: 317] [Article Influence: 22.3] [Reference Citation Analysis]
63 Chen HW, Huang XD, Li HC, He S, Ni RZ, Chen CH, Peng C, Wu G, Wang GH, Wang YY, Zhao YH, Zhang YX, Shen AG, Wang HM. Expression of FOXJ1 in hepatocellular carcinoma: correlation with patients' prognosis and tumor cell proliferation. Mol Carcinog 2013;52:647-59. [PMID: 22488567 DOI: 10.1002/mc.21904] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 3.0] [Reference Citation Analysis]
64 Uemura T, Kametaka S, Waguri S. GGA2 interacts with EGFR cytoplasmic domain to stabilize the receptor expression and promote cell growth. Sci Rep 2018;8:1368. [PMID: 29358589 DOI: 10.1038/s41598-018-19542-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
65 Hamed O, Kimchi ET, Sehmbey M, Gusani NJ, Kaifi JT, Staveley-O’Carroll K. Impact of genetic targets on cancer therapy: hepatocellular cancer. Adv Exp Med Biol. 2013;779:67-90. [PMID: 23288636 DOI: 10.1007/978-1-4614-6176-0_4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
66 Ilboudo A, Nault JC, Dubois-Pot-Schneider H, Corlu A, Zucman-Rossi J, Samson M, Le Seyec J. Overexpression of phosphatidylinositol 4-kinase type IIIα is associated with undifferentiated status and poor prognosis of human hepatocellular carcinoma. BMC Cancer. 2014;14:7. [PMID: 24393405 DOI: 10.1186/1471-2407-14-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
67 Nalesnik MA, Tseng G, Ding Y, Xiang GS, Zheng ZL, Yu Y, Marsh JW, Michalopoulos GK, Luo JH. Gene deletions and amplifications in human hepatocellular carcinomas: correlation with hepatocyte growth regulation. Am J Pathol 2012;180:1495-508. [PMID: 22326833 DOI: 10.1016/j.ajpath.2011.12.021] [Cited by in Crossref: 47] [Cited by in F6Publishing: 42] [Article Influence: 4.7] [Reference Citation Analysis]
68 Bayrak T, Oğul H. A New Approach for Predicting the Value of Gene Expression: Two-way Collaborative Filtering. CBIO 2019;14:480-90. [DOI: 10.2174/1574893614666190126144139] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
69 Muñoz-gámez J, Quiles-pérez R, Ruiz-extremera A, Martín-álvarez A, Sanjuan-nuñez L, Carazo A, León J, Oliver F, Salmerón J. Inhibition of poly (ADP-ribose) polymerase-1 enhances doxorubicin activity against liver cancer cells. Cancer Letters 2011;301:47-56. [DOI: 10.1016/j.canlet.2010.10.026] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
70 Zhao Y, Zhang L, Zhang Y, Meng B, Ying W, Qian X. Identification of hedgehog signaling as a potential oncogenic driver in an aggressive subclass of human hepatocellular carcinoma: A reanalysis of the TCGA cohort. Sci China Life Sci 2019;62:1481-91. [PMID: 31313086 DOI: 10.1007/s11427-019-9560-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
71 Zhu GQ, Liu WR, Tang Z, Qu WF, Fang Y, Jiang XF, Song SS, Wang H, Tao CY, Zhou PY, Huang R, Gao J, Sun HX, Ding ZB, Peng YF, Dai Z, Zhou J, Fan J, Shi YH. Serial circulating tumor DNA to predict early recurrence in patients with hepatocellular carcinoma: a prospective study. Mol Oncol 2021. [PMID: 34543520 DOI: 10.1002/1878-0261.13105] [Reference Citation Analysis]
72 Verslype C, Van Cutsem E, Dicato M, Arber N, Berlin JD, Cunningham D, De Gramont A, Diaz-Rubio E, Ducreux M, Gruenberger T, Haller D, Haustermans K, Hoff P, Kerr D, Labianca R, Moore M, Nordlinger B, Ohtsu A, Rougier P, Scheithauer W, Schmoll HJ, Sobrero A, Tabernero J, van de Velde C. The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 10th World Congress on Gastrointestinal Cancer, Barcelona, 2008. Ann Oncol. 2009;20 Suppl 7:vii1-vii6. [PMID: 19497945 DOI: 10.1093/annonc/mdp281] [Cited by in Crossref: 54] [Cited by in F6Publishing: 64] [Article Influence: 4.2] [Reference Citation Analysis]
73 Stauffer JK, Scarzello AJ, Andersen JB, De Kluyver RL, Back TC, Weiss JM, Thorgeirsson SS, Wiltrout RH. Coactivation of AKT and β-catenin in mice rapidly induces formation of lipogenic liver tumors. Cancer Res. 2011;71:2718-2727. [PMID: 21324921 DOI: 10.1158/0008-5472.can-10-2705] [Cited by in Crossref: 50] [Cited by in F6Publishing: 36] [Article Influence: 4.5] [Reference Citation Analysis]
74 Boucher E, Forner A, Reig M, Bruix J. New drugs for the treatment of hepatocellular carcinoma. Liver Int 2009;29 Suppl 1:148-58. [PMID: 19207980 DOI: 10.1111/j.1478-3231.2008.01929.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
75 Ribeiro OD, Canedo NH, Pannain VL. Immunohistochemical angiogenic biomarkers in hepatocellular carcinoma and cirrhosis: correlation with pathological features. Clinics (Sao Paulo) 2016;71:639-43. [PMID: 27982164 DOI: 10.6061/clinics/2016(11)04] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
76 El Jabbour T, Lagana SM, Lee H. Update on hepatocellular carcinoma: Pathologists’ review. World J Gastroenterol 2019; 25(14): 1653-1665 [PMID: 31011252 DOI: 10.3748/wjg.v25.i14.1653] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 34] [Article Influence: 12.0] [Reference Citation Analysis]
77 Chaudhary K, Poirion OB, Lu L, Garmire LX. Deep Learning-Based Multi-Omics Integration Robustly Predicts Survival in Liver Cancer. Clin Cancer Res. 2018;24:1248-1259. [PMID: 28982688 DOI: 10.1158/1078-0432.ccr-17-0853] [Cited by in Crossref: 272] [Cited by in F6Publishing: 164] [Article Influence: 54.4] [Reference Citation Analysis]
78 Lee YH, Andersen JB, Song HT, Judge AD, Seo D, Ishikawa T, Marquardt JU, Kitade M, Durkin ME, Raggi C, Woo HG, Conner EA, Avital I, Maclachlan I, Factor VM, Thorgeirsson SS. Definition of ubiquitination modulator COP1 as a novel therapeutic target in human hepatocellular carcinoma. Cancer Res 2010;70:8264-9. [PMID: 20959491 DOI: 10.1158/0008-5472.CAN-10-0749] [Cited by in Crossref: 46] [Cited by in F6Publishing: 31] [Article Influence: 3.8] [Reference Citation Analysis]
79 Villanueva A, Hoshida Y, Toffanin S, Lachenmayer A, Alsinet C, Savic R, Cornella H, Llovet JM. New strategies in hepatocellular carcinoma: genomic prognostic markers. Clin Cancer Res 2010;16:4688-94. [PMID: 20713493 DOI: 10.1158/1078-0432.CCR-09-1811] [Cited by in Crossref: 92] [Cited by in F6Publishing: 59] [Article Influence: 7.7] [Reference Citation Analysis]
80 Angenard G, Merdrignac A, Louis C, Edeline J, Coulouarn C. Expression of long non-coding RNA ANRIL predicts a poor prognosis in intrahepatic cholangiocarcinoma. Dig Liver Dis. 2019;51:1337-1343. [PMID: 31040073 DOI: 10.1016/j.dld.2019.03.019] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
81 Kim E, Viatour P. Hepatocellular carcinoma: old friends and new tricks. Exp Mol Med. 2020;52:1898-1907. [PMID: 33268834 DOI: 10.1038/s12276-020-00527-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 5.5] [Reference Citation Analysis]
82 Severi T, van Malenstein H, Verslype C, van Pelt JF. Tumor initiation and progression in hepatocellular carcinoma: risk factors, classification, and therapeutic targets. Acta Pharmacol Sin 2010;31:1409-20. [PMID: 20953207 DOI: 10.1038/aps.2010.142] [Cited by in Crossref: 103] [Cited by in F6Publishing: 101] [Article Influence: 8.6] [Reference Citation Analysis]
83 Roessler S, Budhu A, Wang XW. Future of molecular profiling of human hepatocellular carcinoma. Future Oncol. 2007;3:429-439. [PMID: 17661718 DOI: 10.2217/14796694.3.4.429] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 1.1] [Reference Citation Analysis]
84 Pontisso P. Role of SERPINB3 in hepatocellular carcinoma. Annals of Hepatology 2014;13:722-7. [DOI: 10.1016/s1665-2681(19)30974-3] [Cited by in Crossref: 21] [Article Influence: 2.6] [Reference Citation Analysis]
85 Murthy SS, Narsaiah TB. Cytotoxic Effect of Bromelain on HepG2 Hepatocellular Carcinoma Cell Line. Appl Biochem Biotechnol 2021;193:1873-97. [PMID: 33735410 DOI: 10.1007/s12010-021-03505-z] [Reference Citation Analysis]
86 Zhang X, Bai Y, Xu L, Zhang B, Feng S, Xu L, Zhang H, Xu L, Yang P, Niu T, Zheng S, Liu J. Clinical and morpho-molecular classifiers for prediction of hepatocellular carcinoma prognosis and recurrence after surgical resection. Hepatol Int 2019;13:715-25. [PMID: 31531761 DOI: 10.1007/s12072-019-09978-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
87 Tang Y, Kitisin K, Jogunoori W, Li C, Deng CX, Mueller SC, Ressom HW, Rashid A, He AR, Mendelson JS. Progenitor/stem cells give rise to liver cancer due to aberrant TGF-beta and IL-6 signaling. Proc Natl Acad Sci USA. 2008;105:2445-2450. [PMID: 18263735 DOI: 10.1073/pnas.0705395105] [Cited by in Crossref: 223] [Cited by in F6Publishing: 230] [Article Influence: 15.9] [Reference Citation Analysis]
88 Pedro B, Rupji M, Dwivedi B, Kowalski J, Konen JM, Owonikoko TK, Ramalingam SS, Vertino PM, Marcus AI. Prognostic significance of an invasive leader cell-derived mutation cluster on chromosome 16q. Cancer 2020;126:3140-50. [PMID: 32315457 DOI: 10.1002/cncr.32903] [Reference Citation Analysis]
89 Di Bisceglie AM. Pretransplant treatments for hepatocellular carcinoma: do they improve outcomes? Liver Transpl. 2005;S10-S13. [PMID: 16237728 DOI: 10.1002/lt.20598] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
90 Wang K, Bai Y, Chen S, Huang J, Yuan J, Chen W, Yao P, Miao X, Wang Y, Liang Y, Zhang X, He M, Yang H, Guo H, Wei S. Genetic correction of serum AFP level improves risk prediction of primary hepatocellular carcinoma in the Dongfeng-Tongji cohort study. Cancer Med 2018;7:2691-8. [PMID: 29696820 DOI: 10.1002/cam4.1481] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
91 Zhu HT, Dong QZ, Sheng YY, Wei JW, Wang G, Zhou HJ, Ren N, Jia HL, Ye QH, Qin LX. MicroRNA-29a-5p is a novel predictor for early recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection. PLoS One 2012;7:e52393. [PMID: 23285022 DOI: 10.1371/journal.pone.0052393] [Cited by in Crossref: 34] [Cited by in F6Publishing: 40] [Article Influence: 3.4] [Reference Citation Analysis]
92 Bévant K, Desoteux M, Angenard G, Pineau R, Caruso S, Louis C, Papoutsoglou P, Sulpice L, Gilot D, Zucman-Rossi J, Coulouarn C. TGFβ-induced FOXS1 controls epithelial-mesenchymal transition and predicts a poor prognosis in liver cancer. Hepatol Commun 2021. [PMID: 34825776 DOI: 10.1002/hep4.1866] [Reference Citation Analysis]
93 Pérez-Carreón JI, López-García C, Fattel-Fazenda S, Arce-Popoca E, Alemán-Lazarini L, Hernández-García S, Le Berre V, Sokol S, Francois JM, Villa-Treviño S. Gene expression profile related to the progression of preneoplastic nodules toward hepatocellular carcinoma in rats. Neoplasia 2006;8:373-83. [PMID: 16790086 DOI: 10.1593/neo.05841] [Cited by in Crossref: 29] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
94 Sukowati CH, Rosso N, Crocè LS, Tiribelli C. Hepatic cancer stem cells and drug resistance: Relevance in targeted therapies for hepatocellular carcinoma. World J Hepatol 2010; 2(3): 114-126 [PMID: 21160982 DOI: 10.4254/wjh.v2.i3.114] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 2.3] [Reference Citation Analysis]
95 Li W, Yu J, Lian B, Sun H, Li J, Zhang M, Li L, Li Y, Liu Q, Xie L. Identifying prognostic features by bottom-up approach and correlating to drug repositioning. PLoS One 2015;10:e0118672. [PMID: 25738841 DOI: 10.1371/journal.pone.0118672] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
96 Chew V, Chen J, Lee D, Loh E, Lee J, Lim KH, Weber A, Slankamenac K, Poon RT, Yang H, Ooi LL, Toh HC, Heikenwalder M, Ng IO, Nardin A, Abastado JP. Chemokine-driven lymphocyte infiltration: an early intratumoural event determining long-term survival in resectable hepatocellular carcinoma. Gut. 2012;61:427-438. [PMID: 21930732 DOI: 10.1136/gutjnl-2011-300509] [Cited by in Crossref: 192] [Cited by in F6Publishing: 184] [Article Influence: 17.5] [Reference Citation Analysis]
97 Andersen JB, Spee B, Blechacz BR, Avital I, Komuta M, Barbour A, Conner EA, Gillen MC, Roskams T, Roberts LR. Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. Gastroenterology. 2012;142:1021-1031.e15. [PMID: 22178589 DOI: 10.1053/j.gastro.2011.12.005] [Cited by in Crossref: 272] [Cited by in F6Publishing: 304] [Article Influence: 24.7] [Reference Citation Analysis]
98 Gougelet A, Sartor C, Bachelot L, Godard C, Marchiol C, Renault G, Tores F, Nitschke P, Cavard C, Terris B, Perret C, Colnot S. Antitumour activity of an inhibitor of miR-34a in liver cancer with β-catenin-mutations. Gut 2016;65:1024-34. [PMID: 25792709 DOI: 10.1136/gutjnl-2014-308969] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 6.0] [Reference Citation Analysis]
99 Pineda-Solis K, McAlister V. Wading through the noise of "multi-omics" to identify prognostic biomarkers in hepatocellular carcinoma. Hepatobiliary Surg Nutr 2015;4:293-4. [PMID: 26312246 DOI: 10.3978/j.issn.2304-3881.2015.04.05] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
100 Kim H, Park YN. Role of biopsy sampling for diagnosis of early and progressed hepatocellular carcinoma. Best Practice & Research Clinical Gastroenterology 2014;28:813-29. [DOI: 10.1016/j.bpg.2014.08.012] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
101 Villanueva A, Toffanin S, Llovet JM. Linking molecular classification of hepatocellular carcinoma and personalized medicine: preliminary steps. Curr Opin Oncol. 2008;20:444-453. [PMID: 18525342 DOI: 10.1097/CCO.0b013e328302c9e9] [Cited by in Crossref: 52] [Cited by in F6Publishing: 21] [Article Influence: 3.7] [Reference Citation Analysis]
102 Govaere O, Roskams T. Pathogenesis and prognosis of hepatocellular carcinoma at the cellular and molecular levels. Clin Liver Dis. 2015;19:261-276. [PMID: 25921662 DOI: 10.1016/j.cld.2015.01.002] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.9] [Reference Citation Analysis]
103 Nam SW, Park JY, Ramasamy A, Shevade S, Islam A, Long PM, Park CK, Park SE, Kim SY, Lee SH, Park WS, Yoo NJ, Liu ET, Miller LD, Lee JY. Molecular changes from dysplastic nodule to hepatocellular carcinoma through gene expression profiling. Hepatology 2005;42:809-18. [PMID: 16175600 DOI: 10.1002/hep.20878] [Cited by in Crossref: 127] [Cited by in F6Publishing: 115] [Article Influence: 7.5] [Reference Citation Analysis]
104 Ruiz E, Pineau P, Flores C, Fernández R, Cano L, Cerapio JP, Casavilca-Zambrano S, Berrospi F, Chávez I, Roche B, Bertani S. A preoperative nomogram for predicting long-term survival after resection of large hepatocellular carcinoma (>10 cm). HPB (Oxford) 2021:S1365-182X(21)00177-5. [PMID: 34226129 DOI: 10.1016/j.hpb.2021.06.006] [Reference Citation Analysis]
105 Cai J, Li B, Zhu Y, Fang X, Zhu M, Wang M, Liu S, Jiang X, Zheng J, Zhang X, Chen P. Prognostic Biomarker Identification Through Integrating the Gene Signatures of Hepatocellular Carcinoma Properties. EBioMedicine 2017;19:18-30. [PMID: 28434945 DOI: 10.1016/j.ebiom.2017.04.014] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 5.6] [Reference Citation Analysis]
106 Wurmbach E, Chen YB, Khitrov G, Zhang W, Roayaie S, Schwartz M, Fiel I, Thung S, Mazzaferro V, Bruix J. Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepatology. 2007;45:938-947. [PMID: 17393520 DOI: 10.1002/hep.21622] [Cited by in Crossref: 430] [Cited by in F6Publishing: 437] [Article Influence: 28.7] [Reference Citation Analysis]
107 Huang Q, Lin B, Liu H, Ma X, Mo F, Yu W, Li L, Li H, Tian T, Wu D, Shen F, Xing J, Chen ZN. RNA-Seq analyses generate comprehensive transcriptomic landscape and reveal complex transcript patterns in hepatocellular carcinoma. PLoS One 2011;6:e26168. [PMID: 22043308 DOI: 10.1371/journal.pone.0026168] [Cited by in Crossref: 67] [Cited by in F6Publishing: 70] [Article Influence: 6.1] [Reference Citation Analysis]
108 Kwon SM, Kim DS, Won NH, Park SJ, Chwae YJ, Kang HC, Lee SH, Baik EJ, Thorgeirsson SS, Woo HG. Genomic copy number alterations with transcriptional deregulation at 6p identify an aggressive HCC phenotype. Carcinogenesis. 2013;34:1543-1550. [PMID: 23508637 DOI: 10.1093/carcin/bgt095] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
109 Lin YT, Lu HP, Chao CC. Oncogenic c-Myc and prothymosin-alpha protect hepatocellular carcinoma cells against sorafenib-induced apoptosis. Biochem Pharmacol 2015;93:110-24. [PMID: 25451688 DOI: 10.1016/j.bcp.2014.10.012] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
110 Thorgeirsson SS, Lee JS, Grisham JW. Functional genomics of hepatocellular carcinoma. Hepatology. 2006;43:S145-S150. [PMID: 16447291 DOI: 10.1002/hep.21063] [Cited by in Crossref: 102] [Cited by in F6Publishing: 94] [Article Influence: 6.4] [Reference Citation Analysis]
111 Howell J, Atkinson SR, Pinato DJ, Knapp S, Ward C, Minisini R, Burlone ME, Leutner M, Pirisi M, Büttner R, Khan SA, Thursz M, Odenthal M, Sharma R. Identification of mutations in circulating cell-free tumour DNA as a biomarker in hepatocellular carcinoma. Eur J Cancer 2019;116:56-66. [PMID: 31173963 DOI: 10.1016/j.ejca.2019.04.014] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
112 Wu X, Chen H, Gao Q, Bai J, Wang X, Zhou J, Qiu S, Xu Y, Shi Y, Wang X, Zhou J, Fan J. Downregulation of JWA promotes tumor invasion and predicts poor prognosis in human hepatocellular carcinoma. Mol Carcinog 2014;53:325-36. [PMID: 23169062 DOI: 10.1002/mc.21981] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
113 Staib F, Krupp M, Maass T, Itzel T, Weinmann A, Lee JS, Schmidt B, Müller M, Thorgeirsson SS, Galle PR. CellMinerHCC: a microarray-based expression database for hepatocellular carcinoma cell lines. Liver Int. 2013;Jul 31; Epub ahead of print. [PMID: 24016071 DOI: 10.1111/liv.12292] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
114 Pang RWC, Joh JW, Johnson PJ, Monden M, Pawlik TM, Poon RTP. Biology of Hepatocellular Carcinoma. Ann Surg Oncol 2008;15:962-71. [DOI: 10.1245/s10434-007-9730-z] [Cited by in Crossref: 122] [Cited by in F6Publishing: 118] [Article Influence: 8.7] [Reference Citation Analysis]
115 Tao QF, Yuan SX, Yang F, Yang S, Yang Y, Yuan JH, Wang ZG, Xu QG, Lin KY, Cai J, Yu J, Huang WL, Teng XL, Zhou CC, Wang F, Sun SH, Zhou WP. Aldolase B inhibits metastasis through Ten-Eleven Translocation 1 and serves as a prognostic biomarker in hepatocellular carcinoma. Mol Cancer 2015;14:170. [PMID: 26376879 DOI: 10.1186/s12943-015-0437-7] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 5.9] [Reference Citation Analysis]
116 Liu J, Kruswick A, Dang H, Tran AD, Kwon SM, Wang XW, Oberdoerffer P. Ubiquitin-specific protease 21 stabilizes BRCA2 to control DNA repair and tumor growth. Nat Commun 2017;8:137. [PMID: 28743957 DOI: 10.1038/s41467-017-00206-2] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 4.4] [Reference Citation Analysis]
117 Fowler KJ, Burgoyne A, Fraum TJ, Hosseini M, Ichikawa S, Kim S, Kitao A, Lee JM, Paradis V, Taouli B, Theise ND, Vilgrain V, Wang J, Sirlin CB, Chernyak V. Pathologic, Molecular, and Prognostic Radiologic Features of Hepatocellular Carcinoma. Radiographics 2021;41:1611-31. [PMID: 34597222 DOI: 10.1148/rg.2021210009] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
118 Takai A, Dang HT, Wang XW. Identification of drivers from cancer genome diversity in hepatocellular carcinoma. Int J Mol Sci. 2014;15:11142-11160. [PMID: 24955791 DOI: 10.3390/ijms150611142] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 3.5] [Reference Citation Analysis]
119 Li X, Yao Q, Liu C, Wang J, Zhang H, Li S, Cai P. Macrotrabecular-Massive Hepatocellular Carcinoma: What Should We Know? JHC 2022;Volume 9:379-87. [DOI: 10.2147/jhc.s364742] [Reference Citation Analysis]
120 Lee JS. Genomic profiling of liver cancer. Genomics Inform 2013;11:180-5. [PMID: 24465228 DOI: 10.5808/GI.2013.11.4.180] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
121 Abou Khouzam R, Goutham HV, Zaarour RF, Chamseddine AN, Francis A, Buart S, Terry S, Chouaib S. Integrating tumor hypoxic stress in novel and more adaptable strategies for cancer immunotherapy. Semin Cancer Biol 2020;65:140-54. [PMID: 31927131 DOI: 10.1016/j.semcancer.2020.01.003] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 7.5] [Reference Citation Analysis]
122 Dhanasekaran R, Nault JC, Roberts LR, Zucman-Rossi J. Genomic Medicine and Implications for Hepatocellular Carcinoma Prevention and Therapy. Gastroenterology 2019;156:492-509. [PMID: 30404026 DOI: 10.1053/j.gastro.2018.11.001] [Cited by in Crossref: 65] [Cited by in F6Publishing: 71] [Article Influence: 16.3] [Reference Citation Analysis]
123 Dhanasekaran R, Nakamura I, Hu C, Chen G, Oseini AM, Seven ES, Miamen AG, Moser CD, Zhou W, van Kuppevelt TH, van Deursen JM, Mounajjed T, Fernandez-Zapico ME, Roberts LR. Activation of the transforming growth factor-β/SMAD transcriptional pathway underlies a novel tumor-promoting role of sulfatase 1 in hepatocellular carcinoma. Hepatology 2015;61:1269-83. [PMID: 25503294 DOI: 10.1002/hep.27658] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 4.4] [Reference Citation Analysis]
124 Ijaz B, Ahmad W, Das T, Shabbiri K, Husnain T, Hassan S. HCV infection causes cirrhosis in human by step-wise regulation of host genes involved in cellular functioning and defense during fibrosis: Identification of bio-markers. Genes Dis 2019;6:304-17. [PMID: 32042870 DOI: 10.1016/j.gendis.2019.04.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
125 Lee SA, Ho C, Roy R, Kosinski C, Patil MA, Tward AD, Fridlyand J, Chen X. Integration of genomic analysis and in vivo transfection to identify sprouty 2 as a candidate tumor suppressor in liver cancer. Hepatology 2008;47:1200-10. [PMID: 18214995 DOI: 10.1002/hep.22169] [Cited by in Crossref: 74] [Cited by in F6Publishing: 69] [Article Influence: 5.3] [Reference Citation Analysis]
126 Hu J, Mao F, Li L, Wang X, Cai D, He L, Wu Q, Wang C, Zhang N, Ma Y, Wu X, Qu K, Wang X. Analysis of the Heterogeneity of the Tumor Microenvironment and the Prognosis and Immunotherapy Response of Different Immune Subtypes in Hepatocellular Carcinoma. J Oncol 2022;2022:1087399. [PMID: 35401750 DOI: 10.1155/2022/1087399] [Reference Citation Analysis]
127 Carr BI, Buch SC, Kondragunta V, Pancoska P, Branch RA. Tumor and liver determinants of prognosis in unresectable hepatocellular carcinoma: a case cohort study. J Gastroenterol Hepatol. 2008;23:1259-1266. [PMID: 18699979 DOI: 10.1111/j.1440-1746.2008.05487.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 1.8] [Reference Citation Analysis]
128 Budhu A, Forgues M, Ye QH, Jia HL, He P, Zanetti KA, Kammula US, Chen Y, Qin LX, Tang ZY, Wang XW. Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell. 2006;10:99-111. [PMID: 16904609 DOI: 10.1016/j.ccr.2006.06.016] [Cited by in Crossref: 554] [Cited by in F6Publishing: 529] [Article Influence: 34.6] [Reference Citation Analysis]
129 Patil MA, Chua MS, Pan KH, Lin R, Lih CJ, Cheung ST, Ho C, Li R, Fan ST, Cohen SN, Chen X, So S. An integrated data analysis approach to characterize genes highly expressed in hepatocellular carcinoma. Oncogene 2005;24:3737-47. [PMID: 15735714 DOI: 10.1038/sj.onc.1208479] [Cited by in Crossref: 84] [Cited by in F6Publishing: 87] [Article Influence: 4.9] [Reference Citation Analysis]
130 Bedossa P, Paradis V, Zucman-rossi J. Cellular and Molecular Techniques. Macsween's Pathology of the Liver. Elsevier; 2018. pp. 88-110. [DOI: 10.1016/b978-0-7020-6697-9.00002-9] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
131 Butterfield LH. Lessons learned from cancer vaccine trials and target antigen choice. Cancer Immunol Immunother 2016;65:805-12. [PMID: 26842127 DOI: 10.1007/s00262-016-1801-1] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
132 Sukowati CHC, El-Khobar KE, Tiribelli C. Immunotherapy against programmed death-1/programmed death ligand 1 in hepatocellular carcinoma: Importance of molecular variations, cellular heterogeneity, and cancer stem cells. World J Stem Cells 2021; 13(7): 795-824 [PMID: 34367478 DOI: 10.4252/wjsc.v13.i7.795] [Reference Citation Analysis]
133 Goossens N, Hoshida Y. Is Hepatocellular Cancer the Same Disease in Alcoholic and Nonalcoholic Fatty Liver Diseases? Gastroenterology 2016;150:1710-7. [PMID: 26784140 DOI: 10.1053/j.gastro.2016.01.006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
134 Bertram K, Valcu CM, Weitnauer M, Linne U, Görlach A. NOX1 supports the metabolic remodeling of HepG2 cells. PLoS One 2015;10:e0122002. [PMID: 25806803 DOI: 10.1371/journal.pone.0122002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
135 Maass T, Marquardt J, Lee JS, Krupp M, Scholz-Kreisel P, Mogler C, Schirmacher P, Müller M, Westphal H, Galle PR, Teufel A. Increased liver carcinogenesis and enrichment of stem cell properties in livers of Dickkopf 2 (Dkk2) deleted mice. Oncotarget 2016;7:28903-13. [PMID: 25826080 DOI: 10.18632/oncotarget.3293] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
136 Maluf DG, Stravitz RT, Williams B, Cotterell AH, Mas VR, Heuman D, Luketic V, Shiffman ML, Sterling R, Posner MP, Fisher RA. Multimodality therapy and liver transplantation in patients with cirrhosis and hepatocellular carcinoma: 6 years, single-center experience. Transplant Proc 2007;39:153-9. [PMID: 17275495 DOI: 10.1016/j.transproceed.2006.10.029] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
137 Cho HJ, Kim SS, Wang HJ, Kim BW, Cho H, Jung J, Cho SS, Kim JK, Lee JH, Kim YB. Detection of Novel Genomic Markers for Predicting Prognosis in Hepatocellular Carcinoma Patients by Integrative Analysis of Copy Number Aberrations and Gene Expression Profiles: Results from a Long-Term Follow-Up. DNA Cell Biol. 2016;35:71-80. [PMID: 26624274 DOI: 10.1089/dna.2015.3026] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
138 Chua P, Yip GW, Bay B. Cell Cycle Arrest Induced by Hydrogen Peroxide Is Associated with Modulation of Oxidative Stress Related Genes in Breast Cancer Cells. Exp Biol Med (Maywood) 2009;234:1086-94. [DOI: 10.3181/0903-rm-98] [Cited by in Crossref: 45] [Cited by in F6Publishing: 21] [Article Influence: 3.5] [Reference Citation Analysis]
139 Funk K, Czauderna C, Klesse R, Becker D, Hajduk J, Oelgeklaus A, Reichenbach F, Fimm-Todt F, Lauterwasser J, Galle PR, Marquardt JU, Edlich F. BAX Redistribution Induces Apoptosis Resistance and Selective Stress Sensitivity in Human HCC. Cancers (Basel) 2020;12:E1437. [PMID: 32486514 DOI: 10.3390/cancers12061437] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
140 Iavarone M, Colombo M. HBV infection and hepatocellular carcinoma. Clin Liver Dis. 2013;17:375-397. [PMID: 23905811 DOI: 10.1016/j.cld.2013.05.002] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 3.4] [Reference Citation Analysis]
141 Chen B, Garmire L, Calvisi DF, Chua MS, Kelley RK, Chen X. Harnessing big 'omics' data and AI for drug discovery in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2020;17:238-51. [PMID: 31900465 DOI: 10.1038/s41575-019-0240-9] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 14.5] [Reference Citation Analysis]
142 Yang C, Chen J, Li Y, Huang X, Liu Z, Wang J, Jiang H, Qin W, Lv Y, Wang H, Wang C. Exploring subclass-specific therapeutic agents for hepatocellular carcinoma by informatics-guided drug screen. Brief Bioinform 2021;22:bbaa295. [PMID: 33167027 DOI: 10.1093/bib/bbaa295] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
143 Nault JC, De Reyniès A, Villanueva A, Calderaro J, Rebouissou S, Couchy G, Decaens T, Franco D, Imbeaud S, Rousseau F. A hepatocellular carcinoma 5-gene score associated with survival of patients after liver resection. Gastroenterology. 2013;145:176-187. [PMID: 23567350 DOI: 10.1053/j.gastro.2013.03.051] [Cited by in Crossref: 226] [Cited by in F6Publishing: 209] [Article Influence: 25.1] [Reference Citation Analysis]
144 Studach LL, Menne S, Cairo S, Buendia MA, Hullinger RL, Lefrançois L, Merle P, Andrisani OM. Subset of Suz12/PRC2 target genes is activated during hepatitis B virus replication and liver carcinogenesis associated with HBV X protein. Hepatology. 2012;56:1240-1251. [PMID: 22505317 DOI: 10.1002/hep.25781] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 3.4] [Reference Citation Analysis]
145 Schirmacher P, Calvisi DF. Molecular diagnostic algorithms in hepatocellular carcinoma: dead-end street or light at the end of the tunnel? Gastroenterology 2013;145:49-53. [PMID: 23727497 DOI: 10.1053/j.gastro.2013.05.026] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
146 Costantini S, Di Bernardo G, Cammarota M, Castello G, Colonna G. Gene expression signature of human HepG2 cell line. Gene 2013;518:335-45. [DOI: 10.1016/j.gene.2012.12.106] [Cited by in Crossref: 61] [Cited by in F6Publishing: 61] [Article Influence: 6.8] [Reference Citation Analysis]
147 Kong D, Chen H, Chen W, Liu S, Wang H, Wu T, Lu H, Kong Q, Huang X, Lu Z. Gene expression profiling analysis of hepatocellular carcinoma. Eur J Med Res 2013;18:44. [PMID: 24229431 DOI: 10.1186/2047-783X-18-44] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
148 Lee YH, Seo D, Choi KJ, Andersen JB, Won MA, Kitade M, Gómez-Quiroz LE, Judge AD, Marquardt JU, Raggi C, Conner EA, MacLachlan I, Factor VM, Thorgeirsson SS. Antitumor effects in hepatocarcinoma of isoform-selective inhibition of HDAC2. Cancer Res 2014;74:4752-61. [PMID: 24958469 DOI: 10.1158/0008-5472.CAN-13-3531] [Cited by in Crossref: 50] [Cited by in F6Publishing: 27] [Article Influence: 6.3] [Reference Citation Analysis]
149 Verma M. The Role of Epigenomics in the Study of Cancer Biomarkers and in the Development of Diagnostic Tools. Adv Exp Med Biol 2015;867:59-80. [PMID: 26530360 DOI: 10.1007/978-94-017-7215-0_5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
150 Kim H, Lee JY, Park SJ, Kwag E, Koo O, Shin JH. ZNF746/PARIS promotes the occurrence of hepatocellular carcinoma. Biochem Biophys Res Commun 2021;563:98-104. [PMID: 34062393 DOI: 10.1016/j.bbrc.2021.05.051] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
151 Mínguez B, Tovar V, Chiang D, Villanueva A, Llovet JM. Pathogenesis of hepatocellular carcinoma and molecular therapies. Curr Opin Gastroenterol. 2009;25:186-194. [PMID: 19387255 DOI: 10.1097/mog.0b013e32832962a1] [Cited by in Crossref: 101] [Cited by in F6Publishing: 51] [Article Influence: 7.8] [Reference Citation Analysis]
152 Taouli B, Hoshida Y, Kakite S, Chen X, Tan PS, Sun X, Kihira S, Kojima K, Toffanin S, Fiel MI, Hirschfield H, Wagner M, Llovet JM. Imaging-based surrogate markers of transcriptome subclasses and signatures in hepatocellular carcinoma: preliminary results. Eur Radiol. 2017;27:4472-4481. [PMID: 28439654 DOI: 10.1007/s00330-017-4844-6] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 5.0] [Reference Citation Analysis]
153 Dekervel J, Popovic D, van Malenstein H, Windmolders P, Heylen L, Libbrecht L, Bulle A, De Moor B, Van Cutsem E, Nevens F, Verslype C, van Pelt J. A Global Risk Score (GRS) to Simultaneously Predict Early and Late Tumor Recurrence Risk after Resection of Hepatocellular Carcinoma. Transl Oncol 2016;9:139-46. [PMID: 27084430 DOI: 10.1016/j.tranon.2016.02.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
154 Doyle A, Sherman M. Liver Biopsy for Hepatocellular Carcinoma (HCC): Should this be a Routine? Curr Hepatology Rep 2017;16:46-50. [DOI: 10.1007/s11901-017-0333-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
155 Calvisi DF, Ladu S, Conner EA, Seo D, Hsieh JT, Factor VM, Thorgeirsson SS. Inactivation of Ras GTPase-activating proteins promotes unrestrained activity of wild-type Ras in human liver cancer. J Hepatol. 2011;54:311-319. [PMID: 21067840 DOI: 10.1016/j.jhep.2010.06.036] [Cited by in Crossref: 105] [Cited by in F6Publishing: 100] [Article Influence: 8.8] [Reference Citation Analysis]
156 Colecchia A, Schiumerini R, Cucchetti A, Cescon M, Taddia M, Marasco G, Festi D. Prognostic factors for hepatocellular carcinoma recurrence. World J Gastroenterol 2014; 20(20): 5935-5950 [PMID: 24876717 DOI: 10.3748/wjg.v20.i20.5935] [Cited by in CrossRef: 87] [Cited by in F6Publishing: 90] [Article Influence: 10.9] [Reference Citation Analysis]
157 Mato JM, Martínez-Chantar ML, Lu SC. Systems biology for hepatologists. Hepatology 2014;60:736-43. [PMID: 24449428 DOI: 10.1002/hep.27023] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
158 Villanueva A, Llovet JM. Targeted therapies for hepatocellular carcinoma. Gastroenterology 2011;140:1410-26. [PMID: 21406195 DOI: 10.1053/j.gastro.2011.03.006] [Cited by in Crossref: 310] [Cited by in F6Publishing: 310] [Article Influence: 28.2] [Reference Citation Analysis]
159 Coulouarn C, Corlu A, Glaise D, Guénon I, Thorgeirsson SS, Clément B. Hepatocyte-stellate cell cross-talk in the liver engenders a permissive inflammatory microenvironment that drives progression in hepatocellular carcinoma. Cancer Res. 2012;72:2533-2542. [PMID: 22419664 DOI: 10.1158/0008-5472.can-11-3317] [Cited by in Crossref: 133] [Cited by in F6Publishing: 67] [Article Influence: 13.3] [Reference Citation Analysis]
160 Paradis V. Hepatocellular Carcinomas: Towards a pathomolecular approach. Liver Int 2021;41 Suppl 1:83-8. [PMID: 34155797 DOI: 10.1111/liv.14867] [Reference Citation Analysis]
161 Liu B, Zhang J, Huang C, Liu H. Dyskerin overexpression in human hepatocellular carcinoma is associated with advanced clinical stage and poor patient prognosis. PLoS One 2012;7:e43147. [PMID: 22912812 DOI: 10.1371/journal.pone.0043147] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 3.3] [Reference Citation Analysis]
162 Li D, Wei P, Peng Z, Huang C, Tang H, Jia Z, Cui J, Le X, Huang S, Xie K. The critical role of dysregulated FOXM1-PLAUR signaling in human colon cancer progression and metastasis. Clin Cancer Res. 2013;19:62-72. [PMID: 23136192 DOI: 10.1158/1078-0432.CCR-12-1588] [Cited by in Crossref: 55] [Cited by in F6Publishing: 48] [Article Influence: 5.5] [Reference Citation Analysis]
163 Schwartz JD, Llovet JM. Molecular Targeting in Hepatocellular Carcinoma. In: Kaufman HL, Wadler S, Antman K, editors. Molecular Targeting in Oncology. Totowa: Humana Press; 2008. pp. 165-210. [DOI: 10.1007/978-1-59745-337-0_8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
164 Goossens N, Sun X, Hoshida Y. Molecular classification of hepatocellular carcinoma: potential therapeutic implications. Hepat Oncol 2015;2:371-9. [PMID: 26617981 DOI: 10.2217/hep.15.26] [Cited by in Crossref: 63] [Cited by in F6Publishing: 59] [Article Influence: 9.0] [Reference Citation Analysis]
165 Ladu S, Calvisi DF, Conner EA, Farina M, Factor VM, Thorgeirsson SS. E2F1 inhibits c-Myc-driven apoptosis via PIK3CA/Akt/mTOR and COX-2 in a mouse model of human liver cancer. Gastroenterology. 2008;135:1322-1332. [PMID: 18722373 DOI: 10.1053/j.gastro.2008.07.012] [Cited by in Crossref: 83] [Cited by in F6Publishing: 81] [Article Influence: 5.9] [Reference Citation Analysis]
166 Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol. 2008;48 Suppl 1:S20-S37. [PMID: 18304676 DOI: 10.1016/j.jhep.2008.01.022] [Cited by in Crossref: 576] [Cited by in F6Publishing: 571] [Article Influence: 41.1] [Reference Citation Analysis]
167 Carrasco-torres G, Fattel-fazenda S, López-alvarez GS, García-román R, Villa-treviño S, Vásquez-garzón VR. The transmembrane transporter ABCC3 participates in liver cancer progression and is a potential biomarker. Tumor Biol 2016;37:2007-14. [DOI: 10.1007/s13277-015-3999-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
168 Caboux E, Paciencia M, Durand G, Robinot N, Wozniak MB, Galateau-Salle F, Byrnes G, Hainaut P, Le Calvez-Kelm F. Impact of delay to cryopreservation on RNA integrity and genome-wide expression profiles in resected tumor samples. PLoS One 2013;8:e79826. [PMID: 24278187 DOI: 10.1371/journal.pone.0079826] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
169 Calvisi DF, Pinna F, Ladu S, Pellegrino R, Muroni MR, Simile MM, Frau M, Tomasi ML, De Miglio MR, Seddaiu MA, Daino L, Sanna V, Feo F, Pascale RM. Aberrant iNOS signaling is under genetic control in rodent liver cancer and potentially prognostic for the human disease. Carcinogenesis 2008;29:1639-47. [DOI: 10.1093/carcin/bgn155] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 3.1] [Reference Citation Analysis]
170 Gao X, Huang H, Wang Y, Pan C, Yin S, Zhou L, Zheng S. Tumor Immune Microenvironment Characterization in Hepatocellular Carcinoma Identifies Four Prognostic and Immunotherapeutically Relevant Subclasses. Front Oncol 2020;10:610513. [PMID: 33680932 DOI: 10.3389/fonc.2020.610513] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
171 Kim H, Jang M, Park YN. Histopathological Variants of Hepatocellular Carcinomas: an Update According to the 5th Edition of the WHO Classification of Digestive System Tumors. J Liver Cancer 2020;20:17-24. [DOI: 10.17998/jlc.20.1.17] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
172 Hernandez S, Simoni-Nieves A, Gerardo-Ramírez M, Torres S, Fucho R, Gonzalez J, Castellanos-Tapia L, Hernández-Pando R, Tejero-Barrera E, Bucio L, Souza V, Miranda-Labra R, Fernández-Checa JC, Marquardt JU, Gomez-Quiroz LE, García-Ruiz C, Gutiérrez-Ruiz MC. GDF11 restricts aberrant lipogenesis and changes in mitochondrial structure and function in human hepatocellular carcinoma cells. J Cell Physiol 2021;236:4076-90. [PMID: 33174245 DOI: 10.1002/jcp.30151] [Reference Citation Analysis]
173 Man Z, Chen Y, Gao L, Xei G, Li Q, Lu Q, Yan J. A Prognostic Model Based on RNA Binding Protein Predicts Clinical Outcomes in Hepatocellular Carcinoma Patients. Front Oncol 2020;10:613102. [PMID: 33643914 DOI: 10.3389/fonc.2020.613102] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
174 Frades I, Andreasson E, Mato JM, Alexandersson E, Matthiesen R, Martínez-Chantar ML. Integrative genomic signatures of hepatocellular carcinoma derived from nonalcoholic Fatty liver disease. PLoS One 2015;10:e0124544. [PMID: 25993042 DOI: 10.1371/journal.pone.0124544] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.9] [Reference Citation Analysis]
175 Liu LY, Ma XZ, Ouyang B, Ings DP, Marwah S, Liu J, Chen AY, Gupta R, Manuel J, Chen XC, Gage BK, Cirlan I, Khuu N, Chung S, Camat D, Cheng M, Sekhon M, Zagorovsky K, Abdou Mohamed MA, Thoeni C, Atif J, Echeverri J, Kollmann D, Fischer S, Bader GD, Chan WCW, Michalak TI, McGilvray ID, MacParland SA. Nanoparticle Uptake in a Spontaneous and Immunocompetent Woodchuck Liver Cancer Model. ACS Nano. 2020;14:4698-4715. [PMID: 32255624 DOI: 10.1021/acsnano.0c00468] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
176 Wang IC, Meliton L, Tretiakova M, Costa RH, Kalinichenko VV, Kalin TV. Transgenic expression of the forkhead box M1 transcription factor induces formation of lung tumors. Oncogene 2008;27:4137-49. [PMID: 18345025 DOI: 10.1038/onc.2008.60] [Cited by in Crossref: 62] [Cited by in F6Publishing: 59] [Article Influence: 4.4] [Reference Citation Analysis]
177 Tan Y, Raychaudhuri P, Costa RH. Chk2 mediates stabilization of the FoxM1 transcription factor to stimulate expression of DNA repair genes. Mol Cell Biol 2007;27:1007-16. [PMID: 17101782 DOI: 10.1128/MCB.01068-06] [Cited by in Crossref: 158] [Cited by in F6Publishing: 122] [Article Influence: 9.9] [Reference Citation Analysis]
178 Lawless MW, Norris S, O'Byrne KJ, Gray SG. Targeting histone deacetylases for the treatment of disease. J Cell Mol Med 2009;13:826-52. [PMID: 19175682 DOI: 10.1111/j.1582-4934.2008.00571.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 2.5] [Reference Citation Analysis]
179 Paradis V. Histopathology of hepatocellular carcinoma. Recent Results Cancer Res. 2013;190:21-32. [PMID: 22941011 DOI: 10.1007/978-3-642-16037-0_2] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 3.7] [Reference Citation Analysis]
180 Yang C, Huang X, Liu Z, Qin W, Wang C. Metabolism-associated molecular classification of hepatocellular carcinoma.Mol Oncol. 2020;14:896-913. [PMID: 31955511 DOI: 10.1002/1878-0261.12639] [Cited by in Crossref: 25] [Cited by in F6Publishing: 30] [Article Influence: 12.5] [Reference Citation Analysis]
181 Cariani E, Pilli M, Zerbini A, Rota C, Olivani A, Pelosi G, Schianchi C, Soliani P, Campanini N, Silini EM, Trenti T, Ferrari C, Missale G. Immunological and molecular correlates of disease recurrence after liver resection for hepatocellular carcinoma. PLoS One 2012;7:e32493. [PMID: 22396772 DOI: 10.1371/journal.pone.0032493] [Cited by in Crossref: 50] [Cited by in F6Publishing: 47] [Article Influence: 5.0] [Reference Citation Analysis]
182 Kim SM, Park YY, Park ES, Cho JY, Izzo JG, Zhang D, Kim SB, Lee JH, Bhutani MS, Swisher SG, Wu X, Coombes KR, Maru D, Wang KK, Buttar NS, Ajani JA, Lee JS. Prognostic biomarkers for esophageal adenocarcinoma identified by analysis of tumor transcriptome. PLoS One. 2010;5:e15074. [PMID: 21152079 DOI: 10.1371/journal.pone.0015074] [Cited by in Crossref: 93] [Cited by in F6Publishing: 88] [Article Influence: 7.8] [Reference Citation Analysis]
183 Meier T, Timm M, Montani M, Wilkens L. Gene networks and transcriptional regulators associated with liver cancer development and progression. BMC Med Genomics 2021;14:41. [PMID: 33541355 DOI: 10.1186/s12920-021-00883-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
184 Hwang JW, Jang SK, Lee DJ. Genomic analysis of pancreatic cancer reveals 3 molecular subtypes with different clinical outcomes. Medicine (Baltimore) 2021;100:e24969. [PMID: 33832071 DOI: 10.1097/MD.0000000000024969] [Reference Citation Analysis]
185 Zhu W, Zhang Q, Liu M, Yan M, Chu X, Li Y. Identification of DNA repair-related genes predicting pathogenesis and prognosis for liver cancer. Cancer Cell Int 2021;21:81. [PMID: 33516217 DOI: 10.1186/s12935-021-01779-1] [Reference Citation Analysis]
186 Coulouarn C, Gomez-Quiroz LE, Lee JS, Kaposi-Novak P, Conner EA, Goldina TA, Onishchenko GE, Factor VM, Thorgeirsson SS. Oncogene-specific gene expression signatures at preneoplastic stage in mice define distinct mechanisms of hepatocarcinogenesis. Hepatology. 2006;44:1003-1011. [PMID: 17006931 DOI: 10.1002/hep.21293] [Cited by in Crossref: 49] [Cited by in F6Publishing: 44] [Article Influence: 3.1] [Reference Citation Analysis]
187 Su CL, Tseng CL, Ramesh C, Liu HS, Huang CF, Yao CF. Using gene expression database to uncover biology functions of 1,4-disubstituted 1,2,3-triazole analogues synthesized via a copper (I)-catalyzed reaction. Eur J Med Chem 2017;132:90-107. [PMID: 28342400 DOI: 10.1016/j.ejmech.2017.03.034] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 3.2] [Reference Citation Analysis]
188 Heo J, Lee JS, Chu IS, Takahama Y, Thorgeirsson SS. Spontaneous differentiation of mouse embryonic stem cells in vitro: characterization by global gene expression profiles. Biochem Biophys Res Commun 2005;332:1061-9. [PMID: 15922302 DOI: 10.1016/j.bbrc.2005.04.173] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 1.4] [Reference Citation Analysis]
189 Kremer-Tal S, Narla G, Chen Y, Hod E, DiFeo A, Yea S, Lee JS, Schwartz M, Thung SN, Fiel IM. Downregulation of KLF6 is an early event in hepatocarcinogenesis, and stimulates proliferation while reducing differentiation. J Hepatol. 2007;46:645-654. [PMID: 17196295 DOI: 10.1016/j.jhep.2006.10.012] [Cited by in Crossref: 64] [Cited by in F6Publishing: 61] [Article Influence: 4.0] [Reference Citation Analysis]
190 Dang H, Takai A, Forgues M, Pomyen Y, Mou H, Xue W, Ray D, Ha KCH, Morris QD, Hughes TR, Wang XW. Oncogenic Activation of the RNA Binding Protein NELFE and MYC Signaling in Hepatocellular Carcinoma. Cancer Cell 2017;32:101-114.e8. [PMID: 28697339 DOI: 10.1016/j.ccell.2017.06.002] [Cited by in Crossref: 69] [Cited by in F6Publishing: 64] [Article Influence: 13.8] [Reference Citation Analysis]
191 Reinhart D, Damjanovic L, Castan A, Ernst W, Kunert R. Differential gene expression of a feed-spiked super-producing CHO cell line. J Biotechnol 2018;285:23-37. [PMID: 30157452 DOI: 10.1016/j.jbiotec.2018.08.013] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
192 Bruix J, Llovet JM. Major achievements in hepatocellular carcinoma. Lancet. 2009;373:614-616. [PMID: 19231618 DOI: 10.1016/s0140-6736(09)60381-0] [Cited by in Crossref: 205] [Cited by in F6Publishing: 105] [Article Influence: 15.8] [Reference Citation Analysis]
193 Ezzeldin M, Borrego-Diaz E, Taha M, Esfandyari T, Wise AL, Peng W, Rouyanian A, Asvadi Kermani A, Soleimani M, Patrad E, Lialyte K, Wang K, Williamson S, Abdulkarim B, Olyaee M, Farassati F. RalA signaling pathway as a therapeutic target in hepatocellular carcinoma (HCC). Mol Oncol 2014;8:1043-53. [PMID: 24785097 DOI: 10.1016/j.molonc.2014.03.020] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 2.9] [Reference Citation Analysis]
194 Kumar M, Zhao X, Wang XW. Molecular carcinogenesis of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: one step closer to personalized medicine? Cell Biosci. 2011;1:5. [PMID: 21711594 DOI: 10.1186/2045-3701-1-5] [Cited by in Crossref: 58] [Cited by in F6Publishing: 52] [Article Influence: 5.3] [Reference Citation Analysis]
195 Kukkula A, Ojala VK, Mendez LM, Sistonen L, Elenius K, Sundvall M. Therapeutic Potential of Targeting the SUMO Pathway in Cancer. Cancers (Basel) 2021;13:4402. [PMID: 34503213 DOI: 10.3390/cancers13174402] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
196 Marquardt JU, Gomez-Quiroz L, Arreguin Camacho LO, Pinna F, Lee YH, Kitade M, Domínguez MP, Castven D, Breuhahn K, Conner EA. Curcumin effectively inhibits oncogenic NF-κB signaling and restrains stemness features in liver cancer. J Hepatol. 2015;63:661-669. [PMID: 25937435 DOI: 10.1016/j.jhep.2015.04.018] [Cited by in Crossref: 126] [Cited by in F6Publishing: 125] [Article Influence: 18.0] [Reference Citation Analysis]
197 Benfeitas R, Bidkhori G, Mukhopadhyay B, Klevstig M, Arif M, Zhang C, Lee S, Cinar R, Nielsen J, Uhlen M, Boren J, Kunos G, Mardinoglu A. Characterization of heterogeneous redox responses in hepatocellular carcinoma patients using network analysis. EBioMedicine 2019;40:471-87. [PMID: 30606699 DOI: 10.1016/j.ebiom.2018.12.057] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 5.8] [Reference Citation Analysis]
198 Masuzaki R, Kanda T, Sasaki R, Matsumoto N, Nirei K, Ogawa M, Karp SJ, Moriyama M, Kogure H. Suppressors of Cytokine Signaling and Hepatocellular Carcinoma. Cancers 2022;14:2549. [DOI: 10.3390/cancers14102549] [Reference Citation Analysis]
199 Choi MJ, Jung KH, Kim D, Lee H, Zheng HM, Park BH, Hong SW, Kim MH, Hong S, Hong SS. Anti-cancer effects of a novel compound HS-113 on cell growth, apoptosis, and angiogenesis in human hepatocellular carcinoma cells. Cancer Lett 2011;306:190-6. [PMID: 21463918 DOI: 10.1016/j.canlet.2011.03.005] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
200 Park HS, Park KI, Lee DH, Kang SR, Nagappan A, Kim JA, Kim EH, Lee WS, Shin SC, Hah YS, Kim GS. Polyphenolic extract isolated from Korean Lonicera japonica Thunb. induce G2/M cell cycle arrest and apoptosis in HepG2 cells: involvements of PI3K/Akt and MAPKs. Food Chem Toxicol 2012;50:2407-16. [PMID: 22561682 DOI: 10.1016/j.fct.2012.04.034] [Cited by in Crossref: 48] [Cited by in F6Publishing: 42] [Article Influence: 4.8] [Reference Citation Analysis]
201 Calderaro J, Couchy G, Imbeaud S, Amaddeo G, Letouzé E, Blanc JF, Laurent C, Hajji Y, Azoulay D, Bioulac-Sage P, Nault JC, Zucman-Rossi J. Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification. J Hepatol 2017;67:727-38. [PMID: 28532995 DOI: 10.1016/j.jhep.2017.05.014] [Cited by in Crossref: 222] [Cited by in F6Publishing: 213] [Article Influence: 44.4] [Reference Citation Analysis]
202 Varnholt H. The role of microRNAs in primary liver cancer. Annals of Hepatology 2008;7:104-13. [DOI: 10.1016/s1665-2681(19)31864-2] [Cited by in Crossref: 40] [Article Influence: 2.9] [Reference Citation Analysis]
203 Simoni-Nieves A, Salas-Silva S, Chávez-Rodríguez L, Escobedo-Calvario A, Desoteux M, Bucio L, Souza V, Miranda-Labra RU, Muñoz-Espinosa LE, Coulouarn C, Gutiérrez-Ruiz MC, Marquardt JU, Gomez-Quiroz LE. The Consumption of Cholesterol-Enriched Diets Conditions the Development of a Subtype of HCC with High Aggressiveness and Poor Prognosis. Cancers (Basel) 2021;13:1721. [PMID: 33917315 DOI: 10.3390/cancers13071721] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
204 Levrero M, Zucman-Rossi J. Mechanisms of HBV-induced hepatocellular carcinoma. J Hepatol. 2016;64:S84-S101. [PMID: 27084040 DOI: 10.1016/j.jhep.2016.02.021] [Cited by in Crossref: 330] [Cited by in F6Publishing: 335] [Article Influence: 66.0] [Reference Citation Analysis]
205 Andersen JB, Factor VM, Marquardt JU, Raggi C, Lee YH, Seo D, Conner EA, Thorgeirsson SS. An integrated genomic and epigenomic approach predicts therapeutic response to zebularine in human liver cancer. Sci Transl Med 2010;2:54ra77. [PMID: 20962331 DOI: 10.1126/scitranslmed.3001338] [Cited by in Crossref: 62] [Cited by in F6Publishing: 69] [Article Influence: 5.6] [Reference Citation Analysis]
206 Budhu A, Jia HL, Forgues M, Liu CG, Goldstein D, Lam A, Zanetti KA, Ye QH, Qin LX, Croce CM, Tang ZY, Wang XW. Identification of metastasis-related microRNAs in hepatocellular carcinoma. Hepatology. 2008;47:897-907. [PMID: 18176954 DOI: 10.1002/hep.22160] [Cited by in Crossref: 513] [Cited by in F6Publishing: 500] [Article Influence: 36.6] [Reference Citation Analysis]
207 Calvisi DF, Ladu S, Gorden A, Farina M, Conner EA, Lee JS, Factor VM, Thorgeirsson SS. Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology. 2006;130:1117-1128. [PMID: 16618406 DOI: 10.1053/j.gastro.2006.01.006] [Cited by in Crossref: 499] [Cited by in F6Publishing: 450] [Article Influence: 31.2] [Reference Citation Analysis]
208 Zhang Z, Wang S, Qiu H, Duan C, Ding K, Wang Z. Waltonitone induces human hepatocellular carcinoma cells apoptosis in vitro and in vivo. Cancer Letters 2009;286:223-31. [DOI: 10.1016/j.canlet.2009.05.023] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
209 Frenette C, Gish RG. Hepatocellular carcinoma: molecular and genomic guideline for the clinician. Clin Liver Dis 2011;15:307-21, vii-x. [PMID: 21689615 DOI: 10.1016/j.cld.2011.03.010] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
210 Miao R, Luo H, Zhou H, Li G, Bu D, Yang X, Zhao X, Zhang H, Liu S, Zhong Y. Identification of prognostic biomarkers in hepatitis B virus-related hepatocellular carcinoma and stratification by integrative multi-omics analysis. J Hepatol. 2014;61:840-849. [PMID: 24859455 DOI: 10.1016/j.jhep.2014.05.025] [Cited by in Crossref: 75] [Cited by in F6Publishing: 79] [Article Influence: 9.4] [Reference Citation Analysis]
211 Mas VR, Maluf DG, Archer KJ, Yanek KC, Fisher RA. Angiogenesis soluble factors as hepatocellular carcinoma noninvasive markers for monitoring hepatitis C virus cirrhotic patients awaiting liver transplantation. Transplantation. 2007;84:1262-1271. [PMID: 18049111 DOI: 10.1097/01.tp.0000287596.91520.1a] [Cited by in Crossref: 44] [Cited by in F6Publishing: 44] [Article Influence: 2.9] [Reference Citation Analysis]
212 Luo JH, Ren B, Keryanov S, Tseng GC, Rao UN, Monga SP, Strom S, Demetris AJ, Nalesnik M, Yu YP. Transcriptomic and genomic analysis of human hepatocellular carcinomas and hepatoblastomas. Hepatology. 2006;44:1012-1024. [PMID: 17006932 DOI: 10.1002/hep.21328] [Cited by in Crossref: 200] [Cited by in F6Publishing: 216] [Article Influence: 12.5] [Reference Citation Analysis]
213 Nakanishi H, Kurosaki M, Tsuchiya K, Yasui Y, Higuchi M, Yoshida T, Komiyama Y, Takaura K, Hayashi T, Kuwabara K, Nakakuki N, Takada H, Ueda M, Tamaki N, Suzuki S, Itakura J, Takahashi Y, Izumi N. Novel Pretreatment Scoring Incorporating C-reactive Protein to Predict Overall Survival in Advanced Hepatocellular Carcinoma with Sorafenib Treatment. Liver Cancer 2016;5:257-68. [PMID: 27781198 DOI: 10.1159/000449337] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
214 Llovet JM, Villanueva A, Lachenmayer A, Finn RS. Advances in targeted therapies for hepatocellular carcinoma in the genomic era. Nat Rev Clin Oncol. 2015;12:408-424. [PMID: 26054909 DOI: 10.1038/nrclinonc.2015.103] [Cited by in Crossref: 260] [Cited by in F6Publishing: 261] [Article Influence: 37.1] [Reference Citation Analysis]
215 Zhang H, Ke J, Shao T, Li J, Duan Y, He Y, Zhang C, Chen G, Sun G, Sun X. Cytotoxic effects of procyanidins from Castanea mollissima Bl. shell on human hepatoma G2 cells in vitro. Food and Chemical Toxicology 2014;64:166-76. [DOI: 10.1016/j.fct.2013.11.026] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
216 Min S, Lee YK, Hong J, Park TJ, Woo HG, Kwon SM, Yoon G. MRPS31 loss is a key driver of mitochondrial deregulation and hepatocellular carcinoma aggressiveness. Cell Death Dis 2021;12:1076. [PMID: 34772924 DOI: 10.1038/s41419-021-04370-8] [Reference Citation Analysis]
217 Schaeffeler E, Hellerbrand C, Nies AT, Winter S, Kruck S, Hofmann U, van der Kuip H, Zanger UM, Koepsell H, Schwab M. DNA methylation is associated with downregulation of the organic cation transporter OCT1 (SLC22A1) in human hepatocellular carcinoma. Genome Med 2011;3:82. [PMID: 22196450 DOI: 10.1186/gm298] [Cited by in Crossref: 105] [Cited by in F6Publishing: 98] [Article Influence: 9.5] [Reference Citation Analysis]
218 Roskams T, Katoonizadeh A, Komuta M. Hepatic progenitor cells: an update. Clin Liver Dis. 2010;14:705-718. [PMID: 21055691 DOI: 10.1016/j.cld.2010.08.003] [Cited by in Crossref: 46] [Cited by in F6Publishing: 43] [Article Influence: 4.2] [Reference Citation Analysis]
219 Tan PS, Nakagawa S, Goossens N, Venkatesh A, Huang T, Ward SC, Sun X, Song WM, Koh A, Canasto-Chibuque C. Clinicopathological indices to predict hepatocellular carcinoma molecular classification. Liver Int. 2016;36:108-118. [PMID: 26058462 DOI: 10.1111/liv.12889] [Cited by in Crossref: 43] [Cited by in F6Publishing: 46] [Article Influence: 6.1] [Reference Citation Analysis]
220 Loaiza-Bonilla A, Furth EE, Morrissette JJ. Next-generation sequencing and personalized genomic medicine in hepatobiliary malignancies. Hepat Oncol 2015;2:359-70. [PMID: 30191018 DOI: 10.2217/hep.15.20] [Reference Citation Analysis]
221 Huang Y, Yu H, Chai C. Proteins in the ERK pathway are affected by arsenic-treated cells. Toxicol Res 2015;4:1545-54. [DOI: 10.1039/c4tx00218k] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
222 Rim CH. Differences in radiotherapy application according to regional disease characteristics of hepatocellular carcinoma. J Liver Cancer 2021;21:113-23. [DOI: 10.17998/jlc.2021.05.26] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
223 Zhao X, Parpart S, Takai A, Roessler S, Budhu A, Yu Z, Blank M, Zhang YE, Jia HL, Ye QH, Qin LX, Tang ZY, Thorgeirsson SS, Wang XW. Integrative genomics identifies YY1AP1 as an oncogenic driver in EpCAM(+) AFP(+) hepatocellular carcinoma. Oncogene. 2015;34:5095-5104. [PMID: 25597408 DOI: 10.1038/onc.2014.438] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 4.9] [Reference Citation Analysis]
224 Ko BS, Liang SM, Chang TC, Wu JY, Lee PH, Hsu YJ, Kuo CC, Liou JY, Wu KK. Association of Tumor Hydroxyindole O-Methyltransferase and Serum 5-Methoxytryptophan with Long-Term Survival of Hepatocellular Carcinoma. Cancers (Basel) 2021;13:5311. [PMID: 34771474 DOI: 10.3390/cancers13215311] [Reference Citation Analysis]
225 Wan S, Meyer AS, Weiler SME, Rupp C, Tóth M, Sticht C, Singer S, Thomann S, Roessler S, Schorpp-Kistner M, Schmitt J, Gretz N, Angel P, Tschaharganeh DF, Marquardt J, Schirmacher P, Pinna F, Breuhahn K. Cytoplasmic localization of the cell polarity factor scribble supports liver tumor formation and tumor cell invasiveness. Hepatology 2018;67:1842-56. [PMID: 29152770 DOI: 10.1002/hep.29669] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
226 Wang XW, Thorgeirsson SS. Genome-based predictors for HCC outcomes: a matter of tumor and/or stroma. J Hepatol 2009;51:596-7. [PMID: 20625453 DOI: 10.1016/j.jhep.2009.05.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
227 Tan GS, Lim KH, Tan HT, Khoo ML, Tan SH, Toh HC, Ching Ming Chung M. Novel proteomic biomarker panel for prediction of aggressive metastatic hepatocellular carcinoma relapse in surgically resectable patients. J Proteome Res. 2014;13:4833-4846. [PMID: 24946162 DOI: 10.1021/pr500229n] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 3.8] [Reference Citation Analysis]
228 Villanueva A, Chiang DY, Newell P, Peix J, Thung S, Alsinet C, Tovar V, Roayaie S, Minguez B, Sole M, Battiston C, Van Laarhoven S, Fiel MI, Di Feo A, Hoshida Y, Yea S, Toffanin S, Ramos A, Martignetti JA, Mazzaferro V, Bruix J, Waxman S, Schwartz M, Meyerson M, Friedman SL, Llovet JM. Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology. 2008;135:1972-1983, 1983.e1-1983.11. [PMID: 18929564 DOI: 10.1053/j.gastro.2008.08.008] [Cited by in Crossref: 482] [Cited by in F6Publishing: 479] [Article Influence: 34.4] [Reference Citation Analysis]
229 Thomas HE, Mercer CA, Carnevalli LS, Park J, Andersen JB, Conner EA, Tanaka K, Matsutani T, Iwanami A, Aronow BJ. mTOR inhibitors synergize on regression, reversal of gene expression, and autophagy in hepatocellular carcinoma. Sci Transl Med. 2012;4:139ra84. [PMID: 22539746 DOI: 10.1126/scitranslmed.3003923] [Cited by in Crossref: 62] [Cited by in F6Publishing: 68] [Article Influence: 6.2] [Reference Citation Analysis]
230 Chen D, Chen Y, Yan Y, Pan J, Xing W, Li Q, Zeng W. Down-regulation of the tumour suppressor κ-opioid receptor predicts poor prognosis in hepatocellular carcinoma patients. BMC Cancer 2017;17:553. [PMID: 28821282 DOI: 10.1186/s12885-017-3541-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
231 Calvisi DF, Ladu S, Gorden A, Farina M, Lee JS, Conner EA, Schroeder I, Factor VM, Thorgeirsson SS. Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma. J Clin Invest 2007;117:2713-22. [PMID: 17717605 DOI: 10.1172/JCI31457] [Cited by in Crossref: 272] [Cited by in F6Publishing: 152] [Article Influence: 18.1] [Reference Citation Analysis]
232 Shahid M, Cho KM, Nguyen MN, Choi TG, Jo YH, Aryal SN, Yoo JY, Yun HR, Lee JW, Eun YG, Lee JS, Kang I, Ha J, Yoon HJ, Kim SY, Kim SS. Prognostic value and their clinical implication of 89-gene signature in glioma. Oncotarget 2016;7:51237-50. [PMID: 27323413 DOI: 10.18632/oncotarget.9983] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
233 Lai JP, Sandhu DS, Yu C, Moser CD, Hu C, Shire AM, Aderca I, Murphy LM, Adjei AA, Sanderson S, Roberts LR. Sulfatase 2 protects hepatocellular carcinoma cells against apoptosis induced by the PI3K inhibitor LY294002 and ERK and JNK kinase inhibitors. Liver Int 2010;30:1522-8. [PMID: 21040406 DOI: 10.1111/j.1478-3231.2010.02336.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
234 Andersen JB, Loi R, Perra A, Factor VM, Ledda-Columbano GM, Columbano A, Thorgeirsson SS. Progenitor-derived hepatocellular carcinoma model in the rat. Hepatology. 2010;51:1401-1409. [PMID: 20054870 DOI: 10.1002/hep.23488] [Cited by in Crossref: 95] [Cited by in F6Publishing: 99] [Article Influence: 7.9] [Reference Citation Analysis]
235 Li Y, Jiang Z, Xu L, Yao H, Guo J, Ding X. Stability analysis of liver cancer-related microRNAs. Acta Biochim Biophys Sin (Shanghai). 2011;43:69-78. [PMID: 21173058 DOI: 10.1093/abbs/gmq114] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 2.0] [Reference Citation Analysis]
236 Roessler S, Jia HL, Budhu A, Forgues M, Ye QH, Lee JS, Thorgeirsson SS, Sun Z, Tang ZY, Qin LX, Wang XW. A unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patients. Cancer Res. 2010;70:10202-10212. [PMID: 21159642 DOI: 10.1158/0008-5472.can-10-2607] [Cited by in Crossref: 478] [Cited by in F6Publishing: 391] [Article Influence: 43.5] [Reference Citation Analysis]
237 Mann CD, Neal CP, Garcea G, Manson MM, Dennison AR, Berry DP. Prognostic molecular markers in hepatocellular carcinoma: a systematic review. Eur J Cancer. 2007;43:979-992. [PMID: 17291746 DOI: 10.1016/j.ejca.2007.01.004] [Cited by in Crossref: 171] [Cited by in F6Publishing: 156] [Article Influence: 11.4] [Reference Citation Analysis]
238 Bryant R, Laurent A, Tayar C, van Nhieu JT, Luciani A, Cherqui D. Liver resection for hepatocellular carcinoma. Surg Oncol Clin N Am 2008;17:607-33, ix. [PMID: 18486886 DOI: 10.1016/j.soc.2008.02.002] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 2.1] [Reference Citation Analysis]
239 Rutman AM, Kuo MD. Radiogenomics: creating a link between molecular diagnostics and diagnostic imaging. Eur J Radiol. 2009;70:232-241. [PMID: 19303233 DOI: 10.1016/j.ejrad.2009.01.050] [Cited by in Crossref: 174] [Cited by in F6Publishing: 146] [Article Influence: 13.4] [Reference Citation Analysis]
240 Coulouarn C, Factor VM, Conner EA, Thorgeirsson SS. Genomic modeling of tumor onset and progression in a mouse model of aggressive human liver cancer. Carcinogenesis. 2011;32:1434-1440. [PMID: 21771728 DOI: 10.1093/carcin/bgr133] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 2.7] [Reference Citation Analysis]
241 Liu YR, Wang JQ, Huang ZG, Chen RN, Cao X, Zhu DC, Yu HX, Wang XR, Zhou HY, Xia Q, Li J. Histone deacetylase‑2: A potential regulator and therapeutic target in liver disease (Review). Int J Mol Med 2021;48:131. [PMID: 34013366 DOI: 10.3892/ijmm.2021.4964] [Reference Citation Analysis]
242 Vander Borght S, Komuta M, Libbrecht L, Katoonizadeh A, Aerts R, Dymarkowski S, Verslype C, Nevens F, Roskams T. Expression of multidrug resistance-associated protein 1 in hepatocellular carcinoma is associated with a more aggressive tumour phenotype and may reflect a progenitor cell origin. Liver Int. 2008;28:1370-1380. [PMID: 19055643 DOI: 10.1111/j.1478-3231.2008.01889.x] [Cited by in Crossref: 72] [Cited by in F6Publishing: 111] [Article Influence: 5.5] [Reference Citation Analysis]
243 Abou-Alfa GK. Ramucirumab and the controversial role of α-fetoprotein in hepatocellular carcinoma. Lancet Oncol 2019;20:177-9. [PMID: 30665868 DOI: 10.1016/S1470-2045(19)30009-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
244 Minagawa T, Yamazaki K, Masugi Y, Tsujikawa H, Ojima H, Hibi T, Abe Y, Yagi H, Kitago M, Shinoda M, Itano O, Kitagawa Y, Sakamoto M. Activation of extracellular signal‐regulated kinase is associated with hepatocellular carcinoma with aggressive phenotypes. Hepatol Res 2020;50:353-64. [DOI: 10.1111/hepr.13445] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
245 Kim BY, Choi DW, Woo SR, Park ER, Lee JG, Kim SH, Koo I, Park SH, Han CJ, Kim SB, Yeom YI, Yang SJ, Yu A, Lee JW, Jang JJ, Cho MH, Jeon WK, Park YN, Suh KS, Lee KH. Recurrence-associated pathways in hepatitis B virus-positive hepatocellular carcinoma. BMC Genomics 2015;16:279. [PMID: 25888140 DOI: 10.1186/s12864-015-1472-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
246 Fakhri B, Lim KH. Molecular landscape and sub-classification of gastrointestinal cancers: a review of literature. J Gastrointest Oncol. 2017;8:379-386. [PMID: 28736626 DOI: 10.21037/jgo.2016.11.01] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
247 Calvisi DF, Wang C, Ho C, Ladu S, Lee SA, Mattu S, Destefanis G, Delogu S, Zimmermann A, Ericsson J, Brozzetti S, Staniscia T, Chen X, Dombrowski F, Evert M. Increased lipogenesis, induced by AKT-mTORC1-RPS6 signaling, promotes development of human hepatocellular carcinoma. Gastroenterology 2011;140:1071-83. [PMID: 21147110 DOI: 10.1053/j.gastro.2010.12.006] [Cited by in Crossref: 311] [Cited by in F6Publishing: 306] [Article Influence: 25.9] [Reference Citation Analysis]
248 Di Giacomo S, Briz O, Monte MJ, Sanchez-Vicente L, Abete L, Lozano E, Mazzanti G, Di Sotto A, Marin JJG. Chemosensitization of hepatocellular carcinoma cells to sorafenib by β-caryophyllene oxide-induced inhibition of ABC export pumps. Arch Toxicol 2019;93:623-34. [PMID: 30659321 DOI: 10.1007/s00204-019-02395-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
249 Coulouarn C, Factor VM, Thorgeirsson SS. Transforming growth factor-beta gene expression signature in mouse hepatocytes predicts clinical outcome in human cancer. Hepatology. 2008;47:2059-2067. [PMID: 18506891 DOI: 10.1002/hep.22283] [Cited by in Crossref: 227] [Cited by in F6Publishing: 228] [Article Influence: 16.2] [Reference Citation Analysis]
250 Zhang F, Kuo MD. Rapid Evolution of Expression Levels in Hepatocellular Carcinoma. Int J Comput Biol Drug Des 2020;13:454-74. [PMID: 34552665 DOI: 10.1504/ijcbdd.2020.10036395] [Reference Citation Analysis]
251 Barry CT, D'Souza M, McCall M, Safadjou S, Ryan C, Kashyap R, Marroquin C, Orloff M, Almudevar A, Godfrey TE. Micro RNA expression profiles as adjunctive data to assess the risk of hepatocellular carcinoma recurrence after liver transplantation. Am J Transplant. 2012;12:428-437. [PMID: 22008552 DOI: 10.1111/j.1600-6143.2011.03788.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 3.5] [Reference Citation Analysis]
252 King CE, Cuatrecasas M, Castells A, Sepulveda AR, Lee JS, Rustgi AK. LIN28B promotes colon cancer progression and metastasis. Cancer Res. 2011;71:4260-4268. [PMID: 21512136 DOI: 10.1158/0008-5472.can-10-4637] [Cited by in Crossref: 159] [Cited by in F6Publishing: 128] [Article Influence: 14.5] [Reference Citation Analysis]
253 Ferrell LD, Kakar S, Terracciano LM, Wee A. Tumours and Tumour-like Lesions of the Liver. Macsween's Pathology of the Liver. Elsevier; 2018. pp. 780-879. [DOI: 10.1016/b978-0-7020-6697-9.00013-3] [Cited by in Crossref: 5] [Article Influence: 1.3] [Reference Citation Analysis]
254 Nault JC. Molecular Determinants of Prognosis in Hepatocellular Carcinoma. J Clin Transl Hepatol 2014;2:31-6. [PMID: 26357615 DOI: 10.14218/JCTH.2013.00029] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
255 Bu X, Ma L, Liu S, Wen D, Kan A, Xu Y, Lin X, Shi M. A novel qualitative signature based on lncRNA pairs for prognosis prediction in hepatocellular carcinoma. Cancer Cell Int 2022;22:95. [PMID: 35193591 DOI: 10.1186/s12935-022-02507-z] [Reference Citation Analysis]
256 Lee SA, Ladu S, Evert M, Dombrowski F, De Murtas V, Chen X, Calvisi DF. Synergistic role of Sprouty2 inactivation and c-Met up-regulation in mouse and human hepatocarcinogenesis. Hepatology 2010;52:506-17. [PMID: 20683950 DOI: 10.1002/hep.23681] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 3.7] [Reference Citation Analysis]
257 van Malenstein H, van Pelt J, Verslype C. Molecular classification of hepatocellular carcinoma anno 2011. Eur J Cancer. 2011;47:1789-1797. [PMID: 21612914 DOI: 10.1016/j.ejca.2011.04.027] [Cited by in Crossref: 56] [Cited by in F6Publishing: 51] [Article Influence: 5.1] [Reference Citation Analysis]
258 Marquardt JU, Quasdorff M, Varnholt H, Curth HM, Mesghenna S, Protzer U, Goeser T, Nierhoff D. Neighbor of Punc E11, a novel oncofetal marker for hepatocellular carcinoma. Int J Cancer. 2011;128:2353-2363. [PMID: 20658536 DOI: 10.1002/ijc.25567] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
259 Shin MK, Kim J, Kim D, Lee SH, Shin JH, Jeong YS, Sohn BH, Kim J, Kim SR, Ajani JA, Lee JS, Cheong JH. Long non-coding RNAs are significantly associated with prognosis and response to therapies in gastric cancer. Clin Transl Med 2021;11:e421. [PMID: 34185430 DOI: 10.1002/ctm2.421] [Reference Citation Analysis]
260 Potikha T, Stoyanov E, Pappo O, Frolov A, Mizrahi L, Olam D, Shnitzer-Perlman T, Weiss I, Barashi N, Peled A. Interstrain differences in chronic hepatitis and tumor development in a murine model of inflammation-mediated hepatocarcinogenesis. Hepatology. 2013;58:192-204. [PMID: 23423643 DOI: 10.1002/hep.26335] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 3.1] [Reference Citation Analysis]
261 Gillet JP, Gottesman MM. Advances in the molecular detection of ABC transporters involved in multidrug resistance in cancer. Curr Pharm Biotechnol 2011;12:686-92. [PMID: 21118086 DOI: 10.2174/138920111795163931] [Cited by in Crossref: 49] [Cited by in F6Publishing: 45] [Article Influence: 4.5] [Reference Citation Analysis]
262 Iizuka N, Hamamoto Y, Tsunedomi R, Oka M. Translational microarray systems for outcome prediction of hepatocellular carcinoma. Cancer Science 2008;99:659-65. [DOI: 10.1111/j.1349-7006.2008.00751.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
263 Sato F, Hatano E, Kitamura K, Myomoto A, Fujiwara T, Takizawa S, Tsuchiya S, Tsujimoto G, Uemoto S, Shimizu K. MicroRNA profile predicts recurrence after resection in patients with hepatocellular carcinoma within the Milan Criteria. PLoS One. 2011;6:e16435. [PMID: 21298008 DOI: 10.1371/journal.pone.0016435] [Cited by in Crossref: 90] [Cited by in F6Publishing: 83] [Article Influence: 8.2] [Reference Citation Analysis]
264 Marsh JW, Finkelstein SD, Schwartz ME, Fiel MI, Dvorchik I. Advancing the diagnosis and treatment of hepatocellular carcinoma. Liver Transpl 2005;11:469-72. [DOI: 10.1002/lt.20372] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
265 Song GW, Hwang S, Lee SG. [Liver transplantation in patients with hepatocellular carcinoma]. Korean J Gastroenterol. 2010;55:350-360. [PMID: 20571302 DOI: 10.4166/kjg.2010.55.6.350] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
266 Sun N, Lee YT, Kim M, Wang JJ, Zhang C, Teng PC, Qi D, Zhang RY, Tran BV, Lee YT, Ye J, Palomique J, Nissen NN, Han SB, Sadeghi S, Finn RS, Saab S, Busuttil RW, Posadas EM, Liang L, Pei R, Yang JD, You S, Agopian VG, Tseng HR, Zhu Y. Covalent Chemistry-Mediated Multimarker Purification of Circulating Tumor Cells Enables Noninvasive Detection of Molecular Signatures of Hepatocellular Carcinoma. Adv Mater Technol 2021;6:2001056. [PMID: 34212072 DOI: 10.1002/admt.202001056] [Reference Citation Analysis]
267 Iizuka N, Hamamoto Y, Oka M. Predicting individual outcomes in hepatocellular carcinoma. Lancet 2004;364:1837-9. [PMID: 15555651 DOI: 10.1016/S0140-6736(04)17455-2] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
268 Seitz SJ, Schleithoff ES, Koch A, Schuster A, Teufel A, Staib F, Stremmel W, Melino G, Krammer PH, Schilling T, Müller M. Chemotherapy-induced apoptosis in hepatocellular carcinoma involves the p53 family and is mediated via the extrinsic and the intrinsic pathway. Int J Cancer 2010;126:2049-66. [PMID: 19711344 DOI: 10.1002/ijc.24861] [Cited by in Crossref: 6] [Cited by in F6Publishing: 39] [Article Influence: 0.5] [Reference Citation Analysis]
269 Marquardt JU, Factor VM, Thorgeirsson SS. Epigenetic regulation of cancer stem cells in liver cancer: current concepts and clinical implications. J Hepatol 2010;53:568-77. [PMID: 20646772 DOI: 10.1016/j.jhep.2010.05.003] [Cited by in Crossref: 66] [Cited by in F6Publishing: 64] [Article Influence: 5.5] [Reference Citation Analysis]
270 Maass T, Sfakianakis I, Staib F, Krupp M, Galle PR, Teufel A. Microarray-based gene expression analysis of hepatocellular carcinoma. Curr Genomics. 2010;11:261-268. [PMID: 21119890 DOI: 10.2174/138920210791233063] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 1.9] [Reference Citation Analysis]
271 Yim SY, Shim JJ, Shin JH, Jeong YS, Kang SH, Kim SB, Eun YG, Lee DJ, Conner EA, Factor VM, Moore DD, Johnson RL, Thorgeirsson SS, Lee JS. Integrated Genomic Comparison of Mouse Models Reveals Their Clinical Resemblance to Human Liver Cancer. Mol Cancer Res. 2018;16:1713-1723. [PMID: 30082483 DOI: 10.1158/1541-7786.mcr-18-0313] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
272 Calderaro J, Ziol M, Paradis V, Zucman-rossi J. Molecular and histological correlations in liver cancer. Journal of Hepatology 2019;71:616-30. [DOI: 10.1016/j.jhep.2019.06.001] [Cited by in Crossref: 74] [Cited by in F6Publishing: 73] [Article Influence: 24.7] [Reference Citation Analysis]
273 Schwartz M, Dvorchik I, Roayaie S, Fiel MI, Finkelstein S, Marsh JW, Martignetti JA, Llovet JM. Liver transplantation for hepatocellular carcinoma: extension of indications based on molecular markers. J Hepatol. 2008;49:581-588. [PMID: 18602719 DOI: 10.1016/j.jhep.2008.03.032] [Cited by in Crossref: 62] [Cited by in F6Publishing: 62] [Article Influence: 4.4] [Reference Citation Analysis]
274 Yoshida Y, Wang IC, Yoder HM, Davidson NO, Costa RH. The forkhead box M1 transcription factor contributes to the development and growth of mouse colorectal cancer. Gastroenterology. 2007;132:1420-1431. [PMID: 17408638 DOI: 10.1053/j.gastro.2007.01.036] [Cited by in Crossref: 107] [Cited by in F6Publishing: 357] [Article Influence: 7.1] [Reference Citation Analysis]
275 Wang C, Cao Y, Yang C, Bernards R, Qin W. Exploring liver cancer biology through functional genetic screens. Nat Rev Gastroenterol Hepatol 2021. [PMID: 34163045 DOI: 10.1038/s41575-021-00465-x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
276 Kim J, Hong SJ, Park JY, Park JH, Yu Y, Park SY, Lim EK, Choi KY, Lee EK, Paik SS, Lee KG, Wang HJ, Do I, Joh J, Kim DS; on behalf of the Korea Cancer Biomarker Consortium. Epithelial-mesenchymal transition gene signature to predict clinical outcome of hepatocellular carcinoma. Cancer Science 2010;101:1521-8. [DOI: 10.1111/j.1349-7006.2010.01536.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 2.6] [Reference Citation Analysis]
277 Wang WH, Studach LL, Andrisani OM. Proteins ZNF198 and SUZ12 are down-regulated in hepatitis B virus (HBV) X protein-mediated hepatocyte transformation and in HBV replication. Hepatology. 2011;53:1137-1147. [PMID: 21480320 DOI: 10.1002/hep.24163] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 3.6] [Reference Citation Analysis]
278 Tornesello ML, Buonaguro L, Tatangelo F, Botti G, Izzo F, Buonaguro FM. Mutations in TP53, CTNNB1 and PIK3CA genes in hepatocellular carcinoma associated with hepatitis B and hepatitis C virus infections. Genomics. 2013;102:74-83. [PMID: 23583669 DOI: 10.1016/j.ygeno.2013.04.001] [Cited by in Crossref: 89] [Cited by in F6Publishing: 83] [Article Influence: 9.9] [Reference Citation Analysis]
279 Levrero M. Viral hepatitis and liver cancer: the case of hepatitis C. Oncogene 2006;25:3834-47. [DOI: 10.1038/sj.onc.1209562] [Cited by in Crossref: 278] [Cited by in F6Publishing: 265] [Article Influence: 17.4] [Reference Citation Analysis]
280 Wörns MA, Galle PR. Future perspectives in hepatocellular carcinoma. Dig Liver Dis. 2010;42 Suppl 3:S302-S309. [PMID: 20547319 DOI: 10.1016/S1590-8658(10)60521-X] [Cited by in Crossref: 45] [Cited by in F6Publishing: 26] [Article Influence: 3.8] [Reference Citation Analysis]
281 Hamilton JP. Epigenetic mechanisms involved in the pathogenesis of hepatobiliary malignancies. Epigenomics 2010;2:233-43. [PMID: 20556199 DOI: 10.2217/epi.10.9] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
282 Mandruzzato S, Callegaro A, Turcatel G, Francescato S, Montesco MC, Chiarion-Sileni V, Mocellin S, Rossi CR, Bicciato S, Wang E, Marincola FM, Zanovello P. A gene expression signature associated with survival in metastatic melanoma. J Transl Med 2006;4:50. [PMID: 17129373 DOI: 10.1186/1479-5876-4-50] [Cited by in Crossref: 79] [Cited by in F6Publishing: 64] [Article Influence: 4.9] [Reference Citation Analysis]
283 Gao Q, Zhu H, Dong L, Shi W, Chen R, Song Z, Huang C, Li J, Dong X, Zhou Y, Liu Q, Ma L, Wang X, Zhou J, Liu Y, Boja E, Robles AI, Ma W, Wang P, Li Y, Ding L, Wen B, Zhang B, Rodriguez H, Gao D, Zhou H, Fan J. Integrated Proteogenomic Characterization of HBV-Related Hepatocellular Carcinoma. Cell 2019; 179: 561-577. e22. [PMID: 31585088 DOI: 10.1016/j.cell.2019.08.052] [Cited by in Crossref: 134] [Cited by in F6Publishing: 135] [Article Influence: 67.0] [Reference Citation Analysis]
284 Thorgeirsson SS, Lee JS, Grisham JW. Molecular prognostication of liver cancer: end of the beginning. J Hepatol. 2006;44:798-805. [PMID: 16488507 DOI: 10.1016/j.jhep.2006.01.008] [Cited by in Crossref: 47] [Cited by in F6Publishing: 42] [Article Influence: 2.9] [Reference Citation Analysis]
285 Li W, Lu J, Ma Z, Zhao J, Liu J. An Integrated Model Based on a Six-Gene Signature Predicts Overall Survival in Patients With Hepatocellular Carcinoma. Front Genet 2019;10:1323. [PMID: 32010188 DOI: 10.3389/fgene.2019.01323] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 8.5] [Reference Citation Analysis]
286 Chen X, Zhu X, Wei Z, Lv Q. Identification and Differential Expression of microRNA in Response to Elevated Phospholipase Cγ Expression in Liver RH 35 Carcinoma Cells. Cytol Genet 2020;54:555-65. [DOI: 10.3103/s009545272006002x] [Reference Citation Analysis]
287 Hoshida Y, Moeini A, Alsinet C, Kojima K, Villanueva A. Gene Signatures in the Management of Hepatocellular Carcinoma. Seminars in Oncology 2012;39:473-85. [DOI: 10.1053/j.seminoncol.2012.05.003] [Cited by in Crossref: 44] [Cited by in F6Publishing: 44] [Article Influence: 4.4] [Reference Citation Analysis]
288 Menrad H, Werno C, Schmid T, Copanaki E, Deller T, Dehne N, Brüne B. Roles of hypoxia-inducible factor-1alpha (HIF-1alpha) versus HIF-2alpha in the survival of hepatocellular tumor spheroids. Hepatology 2010;51:2183-92. [PMID: 20513003 DOI: 10.1002/hep.23597] [Cited by in Crossref: 80] [Cited by in F6Publishing: 81] [Article Influence: 6.7] [Reference Citation Analysis]
289 Li S, Saviano A, Erstad DJ, Hoshida Y, Fuchs BC, Baumert T, Tanabe KK. Risk Factors, Pathogenesis, and Strategies for Hepatocellular Carcinoma Prevention: Emphasis on Secondary Prevention and Its Translational Challenges. J Clin Med 2020;9:E3817. [PMID: 33255794 DOI: 10.3390/jcm9123817] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
290 Ji F, Zhang Y, Zhu ZB, Guo Y, Shen SL, Cao QH, Li SQ, Peng BG, Liang LJ, Hua YP. Low levels of glycoprotein 96 indicate a worse prognosis in early-stage hepatocellular carcinoma patients after hepatectomy. Hum Pathol 2019;86:193-202. [PMID: 30529751 DOI: 10.1016/j.humpath.2018.11.025] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
291 Duffy A, Greten T. Developing better treatments in hepatocellular carcinoma. Expert Review of Gastroenterology & Hepatology 2014;4:551-60. [DOI: 10.1586/egh.10.58] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
292 Zhu GQ, Yang Y, Chen EB, Wang B, Xiao K, Shi SM, Zhou ZJ, Zhou SL, Wang Z, Shi YH, Fan J, Zhou J, Liu TS, Dai Z. Development and validation of a new tumor-based gene signature predicting prognosis of HBV/HCV-included resected hepatocellular carcinoma patients. J Transl Med 2019;17:203. [PMID: 31215439 DOI: 10.1186/s12967-019-1946-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
293 Lee JS, Thorgeirsson SS. Comparative and integrative functional genomics of HCC. Oncogene 2006;25:3801-9. [PMID: 16799621 DOI: 10.1038/sj.onc.1209561] [Cited by in Crossref: 78] [Cited by in F6Publishing: 81] [Article Influence: 4.9] [Reference Citation Analysis]
294 Lee JS, Kim JH, Park YY, Mills GB. Systems biology approaches to decoding the genome of liver cancer. Cancer Res Treat 2011;43:205-11. [PMID: 22247704 DOI: 10.4143/crt.2011.43.4.205] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
295 Ahn KS, O'Brien DR, Kim YH, Kim TS, Yamada H, Park JW, Park SJ, Kim SH, Zhang C, Li H, Kang KJ, Roberts LR. Associations of Serum Tumor Biomarkers with Integrated Genomic and Clinical Characteristics of Hepatocellular Carcinoma. Liver Cancer 2021;10:593-605. [PMID: 34950182 DOI: 10.1159/000516957] [Reference Citation Analysis]
296 Fouquet G, Debuysscher V, Ouled-Haddou H, Eugenio MS, Demey B, Singh AR, Ossart C, Al Bagami M, Regimbeau JM, Nguyen-Khac E, Naassila M, Marcq I, Bouhlal H. Hepatocyte SLAMF3 reduced specifically the multidrugs resistance protein MRP-1 and increases HCC cells sensitization to anti-cancer drugs. Oncotarget 2016;7:32493-503. [PMID: 27081035 DOI: 10.18632/oncotarget.8679] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
297 Marrero JA. Hepatocellular carcinoma: . Current Opinion in Gastroenterology 2005;21:308-12. [DOI: 10.1097/01.mog.0000159817.55661.ca] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 1.5] [Reference Citation Analysis]
298 Narla G, Kremer-Tal S, Matsumoto N, Zhao X, Yao S, Kelley K, Tarocchi M, Friedman SL. In vivo regulation of p21 by the Kruppel-like factor 6 tumor-suppressor gene in mouse liver and human hepatocellular carcinoma. Oncogene. 2007;26:4428-4434. [PMID: 17297474 DOI: 10.1038/sj.onc.1210223] [Cited by in Crossref: 53] [Cited by in F6Publishing: 57] [Article Influence: 3.5] [Reference Citation Analysis]
299 Forner A, Ayuso C, Isabel Real M, Sastre J, Robles R, Sangro B, Varela M, de la Mata M, Buti M, Martí-Bonmatí L, Bru C, Tabernero J, Llovet JM, Bruix J. [Diagnosis and treatment of hepatocellular carcinoma]. Med Clin (Barc) 2009;132:272-87. [PMID: 19248879 DOI: 10.1016/j.medcli.2008.11.024] [Cited by in Crossref: 56] [Cited by in F6Publishing: 39] [Article Influence: 4.3] [Reference Citation Analysis]
300 Marquardt JU, Thorgeirsson SS. Stem cells in hepatocarcinogenesis: evidence from genomic data. Semin Liver Dis. 2010;30:26-34. [PMID: 20175031 DOI: 10.1055/s-0030-1247130] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 3.1] [Reference Citation Analysis]
301 Cillo C, Schiavo G, Cantile M, Bihl MP, Sorrentino P, Carafa V, D’ Armiento M, Roncalli M, Sansano S, Vecchione R. The HOX gene network in hepatocellular carcinoma. Int J Cancer. 2011;129:2577-2587. [PMID: 21626505 DOI: 10.1002/ijc.25941] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 4.3] [Reference Citation Analysis]
302 Zhang H, Zhu C, Zhao Y, Li M, Wu L, Yang X, Wan X, Wang A, Zhang MQ, Sang X, Zhao H. Long non-coding RNA expression profiles of hepatitis C virus-related dysplasia and hepatocellular carcinoma. Oncotarget 2015;6:43770-8. [PMID: 26540467 DOI: 10.18632/oncotarget.6087] [Cited by in Crossref: 46] [Cited by in F6Publishing: 44] [Article Influence: 7.7] [Reference Citation Analysis]
303 Hoshida Y, Nijman SM, Kobayashi M, Chan JA, Brunet JP, Chiang DY, Villanueva A, Newell P, Ikeda K, Hashimoto M, Watanabe G, Gabriel S, Friedman SL, Kumada H, Llovet JM, Golub TR. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res. 2009;69:7385-7392. [PMID: 19723656 DOI: 10.1158/0008-5472.can-09-1089] [Cited by in Crossref: 619] [Cited by in F6Publishing: 399] [Article Influence: 47.6] [Reference Citation Analysis]
304 Li J, Tao H, Wang W, Li J, Zhang E, Wang F. The Detection and Verification of Two Heterogeneous Subgroups and a Risk Model Based on Ferroptosis-Related Genes in Hepatocellular Carcinoma. Journal of Oncology 2022;2022:1-17. [DOI: 10.1155/2022/1182383] [Reference Citation Analysis]
305 Varghese S, Chen Z, Bartlett DL, Pingpank JF, Libutti SK, Steinberg SM, Wunderlich J, Alexander HR. Activation of the phosphoinositide-3-kinase and mammalian target of rapamycin signaling pathways are associated with shortened survival in patients with malignant peritoneal mesothelioma. Cancer. 2011;117:361-371. [PMID: 20839315 DOI: 10.1002/cncr.25555] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 3.1] [Reference Citation Analysis]
306 Pascale RM, Simile MM, Peitta G, Seddaiu MA, Feo F, Calvisi DF. Experimental Models to Define the Genetic Predisposition to Liver Cancer. Cancers (Basel) 2019;11:E1450. [PMID: 31569678 DOI: 10.3390/cancers11101450] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
307 Lai Q, Melandro F, Pinheiro RS, Donfrancesco A, Fadel BA, Levi Sandri GB, Rossi M, Berloco PB, Frattaroli FM. Alpha-fetoprotein and novel tumor biomarkers as predictors of hepatocellular carcinoma recurrence after surgery: a brilliant star raises again. Int J Hepatol. 2012;2012:893103. [PMID: 22792474 DOI: 10.1155/2012/893103] [Cited by in Crossref: 23] [Cited by in F6Publishing: 30] [Article Influence: 2.3] [Reference Citation Analysis]
308 Oh CR, Kong SY, Im HS, Kim HJ, Kim MK, Yoon KA, Cho EH, Jang JH, Lee J, Kang J, Park SR, Ryoo BY. Genome-wide copy number alteration and VEGFA amplification of circulating cell-free DNA as a biomarker in advanced hepatocellular carcinoma patients treated with Sorafenib. BMC Cancer 2019;19:292. [PMID: 30935424 DOI: 10.1186/s12885-019-5483-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 5.7] [Reference Citation Analysis]
309 Mo YY, Moschos SJ. Targeting Ubc9 for cancer therapy. Expert Opin Ther Targets 2005;9:1203-16. [PMID: 16300471 DOI: 10.1517/14728222.9.6.1203] [Cited by in Crossref: 65] [Cited by in F6Publishing: 62] [Article Influence: 4.1] [Reference Citation Analysis]
310 Davídsdóttir L, Duberg AS, Törner A, Aleman S, Bäck E, Ekdahl K, Blaxhult A, Ekbom A, Hultcrantz R. Hepatocellular carcinoma in individuals with HBV infection or HBV-HCV co-infection in a low endemic country. Scand J Gastroenterol 2010;45:944-52. [PMID: 20384529 DOI: 10.3109/00365521003770251] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
311 Nault JC, Galle PR, Marquardt JU. The role of molecular enrichment on future therapies in hepatocellular carcinoma. J Hepatol. 2018;69:237-247. [PMID: 29505843 DOI: 10.1016/j.jhep.2018.02.016] [Cited by in Crossref: 50] [Cited by in F6Publishing: 52] [Article Influence: 12.5] [Reference Citation Analysis]
312 [DOI: 10.1101/540005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
313 Felipe-Silva A, Wakamatsu A, dos Santos Cirqueira C, Alves VAF. Immunohistochemistry panel segregates molecular types of hepatocellular carcinoma in Brazilian autopsy cases. World J Gastroenterol 2016; 22(27): 6246-6256 [PMID: 27468214 DOI: 10.3748/wjg.v22.i27.6246] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
314 Schaff Z, Kovalszky I, Lotz G, Kiss A. Hepatocellular carcinoma – from macroscopy to molecular pathology. Orvosi Hetilap 2010;151:982-9. [DOI: 10.1556/oh.2010.28875] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
315 Benhenda S, Cougot D, Neuveut C, Buendia MA. Liver cell transformation in chronic HBV infection. Viruses 2009;1:630-46. [PMID: 21994562 DOI: 10.3390/v1030630] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
316 Akiba J, Murakami Y, Noda M, Watari K, Ogasawara S, Yoshida T, Kawahara A, Sanada S, Yasumoto M, Yamaguchi R, Kage M, Kuwano M, Ono M, Yano H. N-myc downstream regulated gene1/Cap43 overexpression suppresses tumor growth by hepatic cancer cells through cell cycle arrest at the G0/G1 phase. Cancer Lett 2011;310:25-34. [PMID: 21775055 DOI: 10.1016/j.canlet.2011.05.034] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
317 Vásquez-Garzón VR, Macias-Pérez JR, Jiménez-García MN, Villegas V, Fattel-Fazenta S, Villa-Treviño S. The chemopreventive capacity of quercetin to induce programmed cell death in hepatocarcinogenesis. Toxicol Pathol 2013;41:857-65. [PMID: 23197198 DOI: 10.1177/0192623312467522] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
318 Samdanci ET, Akatli AN, Soylu NK. Clinicopathological Features of Two Extremely Rare Hepatocellular Carcinoma Variants: a Brief Review of Fibrolamellar and Scirrhous Hepatocellular Carcinoma. J Gastrointest Cancer 2020;51:1187-92. [PMID: 32860202 DOI: 10.1007/s12029-020-00500-1] [Reference Citation Analysis]
319 Ji J, Wang XW. Clinical implications of cancer stem cell biology in hepatocellular carcinoma. Semin Oncol. 2012;39:461-472. [PMID: 22846863 DOI: 10.1053/j.seminoncol.2012.05.011] [Cited by in Crossref: 135] [Cited by in F6Publishing: 131] [Article Influence: 13.5] [Reference Citation Analysis]
320 Varghese S, Burness M, Xu H, Beresnev T, Pingpank J, Alexander HR. Site-specific gene expression profiles and novel molecular prognostic factors in patients with lower gastrointestinal adenocarcinoma diffusely metastatic to liver or peritoneum. Ann Surg Oncol. 2007;14:3460-3471. [PMID: 17899288 DOI: 10.1245/s10434-007-9557-7] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 2.7] [Reference Citation Analysis]
321 Dufour JF, Johnson P. Liver cancer: from molecular pathogenesis to new therapies: summary of the EASL single topic conference. J Hepatol 2010;52:296-304. [PMID: 20006399 DOI: 10.1016/j.jhep.2009.11.010] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 2.2] [Reference Citation Analysis]
322 Setayesh T, Colquhoun SD, Wan YY. Overexpression of Galectin-1 and Galectin-3 in hepatocellular carcinoma. Liver Res 2020;4:173-9. [PMID: 34567824 DOI: 10.1016/j.livres.2020.11.001] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
323 Santamaría E, Muñoz J, Fernández-irigoyen J, Prìeto J, Corrales FJ. Toward the discovery of new biomarkers of hepatocellular carcinoma by proteomics. Liver Int 2007;27:163-73. [DOI: 10.1111/j.1478-3231.2007.01447.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 2.3] [Reference Citation Analysis]
324 Dominguez DA, Wang XW. Impact of Next-Generation Sequencing on Outcomes in Hepatocellular Carcinoma: How Precise Are We Really? J Hepatocell Carcinoma 2020;7:33-7. [PMID: 32257970 DOI: 10.2147/JHC.S217948] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
325 Malz M, Pinna F, Schirmacher P, Breuhahn K. Transcriptional regulators in hepatocarcinogenesis--key integrators of malignant transformation. J Hepatol 2012;57:186-95. [PMID: 22446689 DOI: 10.1016/j.jhep.2011.11.029] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
326 Quiles-Perez R, Muñoz-Gámez JA, Ruiz-Extremera A, O'Valle F, Sanjuán-Nuñez L, Martín-Alvarez AB, Martín-Oliva D, Caballero T, Muñoz de Rueda P, León J, Gonzalez R, Muntané J, Oliver FJ, Salmerón J. Inhibition of poly adenosine diphosphate-ribose polymerase decreases hepatocellular carcinoma growth by modulation of tumor-related gene expression. Hepatology 2010;51:255-66. [PMID: 20034026 DOI: 10.1002/hep.23249] [Cited by in Crossref: 48] [Cited by in F6Publishing: 48] [Article Influence: 4.0] [Reference Citation Analysis]
327 Marquardt JU, Edlich F. Predisposition to Apoptosis in Hepatocellular Carcinoma: From Mechanistic Insights to Therapeutic Strategies. Front Oncol 2019;9:1421. [PMID: 31921676 DOI: 10.3389/fonc.2019.01421] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
328 Martinez-quetglas I, Pinyol R, Dauch D, Torrecilla S, Tovar V, Moeini A, Alsinet C, Portela A, Rodriguez-carunchio L, Solé M, Lujambio A, Villanueva A, Thung S, Esteller M, Zender L, Llovet JM. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models. Gastroenterology 2016;151:1192-205. [DOI: 10.1053/j.gastro.2016.09.001] [Cited by in Crossref: 62] [Cited by in F6Publishing: 57] [Article Influence: 10.3] [Reference Citation Analysis]
329 Zucman-rossi J, Villanueva A, Nault J, Llovet JM. Genetic Landscape and Biomarkers of Hepatocellular Carcinoma. Gastroenterology 2015;149:1226-1239.e4. [DOI: 10.1053/j.gastro.2015.05.061] [Cited by in Crossref: 531] [Cited by in F6Publishing: 530] [Article Influence: 75.9] [Reference Citation Analysis]
330 Quetglas IM, Moeini A, Pinyol R, Llovet JM. Integration of genomic information in the clinical management of HCC. Best Pract Res Clin Gastroenterol 2014;28:831-42. [PMID: 25260311 DOI: 10.1016/j.bpg.2014.08.004] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
331 Cabibbo G, Craxì A. Needle track seeding following percutaneous procedures for hepatocellular carcinoma. World J Hepatol 2009; 1(1): 62-66 [PMID: 21160966 DOI: 10.4254/wjh.v1.i1.62] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
332 Suresh M, Menne S. Application of the woodchuck animal model for the treatment of hepatitis B virus-induced liver cancer. World J Gastrointest Oncol 2021; 13(6): 509-535 [PMID: 34163570 DOI: 10.4251/wjgo.v13.i6.509] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
333 Chen F, Beezhold K, Castranova V. JNK1, a potential therapeutic target for hepatocellular carcinoma. Biochim Biophys Acta 2009;1796:242-51. [PMID: 19591900 DOI: 10.1016/j.bbcan.2009.06.005] [Cited by in Crossref: 9] [Cited by in F6Publishing: 16] [Article Influence: 0.7] [Reference Citation Analysis]
334 Oh SC, Park YY, Park ES, Lim JY, Kim SM, Kim SB, Kim J, Kim SC, Chu IS, Smith JJ, Beauchamp RD, Yeatman TJ, Kopetz S, Lee JS. Prognostic gene expression signature associated with two molecularly distinct subtypes of colorectal cancer. Gut 2012;61:1291-8. [PMID: 21997556 DOI: 10.1136/gutjnl-2011-300812] [Cited by in Crossref: 61] [Cited by in F6Publishing: 58] [Article Influence: 5.5] [Reference Citation Analysis]
335 Koufaris C, Kirmizis A. Identification of NAA40 as a Potential Prognostic Marker for Aggressive Liver Cancer Subtypes. Front Oncol 2021;11:691950. [PMID: 34150665 DOI: 10.3389/fonc.2021.691950] [Reference Citation Analysis]
336 Désert R, Nieto N, Musso O. Dimensions of hepatocellular carcinoma phenotypic diversity. World J Gastroenterol 2018; 24(40): 4536-4547 [PMID: 30386103 DOI: 10.3748/wjg.v24.i40.4536] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
337 Locker J. A new way to look at liver cancer. Hepatology. 2004;40:521-523. [PMID: 15349888 DOI: 10.1002/hep.20368] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
338 Shah SA, Tan JC, McGilvray ID, Cattral MS, Levy GA, Greig PD, Grant DR. Does microvascular invasion affect outcomes after liver transplantation for HCC? A histopathological analysis of 155 consecutive explants. J Gastrointest Surg 2007;11:464-71. [PMID: 17436131 DOI: 10.1007/s11605-006-0033-7] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 2.7] [Reference Citation Analysis]
339 Ao L, Song X, Li X, Tong M, Guo Y, Li J, Li H, Cai H, Li M, Guan Q, Yan H, Guo Z. An individualized prognostic signature and multi‑omics distinction for early stage hepatocellular carcinoma patients with surgical resection. Oncotarget 2016;7:24097-110. [PMID: 27006471 DOI: 10.18632/oncotarget.8212] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 6.3] [Reference Citation Analysis]
340 Lim HC, Gordan JD. Tumor hepatitis B virus RNA identifies a clinically and molecularly distinct subset of hepatocellular carcinoma. PLoS Comput Biol 2021;17:e1008699. [PMID: 33561166 DOI: 10.1371/journal.pcbi.1008699] [Reference Citation Analysis]
341 Fa B, Luo C, Tang Z, Yan Y, Zhang Y, Yu Z. Pathway-based biomarker identification with crosstalk analysis for robust prognosis prediction in hepatocellular carcinoma. EBioMedicine. 2019;44:250-260. [PMID: 31101593 DOI: 10.1016/j.ebiom.2019.05.010] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
342 Chen L, Zhang Q, Chang W, Du Y, Zhang H, Cao G. Viral and host inflammation-related factors that can predict the prognosis of hepatocellular carcinoma. European Journal of Cancer 2012;48:1977-87. [DOI: 10.1016/j.ejca.2012.01.015] [Cited by in Crossref: 64] [Cited by in F6Publishing: 71] [Article Influence: 6.4] [Reference Citation Analysis]
343 Moeini A, Sia D, Zhang Z, Camprecios G, Stueck A, Dong H, Montal R, Torrens L, Martinez-Quetglas I, Fiel MI, Hao K, Villanueva A, Thung SN, Schwartz ME, Llovet JM. Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct molecular entity. J Hepatol 2017;66:952-61. [PMID: 28126467 DOI: 10.1016/j.jhep.2017.01.010] [Cited by in Crossref: 70] [Cited by in F6Publishing: 60] [Article Influence: 14.0] [Reference Citation Analysis]
344 Rodrigues RR, Barry CT. Gene pathway analysis of hepatocellular carcinoma genomic expression datasets. J Surg Res. 2011;170:e85-e92. [PMID: 21601879 DOI: 10.1016/j.jss.2011.04.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
345 Chiang DY, Villanueva A, Hoshida Y, Peix J, Newell P, Minguez B, LeBlanc AC, Donovan DJ, Thung SN, Solé M, Tovar V, Alsinet C, Ramos AH, Barretina J, Roayaie S, Schwartz M, Waxman S, Bruix J, Mazzaferro V, Ligon AH, Najfeld V, Friedman SL, Sellers WR, Meyerson M, Llovet JM. Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res 2008;68:6779-88. [PMID: 18701503 DOI: 10.1158/0008-5472.CAN-08-0742] [Cited by in Crossref: 386] [Cited by in F6Publishing: 240] [Article Influence: 27.6] [Reference Citation Analysis]
346 Chaiteerakij R, Addissie BD, Roberts LR. Update on biomarkers of hepatocellular carcinoma. Clin Gastroenterol Hepatol 2015;13:237-45. [PMID: 24275343 DOI: 10.1016/j.cgh.2013.10.038] [Cited by in Crossref: 72] [Cited by in F6Publishing: 72] [Article Influence: 8.0] [Reference Citation Analysis]
347 Eferl R. A dual role for interferon γ signalling in hepatocellular carcinoma. J Hepatol 2012;57:940-2. [PMID: 22885715 DOI: 10.1016/j.jhep.2012.07.040] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
348 Chiba T, Kita K, Zheng YW, Yokosuka O, Saisho H, Iwama A, Nakauchi H, Taniguchi H. Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties. Hepatology. 2006;44:240-251. [PMID: 16799977 DOI: 10.1002/hep.21227] [Cited by in Crossref: 476] [Cited by in F6Publishing: 454] [Article Influence: 29.8] [Reference Citation Analysis]
349 Calvisi DF, Ladu S, Gorden A, Farina M, Lee JS, Conner EA, Schroeder I, Factor VM, Thorgeirsson SS. Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma. J Clin Invest. 2007;117:2713-2722. [PMID: 17717605 DOI: 10.1172/jci31457ds1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
350 Hochnadel I, Kossatz-Boehlert U, Jedicke N, Lenzen H, Manns MP, Yevsa T. Cancer vaccines and immunotherapeutic approaches in hepatobiliary and pancreatic cancers. Hum Vaccin Immunother. 2017;13:2931-2952. [PMID: 29112462 DOI: 10.1080/21645515.2017.1359362] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.6] [Reference Citation Analysis]
351 Maida M, Iavarone M, Raineri M, Cammà C, Cabibbo G. Second line systemic therapies for hepatocellular carcinoma: Reasons for the failure. World J Hepatol 2015; 7(17): 2053-2057 [PMID: 26301047 DOI: 10.4254/wjh.v7.i17.2053] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
352 Ng CKY, Piscuoglio S, Terracciano LM. Molecular classification of hepatocellular carcinoma: The view from metabolic zonation. Hepatology. 2017;66:1377-1380. [PMID: 28599064 DOI: 10.1002/hep.29311] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
353 Stahl S, Ittrich C, Marx-Stoelting P, Köhle C, Altug-Teber O, Riess O, Bonin M, Jobst J, Kaiser S, Buchmann A, Schwarz M. Genotype-phenotype relationships in hepatocellular tumors from mice and man. Hepatology 2005;42:353-61. [PMID: 15965925 DOI: 10.1002/hep.20768] [Cited by in Crossref: 70] [Cited by in F6Publishing: 62] [Article Influence: 4.1] [Reference Citation Analysis]
354 Hoshida Y, Villanueva A, Llovet JM. Molecular profiling to predict hepatocellular carcinoma outcome. Expert Rev Gastroenterol Hepatol 2009;3:101-3. [PMID: 19351279 DOI: 10.1586/egh.09.5] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 2.2] [Reference Citation Analysis]
355 Govaere O, Komuta M, Berkers J, Spee B, Janssen C, de Luca F, Katoonizadeh A, Wouters J, van Kempen LC, Durnez A, Verslype C, De Kock J, Rogiers V, van Grunsven LA, Topal B, Pirenne J, Vankelecom H, Nevens F, van den Oord J, Pinzani M, Roskams T. Keratin 19: a key role player in the invasion of human hepatocellular carcinomas. Gut. 2014;63:674-685. [PMID: 23958557 DOI: 10.1136/gutjnl-2012-304351] [Cited by in Crossref: 144] [Cited by in F6Publishing: 190] [Article Influence: 16.0] [Reference Citation Analysis]
356 Tummala KS, Brandt M, Teijeiro A, Graña O, Schwabe RF, Perna C, Djouder N. Hepatocellular Carcinomas Originate Predominantly from Hepatocytes and Benign Lesions from Hepatic Progenitor Cells. Cell Rep 2017;19:584-600. [PMID: 28423321 DOI: 10.1016/j.celrep.2017.03.059] [Cited by in Crossref: 62] [Cited by in F6Publishing: 56] [Article Influence: 12.4] [Reference Citation Analysis]
357 Wang J, Lou J, Fu L, Jin Q. An independent poor-prognosis subtype of hepatocellular carcinoma based on the tumor microenvironment. J Int Med Res 2021;49:300060520980646. [PMID: 33567957 DOI: 10.1177/0300060520980646] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
358 Nahm JH, Park YN. [Up-to-date Knowledge on the Pathological Diagnosis of Hepatocellular Carcinoma]. Korean J Gastroenterol 2021;78:268-83. [PMID: 34824185 DOI: 10.4166/kjg.2021.140] [Reference Citation Analysis]
359 Nagy Á, Lánczky A, Menyhárt O, Győrffy B. Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets. Sci Rep 2018;8:9227. [PMID: 29907753 DOI: 10.1038/s41598-018-27521-y] [Cited by in Crossref: 506] [Cited by in F6Publishing: 602] [Article Influence: 126.5] [Reference Citation Analysis]
360 Cai J, Zhou M, Xu J. N6-methyladenosine (m6A) RNA methylation regulator SNRPC is a prognostic biomarker and is correlated with immunotherapy in hepatocellular carcinoma. World J Surg Oncol 2021;19:241. [PMID: 34389000 DOI: 10.1186/s12957-021-02354-8] [Reference Citation Analysis]
361 Bedossa P, Paradis V. Hepatocellular Carcinoma. Practical Hepatic Pathology: A Diagnostic Approach. Elsevier; 2011. pp. 489-501. [DOI: 10.1016/b978-0-443-06803-4.00035-6] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
362 [DOI: 10.1101/114892] [Cited by in Crossref: 11] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
363 Korhan P, Tercan Avcı S, Yılmaz Y, Öztemur Islakoğlu Y, Atabey N. Role of Biobanks for Cancer Research and Precision Medicine in Hepatocellular Carcinoma. J Gastrointest Cancer 2021. [PMID: 34807351 DOI: 10.1007/s12029-021-00759-y] [Reference Citation Analysis]
364 Hu DG, Marri S, McKinnon RA, Mackenzie PI, Meech R. Deregulation of the Genes that Are Involved in Drug Absorption, Distribution, Metabolism, and Excretion in Hepatocellular Carcinoma. J Pharmacol Exp Ther 2019;368:363-81. [PMID: 30578287 DOI: 10.1124/jpet.118.255018] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 5.3] [Reference Citation Analysis]
365 Gillet JP, Andersen JB, Madigan JP, Varma S, Bagni RK, Powell K, Burgan WE, Wu CP, Calcagno AM, Ambudkar SV. A Gene Expression Signature Associated with Overall Survival in Patients with Hepatocellular Carcinoma Suggests a New Treatment Strategy. Mol Pharmacol. 2016;89:263-272. [PMID: 26668215 DOI: 10.1124/mol.115.101360] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
366 Chang S, Suh K, Yi N, Lee K, Kim B, Jang J. Predicting the Prognosis of Hepatocellular Carcinoma Using Gene Expression. Journal of Surgical Research 2011;171:524-31. [DOI: 10.1016/j.jss.2010.05.023] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
367 Faltermeier C, Busuttil RW, Zarrinpar A. A Surgical Perspective on Targeted Therapy of Hepatocellular Carcinoma. Diseases 2015;3:221-52. [PMID: 28943622 DOI: 10.3390/diseases3040221] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
368 Nia A, Dhanasekaran R. Genomic Landscape of HCC. Curr Hepatol Rep 2020;19:448-61. [PMID: 33816052 DOI: 10.1007/s11901-020-00553-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
369 Mas VR, Maluf DG, Dumur CI, Archer KJ, Yanek K, Jackson-cook C, Fisher RA. Molecular Techniques for Identifying HCC Origin and Biology After Orthotopic Liver Transplantation: . Diagnostic Molecular Pathology 2006;15:90-4. [DOI: 10.1097/00019606-200606000-00005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
370 Finn RS, Aleshin A, Dering J, Yang P, Ginther C, Desai A, Zhao D, von Euw E, Busuttil RW, Slamon DJ. Molecular subtype and response to dasatinib, an Src/Abl small molecule kinase inhibitor, in hepatocellular carcinoma cell lines in vitro. Hepatology 2013;57:1838-46. [PMID: 23299860 DOI: 10.1002/hep.26223] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 3.4] [Reference Citation Analysis]
371 Liu J, Dang H, Wang XW. The significance of intertumor and intratumor heterogeneity in liver cancer. Exp Mol Med. 2018;50:e416. [PMID: 29303512 DOI: 10.1038/emm.2017.165] [Cited by in Crossref: 65] [Cited by in F6Publishing: 57] [Article Influence: 16.3] [Reference Citation Analysis]
372 Fletcher SP, Chin DJ, Ji Y, Iniguez AL, Taillon B, Swinney DC, Ravindran P, Cheng DT, Bitter H, Lopatin U, Ma H, Klumpp K, Menne S. Transcriptomic analysis of the woodchuck model of chronic hepatitis B. Hepatology. 2012;56:820-830. [PMID: 22431061 DOI: 10.1002/hep.25730] [Cited by in Crossref: 73] [Cited by in F6Publishing: 69] [Article Influence: 7.3] [Reference Citation Analysis]
373 Neureiter D, Stintzing S, Kiesslich T, Ocker M. Hepatocellular carcinoma: Therapeutic advances in signaling, epigenetic and immune targets. World J Gastroenterol 2019; 25(25): 3136-3150 [PMID: 31333307 DOI: 10.3748/wjg.v25.i25.3136] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 32] [Article Influence: 9.0] [Reference Citation Analysis]
374 Zindy PJ, L'Helgoualc'h A, Bonnier D, Le Béchec A, Bourd-Boitin K, Zhang CX, Orlando Musso O, Glaise D, Bérangère Troadec M, Loréal O. Upregulation of the tumor suppressor gene menin in hepatocellular carcinomas and its significance in fibrogenesis. Hepatology. 2006;44:1296-1307. [PMID: 17058241 DOI: 10.1002/hep.21367] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
375 Kuo MD, Gollub J, Sirlin CB, Ooi C, Chen X. Radiogenomic analysis to identify imaging phenotypes associated with drug response gene expression programs in hepatocellular carcinoma. J Vasc Interv Radiol. 2007;18:821-831. [PMID: 17609439 DOI: 10.1016/j.jvir.2007.04.031] [Cited by in Crossref: 107] [Cited by in F6Publishing: 96] [Article Influence: 7.1] [Reference Citation Analysis]
376 Antonosante A, d'Angelo M, Castelli V, Catanesi M, Iannotta D, Giordano A, Ippoliti R, Benedetti E, Cimini A. The Involvement of PPARs in the Peculiar Energetic Metabolism of Tumor Cells. Int J Mol Sci 2018;19:E1907. [PMID: 29966227 DOI: 10.3390/ijms19071907] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
377 Lavi O, Skinner J, Gottesman MM. Network features suggest new hepatocellular carcinoma treatment strategies. BMC Syst Biol. 2014;8:88. [PMID: 25070212 DOI: 10.1186/s12918-014-0088-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
378 Saran A. Basal cell carcinoma and the carcinogenic role of aberrant Hedgehog signaling. Future Oncol 2010;6:1003-14. [PMID: 20528237 DOI: 10.2217/fon.10.49] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
379 Pár A. [Hepatitis B virus (HBV) infection and hepatocarcinogenesis]. Orv Hetil. 2010;151:1045-1053. [PMID: 20558351 DOI: 10.1556/OH.2010.28881] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
380 Marquardt JU, Raggi C, Andersen JB, Seo D, Avital I, Geller D, Lee YH, Kitade M, Holczbauer A, Gillen MC, Conner EA, Factor VM, Thorgeirsson SS. Human hepatic cancer stem cells are characterized by common stemness traits and diverse oncogenic pathways. Hepatology. 2011;54:1031-1042. [PMID: 21618577 DOI: 10.1002/hep.24454] [Cited by in Crossref: 59] [Cited by in F6Publishing: 64] [Article Influence: 5.4] [Reference Citation Analysis]
381 Woo HG, Park ES, Lee JS, Lee YH, Ishikawa T, Kim YJ, Thorgeirsson SS. Identification of potential driver genes in human liver carcinoma by genomewide screening. Cancer Res 2009;69:4059-66. [PMID: 19366792 DOI: 10.1158/0008-5472.CAN-09-0164] [Cited by in Crossref: 69] [Cited by in F6Publishing: 49] [Article Influence: 5.3] [Reference Citation Analysis]
382 Mayhew CN, Carter SL, Fox SR, Sexton CR, Reed CA, Srinivasan SV, Liu X, Wikenheiser-Brokamp K, Boivin GP, Lee JS. RB loss abrogates cell cycle control and genome integrity to promote liver tumorigenesis. Gastroenterology. 2007;133:976-984. [PMID: 17854601 DOI: 10.1053/j.gastro.2007.06.025] [Cited by in Crossref: 62] [Cited by in F6Publishing: 64] [Article Influence: 4.1] [Reference Citation Analysis]
383 Hoshida Y. Tumor-derived molecular information and outcome in hepatocellular carcinoma. J Hepatol 2009;51:595-6; author reply 596-7. [PMID: 19586677 DOI: 10.1016/j.jhep.2009.05.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
384 Teufel A, Marquardt JU, Galle PR. Next generation sequencing of HCC from European and Asian HCC cohorts. Back to p53 and Wnt/β-catenin. J Hepatol 2013;58:622-4. [PMID: 23063568 DOI: 10.1016/j.jhep.2012.10.006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
385 Shi Q, Liu Y, Lu M, Lei Q, Chen Z, Wang L, He X. A pathway-guided strategy identifies a metabolic signature for prognosis prediction and precision therapy for hepatocellular carcinoma. Computers in Biology and Medicine 2022;144:105376. [DOI: 10.1016/j.compbiomed.2022.105376] [Reference Citation Analysis]
386 Park YY, Choi HS, Lee JS. Systems-level analysis of gene expression data revealed NR0B2/SHP as potential tumor suppressor in human liver cancer. Mol Cells 2010;30:485-91. [PMID: 20853064 DOI: 10.1007/s10059-010-0136-6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
387 Ninomiya M, Ueno Y, Shimosegawa T. Application of deep sequence technology in hepatology: Application of deep sequencing in hepatology. Hepatol Res 2014;44:141-8. [DOI: 10.1111/hepr.12214] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
388 Chen D, Xing W, Hong J, Wang M, Huang Y, Zhu C, Yuan Y, Zeng W. The beta2-adrenergic receptor is a potential prognostic biomarker for human hepatocellular carcinoma after curative resection. Ann Surg Oncol 2012;19:3556-65. [PMID: 22588469 DOI: 10.1245/s10434-012-2396-1] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 2.3] [Reference Citation Analysis]
389 Lee J, Grisham JW, Thorgeirsson SS. Comparative functional genomics for identifying models of human cancer. Carcinogenesis 2005;26:1013-20. [DOI: 10.1093/carcin/bgi030] [Cited by in Crossref: 43] [Cited by in F6Publishing: 37] [Article Influence: 2.5] [Reference Citation Analysis]
390 Bayo J, Fiore EJ, Dominguez LM, Cantero MJ, Ciarlantini MS, Malvicini M, Atorrasagasti C, Garcia MG, Rossi M, Cavasotto C, Martinez E, Comin J, Mazzolini GD. Bioinformatic analysis of RHO family of GTPases identifies RAC1 pharmacological inhibition as a new therapeutic strategy for hepatocellular carcinoma. Gut 2021;70:1362-74. [PMID: 33106353 DOI: 10.1136/gutjnl-2020-321454] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
391 Boyault S, Rickman DS, de Reyniès A, Balabaud C, Rebouissou S, Jeannot E, Hérault A, Saric J, Belghiti J, Franco D, Bioulac-sage P, Laurent-puig P, Zucman-rossi J. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology 2007;45:42-52. [DOI: 10.1002/hep.21467] [Cited by in Crossref: 693] [Cited by in F6Publishing: 653] [Article Influence: 46.2] [Reference Citation Analysis]
392 Roviello G, Sohbani N, Petrioli R, Rodriquenz MG. Ramucirumab as a second line therapy for advanced HCC: a significant achievement or a wasted opportunity for personalised therapy? Invest New Drugs 2019;37:1274-88. [PMID: 30879152 DOI: 10.1007/s10637-019-00760-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
393 Li C, Wu X, Zhang H, Yang G, Hao M, Sheng S, Sun Y, Long J, Hu C, Sun X, Li L, Zheng J. A Huaier polysaccharide restrains hepatocellular carcinoma growth and metastasis by suppression angiogenesis. Int J Biol Macromol 2015;75:115-20. [PMID: 25597429 DOI: 10.1016/j.ijbiomac.2015.01.016] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 3.4] [Reference Citation Analysis]
394 Kang HJ, Kim H, Lee DH, Hur BY, Hwang YJ, Suh KS, Han JK. Gadoxetate-enhanced MRI Features of Proliferative Hepatocellular Carcinoma Are Prognostic after Surgery. Radiology 2021;:204352. [PMID: 34227881 DOI: 10.1148/radiol.2021204352] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
395 Kim B, Suh K, Lee J, Woo SR, Park I, Park S, Han CJ, Kim S, Jeong S, Yeom YI, Yang S, Kim C, Cho SJ, Yoo YD, Cho M, Jang JJ, Choi DW, Lee K. Integrated Analysis of Prognostic Gene Expression Profiles from Hepatitis B Virus-Positive Hepatocellular Carcinoma and Adjacent Liver Tissue. Ann Surg Oncol 2012;19:328-38. [DOI: 10.1245/s10434-011-1709-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
396 Nishioka ST, Sato MM, Wong LL, Tiirikainen M, Kwee SA. Clinical and molecular sub-classification of hepatocellular carcinoma relative to alpha-fetoprotein level in an Asia-Pacific island cohort. Hepatoma Res 2018;4:1. [PMID: 29376136 DOI: 10.20517/2394-5079.2017.46] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
397 Zhuo JY, Lu D, Tan WY, Zheng SS, Shen YQ, Xu X. CK19-positive Hepatocellular Carcinoma is a Characteristic Subtype. J Cancer 2020;11:5069-77. [PMID: 32742454 DOI: 10.7150/jca.44697] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
398 Shen Y, Hsu C, Cheng A. Molecular targeted therapy for advanced hepatocellular carcinoma: current status and future perspectives. J Gastroenterol 2010;45:794-807. [DOI: 10.1007/s00535-010-0270-0] [Cited by in Crossref: 43] [Cited by in F6Publishing: 46] [Article Influence: 3.6] [Reference Citation Analysis]
399 Matter MS, Marquardt JU, Andersen JB, Quintavalle C, Korokhov N, Stauffer JK, Kaji K, Decaens T, Quagliata L, Elloumi F, Hoang T, Molinolo A, Conner EA, Weber A, Heikenwalder M, Factor VM, Thorgeirsson SS. Oncogenic driver genes and the inflammatory microenvironment dictate liver tumor phenotype. Hepatology 2016;63:1888-99. [PMID: 26844528 DOI: 10.1002/hep.28487] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 3.7] [Reference Citation Analysis]
400 Pellegrino R, Calvisi DF, Ladu S, Ehemann V, Staniscia T, Evert M, Dombrowski F, Schirmacher P, Longerich T. Oncogenic and tumor suppressive roles of polo-like kinases in human hepatocellular carcinoma. Hepatology. 2010;51:857-868. [PMID: 20112253 DOI: 10.1002/hep.23467] [Cited by in Crossref: 26] [Cited by in F6Publishing: 65] [Article Influence: 2.2] [Reference Citation Analysis]
401 Tabor E. Pathogenesis of hepatitis B virus-associated hepatocellular carcinoma. Hepatology Research 2007;37:S110-4. [DOI: 10.1111/j.1872-034x.2007.00172.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
402 Roskams T. Anatomic pathology of hepatocellular carcinoma: impact on prognosis and response to therapy. Clin Liver Dis. 2011;15:245-259, vii-x. [PMID: 21689611 DOI: 10.1016/j.cld.2011.03.004] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 2.3] [Reference Citation Analysis]
403 Llovet JM. Clinical and molecular classification of hepatocellular carcinoma. Liver Transpl 2007;13:S13-6. [PMID: 17969094 DOI: 10.1002/lt.21325] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
404 Wang F, Kuang Y, Salem N, Anderson PW, Lee Z. Cross-species hybridization of woodchuck hepatitis viral infection-induced woodchuck hepatocellular carcinoma using human, rat and mouse oligonucleotide microarrays. J Gastroenterol Hepatol. 2009;24:605-617. [PMID: 19175833 DOI: 10.1111/j.1440-1746.2008.05581.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
405 Villanueva A, Hoshida Y, Battiston C, Tovar V, Sia D, Alsinet C, Cornella H, Liberzon A, Kobayashi M, Kumada H. Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. Gastroenterology. 2011;140:1501-12.e2. [PMID: 21320499 DOI: 10.1053/j.gastro.2011.02.006.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
406 Efroni S, Meerzaman D, Schaefer CF, Greenblum S, Soo-Lyu M, Hu Y, Cultraro C, Meshorer E, Buetow KH. Systems analysis utilising pathway interactions identifies sonic hedgehog pathway as a primary biomarker and oncogenic target in hepatocellular carcinoma. IET Syst Biol 2013;7:243-51. [PMID: 24712101 DOI: 10.1049/iet-syb.2010.0078] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
407 Forner A, Reig M, Varela M, Burrel M, Feliu J, Briceño J, Sastre J, Martí-Bonmati L, Llovet JM, Bilbao JI, Sangro B, Pardo F, Ayuso C, Bru C, Tabernero J, Bruix J. [Diagnosis and treatment of hepatocellular carcinoma. Update consensus document from the AEEH, SEOM, SERAM, SERVEI and SETH]. Med Clin (Barc) 2016;146:511.e1-511.e22. [PMID: 26971984 DOI: 10.1016/j.medcli.2016.01.028] [Cited by in Crossref: 35] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]
408 Wijetunga NA, Pascual M, Tozour J, Delahaye F, Alani M, Adeyeye M, Wolkoff AW, Verma A, Greally JM. A pre-neoplastic epigenetic field defect in HCV-infected liver at transcription factor binding sites and polycomb targets. Oncogene. 2017;36:2030-2044. [PMID: 27721404 DOI: 10.1038/onc.2016.340] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.7] [Reference Citation Analysis]
409 Becht E, Giraldo NA, Germain C, de Reyniès A, Laurent-puig P, Zucman-rossi J, Dieu-nosjean M, Sautès-fridman C, Fridman WH. Immune Contexture, Immunoscore, and Malignant Cell Molecular Subgroups for Prognostic and Theranostic Classifications of Cancers. Tumor Immunology. Elsevier; 2016. pp. 95-190. [DOI: 10.1016/bs.ai.2015.12.002] [Cited by in Crossref: 102] [Cited by in F6Publishing: 96] [Article Influence: 17.0] [Reference Citation Analysis]
410 Ma L, Hernandez MO, Zhao Y, Mehta M, Tran B, Kelly M, Rae Z, Hernandez JM, Davis JL, Martin SP, Kleiner DE, Hewitt SM, Ylaya K, Wood BJ, Greten TF, Wang XW. Tumor Cell Biodiversity Drives Microenvironmental Reprogramming in Liver Cancer. Cancer Cell 2019;36:418-430.e6. [PMID: 31588021 DOI: 10.1016/j.ccell.2019.08.007] [Cited by in Crossref: 121] [Cited by in F6Publishing: 121] [Article Influence: 40.3] [Reference Citation Analysis]
411 Perret C. Methylation profile as a new tool for classification of hepatocellular carcinoma. J Hepatol. 2011;54:602-603. [PMID: 21145852 DOI: 10.1016/j.jhep.2010.10.015] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
412 Zhang Z, Meng G, Wang L, Ma Y, Guan Z. The prognostic role and reduced expression of FOXJ2 in human hepatocellular carcinoma. Mol Med Rep 2016;14:254-62. [PMID: 27177166 DOI: 10.3892/mmr.2016.5261] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
413 Desoteux M, Louis C, Bévant K, Glaise D, Coulouarn C. A Minimal Subset of Seven Genes Associated with Tumor Hepatocyte Differentiation Predicts a Poor Prognosis in Human Hepatocellular Carcinoma. Cancers (Basel) 2021;13:5624. [PMID: 34830779 DOI: 10.3390/cancers13225624] [Reference Citation Analysis]
414 Nishikawa T, Nakajima T, Moriguchi M, Jo M, Sekoguchi S, Ishii M, Takashima H, Katagishi T, Kimura H, Minami M. A green tea polyphenol, epigalocatechin-3-gallate, induces apoptosis of human hepatocellular carcinoma, possibly through inhibition of Bcl-2 family proteins. J Hepatol. 2006;44:1074-1082. [PMID: 16481065 DOI: 10.1016/j.jhep.2005.11.045] [Cited by in Crossref: 112] [Cited by in F6Publishing: 92] [Article Influence: 6.6] [Reference Citation Analysis]
415 Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang DY, Camargo A, Gupta S, Moore J, Wrobel MJ, Lerner J, Reich M, Chan JA, Glickman JN, Ikeda K, Hashimoto M, Watanabe G, Daidone MG, Roayaie S, Schwartz M, Thung S, Salvesen HB, Gabriel S, Mazzaferro V, Bruix J, Friedman SL, Kumada H, Llovet JM, Golub TR. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med. 2008;359:1995-2004. [PMID: 18923165 DOI: 10.1056/nejmoa0804525] [Cited by in Crossref: 886] [Cited by in F6Publishing: 491] [Article Influence: 63.3] [Reference Citation Analysis]
416 Yin J, Zhu JM, Shen XZ. The role and therapeutic implications of RING-finger E3 ubiquitin ligases in hepatocellular carcinoma. Int J Cancer. 2015;136:249-257. [PMID: 24420637 DOI: 10.1002/ijc.28717] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
417 Costa RH, Kalinichenko VV, Major ML, Raychaudhuri P. New and unexpected: forkhead meets ARF. Curr Opin Genet Dev 2005;15:42-8. [PMID: 15661532 DOI: 10.1016/j.gde.2004.12.007] [Cited by in Crossref: 53] [Cited by in F6Publishing: 50] [Article Influence: 3.1] [Reference Citation Analysis]
418 Chaisaingmongkol J, Budhu A, Dang H, Rabibhadana S, Pupacdi B, Kwon SM, Forgues M, Pomyen Y, Bhudhisawasdi V, Lertprasertsuke N, Chotirosniramit A, Pairojkul C, Auewarakul CU, Sricharunrat T, Phornphutkul K, Sangrajrang S, Cam M, He P, Hewitt SM, Ylaya K, Wu X, Andersen JB, Thorgeirsson SS, Waterfall JJ, Zhu YJ, Walling J, Stevenson HS, Edelman D, Meltzer PS, Loffredo CA, Hama N, Shibata T, Wiltrout RH, Harris CC, Mahidol C, Ruchirawat M, Wang XW; TIGER-LC Consortium. Common Molecular Subtypes Among Asian Hepatocellular Carcinoma and Cholangiocarcinoma. Cancer Cell. 2017;32:57-70.e3. [PMID: 28648284 DOI: 10.1016/j.ccell.2017.05.009] [Cited by in Crossref: 144] [Cited by in F6Publishing: 142] [Article Influence: 28.8] [Reference Citation Analysis]
419 Govaere O, Komuta M, Berkers J, Spee B, Janssen C, de Luca F, Katoonizadeh A, Wouters J, van Kempen LC, Durnez A. Keratin 19: a key role player in the invasion of human hepatocellular carcinomas. Gut. 2014;63:674-685. [PMID: 23958557 DOI: 10.1136/gutjnl-2012-30435] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
420 Watari K, Nishitani A, Shibata T, Noda M, Kawahara A, Akiba J, Murakami Y, Yano H, Kuwano M, Ono M. Phosphorylation of mTOR Ser2481 is a key target limiting the efficacy of rapalogs for treating hepatocellular carcinoma. Oncotarget 2016;7:47403-17. [PMID: 27329724 DOI: 10.18632/oncotarget.10161] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
421 Kalin TV, Ustiyan V, Kalinichenko VV. Multiple faces of FoxM1 transcription factor: lessons from transgenic mouse models. Cell Cycle 2011;10:396-405. [PMID: 21270518 DOI: 10.4161/cc.10.3.14709] [Cited by in Crossref: 134] [Cited by in F6Publishing: 133] [Article Influence: 12.2] [Reference Citation Analysis]
422 Tietze L, Kessler SM. The Good, the Bad, the Question-H19 in Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E1261. [PMID: 32429417 DOI: 10.3390/cancers12051261] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
423 Ganne-Carrié N, Nault JC, Ziol M, N'Kontchou G, Nahon P, Grando V, Bourcier V, Barge S, Beaugrand M, Trinchet JC, Seror O. Predicting recurrence following radiofrequency percutaneous ablation for hepatocellular carcinoma. Hepat Oncol 2014;1:395-408. [PMID: 30190975 DOI: 10.2217/hep.14.22] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
424 Sukowati CHC. Heterogeneity of Hepatic Cancer Stem Cells. Adv Exp Med Biol. 2019;1139:59-81. [PMID: 31134495 DOI: 10.1007/978-3-030-14366-4_4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 3.7] [Reference Citation Analysis]
425 Désert R, Rohart F, Canal F, Sicard M, Desille M, Renaud S, Turlin B, Bellaud P, Perret C, Clément B, Lê Cao KA, Musso O. Human hepatocellular carcinomas with a periportal phenotype have the lowest potential for early recurrence after curative resection. Hepatology 2017;66:1502-18. [PMID: 28498607 DOI: 10.1002/hep.29254] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 7.8] [Reference Citation Analysis]
426 Pei Y, Zhang T, Renault V, Zhang X. An overview of hepatocellular carcinoma study by omics-based methods. Acta Biochimica et Biophysica Sinica 2009;41:1-15. [DOI: 10.1093/abbs/gmn001] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 3.0] [Reference Citation Analysis]
427 Huang X, Yang C, Wang J, Sun T, Xiong H. Integrative analysis of DNA methylation and gene expression reveals distinct hepatocellular carcinoma subtypes with therapeutic implications. Aging (Albany NY) 2020;12:4970-95. [PMID: 32201399 DOI: 10.18632/aging.102923] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
428 Kuo TC, Lu HP, Chao CC. The tyrosine kinase inhibitor sorafenib sensitizes hepatocellular carcinoma cells to taxol by suppressing the HURP protein. Biochem Pharmacol 2011;82:184-94. [PMID: 21549688 DOI: 10.1016/j.bcp.2011.04.008] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 2.2] [Reference Citation Analysis]
429 Park ES, Lee JS, Woo HG, Zhan F, Shih JH, Shaughnessy JD Jr, Frederic Mushinski J. Heterologous tissue culture expression signature predicts human breast cancer prognosis. PLoS One 2007;2:e145. [PMID: 17206280 DOI: 10.1371/journal.pone.0000145] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
430 Villa E, Critelli R, Lei B, Marzocchi G, Cammà C, Giannelli G, Pontisso P, Cabibbo G, Enea M, Colopi S, Caporali C, Pollicino T, Milosa F, Karampatou A, Todesca P, Bertolini E, Maccio L, Martinez-chantar ML, Turola E, Del Buono M, De Maria N, Ballestri S, Schepis F, Loria P, Enrico Gerunda G, Losi L, Cillo U. Neoangiogenesis-related genes are hallmarks of fast-growing hepatocellular carcinomas and worst survival. Results from a prospective study. Gut 2016;65:861-9. [DOI: 10.1136/gutjnl-2014-308483] [Cited by in Crossref: 99] [Cited by in F6Publishing: 115] [Article Influence: 14.1] [Reference Citation Analysis]
431 Wang J, McGrail DJ, Bhupal PK, Zhang W, Lin KY, Ku YH, Lin T, Wu H, Tsai KC, Li K, Peng CY, Finegold MJ, Lin SY, Tsai RYL. Nucleostemin Modulates Outcomes of Hepatocellular Carcinoma via a Tumor Adaptive Mechanism to Genomic Stress. Mol Cancer Res 2020;18:723-34. [PMID: 32051231 DOI: 10.1158/1541-7786.MCR-19-0777] [Reference Citation Analysis]
432 Ji J, Eggert T, Budhu A, Forgues M, Takai A, Dang H, Ye Q, Lee JS, Kim JH, Greten TF, Wang XW. Hepatic stellate cell and monocyte interaction contributes to poor prognosis in hepatocellular carcinoma. Hepatology 2015;62:481-95. [PMID: 25833323 DOI: 10.1002/hep.27822] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
433 Schneider C, Tacke F. Distinct anti-tumoral functions of adaptive immune cells in liver cancer. Oncoimmunology 2012;1:937-9. [PMID: 23162763 DOI: 10.4161/onci.20304] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
434 Raja A, Haq F. Molecular classification of hepatocellular carcinoma: prognostic importance and clinical applications. J Cancer Res Clin Oncol 2021. [PMID: 34623518 DOI: 10.1007/s00432-021-03826-w] [Reference Citation Analysis]
435 Melas IN, Lauffenburger DA, Alexopoulos LG. Identification of signaling pathways related to drug efficacy in hepatocellular carcinoma via integration of phosphoproteomic, genomic and clinical data. Proc IEEE Int Symp Bioinformatics Bioeng 2013;2013:14026468. [PMID: 25729777 DOI: 10.1109/BIBE.2013.6701683] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
436 George J, Nigam N, Shukla Y. Tea: age-old beverage as an effective cancer chemopreventive agent. Oncol Rev 2008;1:243-52. [DOI: 10.1007/s12156-008-0029-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
437 Wang L, Sun W, Zhang G, Huo J, Tian Y, Zhang Y, Yang X, Liu Y. T-cell activation is associated with high-grade serous ovarian cancer survival. J Obstet Gynaecol Res 2022. [PMID: 35334503 DOI: 10.1111/jog.15234] [Reference Citation Analysis]
438 Trevisani F, Cantarini MC, Wands JR, Bernardi M. Recent advances in the natural history of hepatocellular carcinoma. Carcinogenesis. 2008;1299-1305. [PMID: 18515282 DOI: 10.1093/carcin/bgn113] [Cited by in Crossref: 105] [Cited by in F6Publishing: 94] [Article Influence: 7.5] [Reference Citation Analysis]
439 Iavarone M, Sangiovanni A, Forzenigo LV, Massironi S, Fraquelli M, Aghemo A, Ronchi G, Biondetti P, Roncalli M, Colombo M. Diagnosis of hepatocellular carcinoma in cirrhosis by dynamic contrast imaging: the importance of tumor cell differentiation. Hepatology. 2010;52:1723-1730. [PMID: 20842697 DOI: 10.1002/hep.23903] [Cited by in Crossref: 47] [Cited by in F6Publishing: 37] [Article Influence: 3.9] [Reference Citation Analysis]
440 Lim HY, Sohn I, Deng S, Lee J, Jung SH, Mao M, Xu J, Wang K, Shi S, Joh JW, Choi YL, Park CK. Prediction of disease-free survival in hepatocellular carcinoma by gene expression profiling. Ann Surg Oncol. 2013;20:3747-3753. [PMID: 23800896 DOI: 10.1245/s10434-013-3070-y] [Cited by in Crossref: 63] [Cited by in F6Publishing: 65] [Article Influence: 7.0] [Reference Citation Analysis]
441 Martin J, Magnino F, Schmidt K, Piguet AC, Lee JS, Semela D, St-Pierre MV, Ziemiecki A, Cassio D, Brenner C, Thorgeirsson SS, Dufour JF. Hint2, a mitochondrial apoptotic sensitizer down-regulated in hepatocellular carcinoma. Gastroenterology 2006;130:2179-88. [PMID: 16762638 DOI: 10.1053/j.gastro.2006.03.024] [Cited by in Crossref: 44] [Cited by in F6Publishing: 43] [Article Influence: 2.8] [Reference Citation Analysis]
442 Tsoulfas G, Agorastou P, Tooulias A, Marakis GN. Current and future challenges in the surgical treatment of hepatocellular carcinoma: a review. Int Surg 2014;99:779-86. [PMID: 25437587 DOI: 10.9738/INTSURG-D-13-00122.1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
443 Sukowati CH, Tiribelli C. The biological implication of cancer stem cells in hepatocellular carcinoma: a possible target for future therapy. Expert Rev Gastroenterol Hepatol. 2013;7:749-757. [PMID: 24161136 DOI: 10.1586/17474124.2013.846826] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
444 Yu MH, Im HG, Kim HI, Lee IS. Induction of apoptosis by immature plum in human hepatocellular carcinoma. J Med Food 2009;12:518-27. [PMID: 19627199 DOI: 10.1089/jmf.2008.1268] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
445 Nacer DF, Liljedahl H, Karlsson A, Lindgren D, Staaf J. Pan-cancer application of a lung-adenocarcinoma-derived gene-expression-based prognostic predictor. Brief Bioinform 2021:bbab154. [PMID: 33971670 DOI: 10.1093/bib/bbab154] [Reference Citation Analysis]
446 Bidkhori G, Benfeitas R, Klevstig M, Zhang C, Nielsen J, Uhlen M, Boren J, Mardinoglu A. Metabolic network-based stratification of hepatocellular carcinoma reveals three distinct tumor subtypes. Proc Natl Acad Sci U S A. 2018;115:E11874-E11883. [PMID: 30482855 DOI: 10.1073/pnas.1807305115] [Cited by in Crossref: 53] [Cited by in F6Publishing: 54] [Article Influence: 13.3] [Reference Citation Analysis]
447 Kancherla V, Abdullazade S, Matter MS, Lanzafame M, Quagliata L, Roma G, Hoshida Y, Terracciano LM, Ng CKY, Piscuoglio S. Genomic Analysis Revealed New Oncogenic Signatures in TP53-Mutant Hepatocellular Carcinoma. Front Genet 2018;9:2. [PMID: 29456550 DOI: 10.3389/fgene.2018.00002] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
448 Song Y, Liu Y, Pan S, Xie S, Wang ZW, Zhu X. Role of the COP1 protein in cancer development and therapy. Semin Cancer Biol 2020;67:43-52. [PMID: 32027978 DOI: 10.1016/j.semcancer.2020.02.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
449 Tsujikawa H, Masugi Y, Yamazaki K, Itano O, Kitagawa Y, Sakamoto M. Immunohistochemical molecular analysis indicates hepatocellular carcinoma subgroups that reflect tumor aggressiveness. Hum Pathol. 2016;50:24-33. [PMID: 26997435 DOI: 10.1016/j.humpath.2015.10.014] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 3.7] [Reference Citation Analysis]
450 Henderson JM, Zhang HE, Polak N, Gorrell MD. Hepatocellular carcinoma: Mouse models and the potential roles of proteases. Cancer Lett 2017;387:106-13. [PMID: 27045475 DOI: 10.1016/j.canlet.2016.03.047] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
451 Calvisi DF, Frau M, Tomasi ML, Feo F, Pascale RM. Deregulation of signalling pathways in prognostic subtypes of hepatocellular carcinoma: novel insights from interspecies comparison. Biochim Biophys Acta 2012;1826:215-37. [PMID: 23393659 DOI: 10.1016/j.bbcan.2012.04.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 21] [Article Influence: 0.6] [Reference Citation Analysis]
452 Matter MS, Decaens T, Andersen JB, Thorgeirsson SS. Targeting the mTOR pathway in hepatocellular carcinoma: current state and future trends. J Hepatol 2014;60:855-65. [PMID: 24308993 DOI: 10.1016/j.jhep.2013.11.031] [Cited by in Crossref: 161] [Cited by in F6Publishing: 168] [Article Influence: 17.9] [Reference Citation Analysis]
453 Zucman-Rossi J. Molecular classification of hepatocellular carcinoma. Dig Liver Dis 2010;42 Suppl 3:S235-41. [PMID: 20547309 DOI: 10.1016/S1590-8658(10)60511-7] [Cited by in Crossref: 54] [Cited by in F6Publishing: 28] [Article Influence: 4.5] [Reference Citation Analysis]
454 Lagraulet A. Current Clinical and Pharmaceutical Applications of Microarrays: From Disease Biomarkers Discovery to Automated Diagnostics. JALA: Journal of the Association for Laboratory Automation 2010;15:405-13. [DOI: 10.1016/j.jala.2010.06.011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
455 Yim SY, Kang SH, Shin JH, Jeong YS, Sohn BH, Um SH, Lee JS. Low ARID1A Expression is Associated with Poor Prognosis in Hepatocellular Carcinoma. Cells 2020;9:E2002. [PMID: 32878261 DOI: 10.3390/cells9092002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
456 Fartoux L, Decaens T. Contribution of biomarkers and imaging in the management of hepatocellular carcinoma. Clin Res Hepatol Gastroenterol. 2011;35 Suppl 1:S21-S30. [PMID: 21742297 DOI: 10.1016/s2210-7401(11)70004-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
457 Knudsen ES, Gopal P, Singal AG. The changing landscape of hepatocellular carcinoma: etiology, genetics, and therapy. Am J Pathol. 2014;184:574-583. [PMID: 24388934 DOI: 10.1016/j.ajpath.2013.10.028] [Cited by in Crossref: 55] [Cited by in F6Publishing: 49] [Article Influence: 6.1] [Reference Citation Analysis]
458 Tovar V, Villanueva A, Llovet JM. Biología celular y genética en el cáncer de hígado. Gastroenterología y Hepatología 2007;30:360-9. [DOI: 10.1157/13107573] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
459 Goodman ZD, Terracciano LM, Wee A. Tumours and tumour-like lesions of the liver. MacSween's Pathology of the Liver. Elsevier; 2012. pp. 761-851. [DOI: 10.1016/b978-0-7020-3398-8.00014-3] [Cited by in Crossref: 21] [Article Influence: 2.1] [Reference Citation Analysis]
460 Mas VR, Fisher RA, Archer KJ, Yanek KC, Williams B, Dumur CI, Maluf DG. Genes Associated With Progression and Recurrence of Hepatocellular Carcinoma in Hepatitis C Patients Waiting and Undergoing Liver Transplantation: Preliminary Results. Transplantation 2007;83:973-81. [DOI: 10.1097/01.tp.0000258643.05294.0b] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 1.5] [Reference Citation Analysis]
461 Miltiadous O, Sia D, Hoshida Y, Fiel MI, Harrington AN, Thung SN, Tan PS, Dong H, Revill K, Chang CY, Roayaie S, Byrne TJ, Mazzaferro V, Rakela J, Florman S, Schwartz M, Llovet JM. Progenitor cell markers predict outcome of patients with hepatocellular carcinoma beyond Milan criteria undergoing liver transplantation. Journal of Hepatology 2015;63:1368-77. [DOI: 10.1016/j.jhep.2015.07.025] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 5.4] [Reference Citation Analysis]
462 Sia D, Hoshida Y, Villanueva A, Roayaie S, Ferrer J, Tabak B, Peix J, Sole M, Tovar V, Alsinet C, Cornella H, Klotzle B, Fan JB, Cotsoglou C, Thung SN, Fuster J, Waxman S, Garcia-Valdecasas JC, Bruix J, Schwartz ME, Beroukhim R, Mazzaferro V, Llovet JM. Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology 2013;144:829-40. [PMID: 23295441 DOI: 10.1053/j.gastro.2013.01.001] [Cited by in Crossref: 275] [Cited by in F6Publishing: 294] [Article Influence: 30.6] [Reference Citation Analysis]
463 Toffanin S, Hoshida Y, Lachenmayer A, Villanueva A, Cabellos L, Minguez B, Savic R, Ward SC, Thung S, Chiang DY. MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a. Gastroenterology. 2011;140:1618-1628.e16. [PMID: 21324318 DOI: 10.1053/j.gastro.2011.02.009] [Cited by in Crossref: 153] [Cited by in F6Publishing: 151] [Article Influence: 13.9] [Reference Citation Analysis]
464 Samuel D, Colombo M, El-Serag H, Sobesky R, Heaton N. Toward optimizing the indications for orthotopic liver transplantation in hepatocellular carcinoma. Liver Transpl. 2011;17 Suppl 2:S6-13. [PMID: 21858912 DOI: 10.1002/lt.22423] [Cited by in Crossref: 39] [Cited by in F6Publishing: 41] [Article Influence: 3.9] [Reference Citation Analysis]
465 Huang K, Liao X, Han C, Wang X, Yu T, Yang C, Liu X, Yu L, Chen Z, Qin W, Zhu G, Su H, Liu Z, Zeng X, Zhou X, Lu S, Huang J, Liang Y, Liu Z, Deng J, Ye X, Peng T. Genetic variants and Expression of Cytochrome p450 Oxidoreductase Predict Postoperative Survival in Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma. J Cancer 2019;10:1453-65. [PMID: 31031855 DOI: 10.7150/jca.28919] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
466 Zamani A, Fan H, Luo G. Identification of cellular genes and pathways important for tumorigenicity of hepatocellular carcinoma cell lines by proteomic profiling. Oncotarget 2017;8:96171-83. [PMID: 29221196 DOI: 10.18632/oncotarget.21821] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
467 Tang J, Zhuo H, Zhang X, Jiang R, Ji J, Deng L, Qian X, Zhang F, Sun B. A novel biomarker Linc00974 interacting with KRT19 promotes proliferation and metastasis in hepatocellular carcinoma. Cell Death Dis. 2014;5:e1549. [PMID: 25476897 DOI: 10.1038/cddis.2014.518] [Cited by in Crossref: 114] [Cited by in F6Publishing: 121] [Article Influence: 14.3] [Reference Citation Analysis]
468 Coulouarn C, Cavard C, Rubbia-Brandt L, Audebourg A, Dumont F, Jacques S, Just PA, Clément B, Gilgenkrantz H, Perret C. Combined hepatocellular-cholangiocarcinomas exhibit progenitor features and activation of Wnt and TGFβ signaling pathways. Carcinogenesis. 2012;33:1791-1796. [PMID: 22696594 DOI: 10.1093/carcin/bgs208] [Cited by in Crossref: 74] [Cited by in F6Publishing: 72] [Article Influence: 7.4] [Reference Citation Analysis]
469 Sherman M. Primary Malignant Neoplasms of the Liver. In: Dooley JS, Lok ASF, Burroughs AK, Heathcote EJ, editors. Sherlock's Diseases of the Liver and Biliary System. Oxford: Wiley-Blackwell; 2011. pp. 681-703. [DOI: 10.1002/9781444341294.ch35] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
470 Marin JJ, Briz O, Herraez E, Lozano E, Asensio M, Di Giacomo S, Romero MR, Osorio-padilla LM, Santos-llamas AI, Serrano MA, Armengol C, Efferth T, Macias RI. Molecular bases of the poor response of liver cancer to chemotherapy. Clinics and Research in Hepatology and Gastroenterology 2018;42:182-92. [DOI: 10.1016/j.clinre.2017.12.006] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 7.8] [Reference Citation Analysis]
471 Frau M, Simile MM, Tomasi ML, Demartis MI, Daino L, Seddaiu MA, Brozzetti S, Feo CF, Massarelli G, Solinas G, Feo F, Lee JS, Pascale RM. An expression signature of phenotypic resistance to hepatocellular carcinoma identified by cross-species gene expression analysis. Cell Oncol (Dordr) 2012;35:163-73. [PMID: 22434528 DOI: 10.1007/s13402-011-0067-z] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
472 Buendia MA, Neuveut C. Hepatocellular carcinoma. Cold Spring Harb Perspect Med. 2015;5:a021444. [PMID: 25646384 DOI: 10.1101/cshperspect.a021444] [Cited by in Crossref: 59] [Cited by in F6Publishing: 61] [Article Influence: 8.4] [Reference Citation Analysis]
473 Wang Z, Zhou J, Fan J, Qiu SJ, Yu Y, Huang XW, Sun J, Tan CJ, Dai Z. Oxaliplatin induces apoptosis in hepatocellular carcinoma cells and inhibits tumor growth. Expert Opin Investig Drugs 2009;18:1595-604. [PMID: 19780708 DOI: 10.1517/13543780903292626] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
474 Fu S, Qi C, Xiao W, Li S, Peng B, Liang L. Glypican-3 is a potential prognostic biomarker for hepatocellular carcinoma after curative resection. Surgery 2013;154:536-44. [DOI: 10.1016/j.surg.2013.02.014] [Cited by in Crossref: 51] [Cited by in F6Publishing: 50] [Article Influence: 5.7] [Reference Citation Analysis]
475 Pascale RM, Simile MM, Calvisi DF, Frau M, Muroni MR, Seddaiu MA, Daino L, Muntoni MD, De Miglio MR, Thorgeirsson SS, Feo F. Role of HSP90, CDC37, and CRM1 as modulators of P16 INK4A activity in rat liver carcinogenesis and human liver cancer. Hepatology 2005;42:1310-9. [DOI: 10.1002/hep.20962] [Cited by in Crossref: 67] [Cited by in F6Publishing: 64] [Article Influence: 3.9] [Reference Citation Analysis]
476 Duan Y, Xu H, Luo X, Zhang H, He Y, Sun G, Sun X. Procyanidins from Nelumbo nucifera Gaertn. Seedpod induce autophagy mediated by reactive oxygen species generation in human hepatoma G2 cells. Biomedicine & Pharmacotherapy 2016;79:135-52. [DOI: 10.1016/j.biopha.2016.01.039] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
477 Pérez-Losada J, Sanchez-Garcia I. New functions for the Snail family of transcription factors: Two-faced proteins. Cell Cycle 2010;9:2706-8. [PMID: 20676033 DOI: 10.4161/cc.9.14.12322] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
478 Ueno A, Masugi Y, Yamazaki K, Komuta M, Effendi K, Tanami Y, Tsujikawa H, Tanimoto A, Okuda S, Itano O, Kitagawa Y, Kuribayashi S, Sakamoto M. OATP1B3 expression is strongly associated with Wnt/β-catenin signalling and represents the transporter of gadoxetic acid in hepatocellular carcinoma. J Hepatol 2014;61:1080-7. [PMID: 24946283 DOI: 10.1016/j.jhep.2014.06.008] [Cited by in Crossref: 38] [Cited by in F6Publishing: 43] [Article Influence: 4.8] [Reference Citation Analysis]
479 Liu M, Yan Q, Sun Y, Nam Y, Hu L, Loong JH, Ouyang Q, Zhang Y, Li HL, Kong FE, Li L, Li Y, Li MM, Cheng W, Jiang LX, Fang S, Yang XD, Mo JQ, Gong YF, Tang YQ, Li Y, Yuan YF, Ma NF, Lin G, Ma S, Wang JG, Guan XY. A hepatocyte differentiation model reveals two subtypes of liver cancer with different oncofetal properties and therapeutic targets. Proc Natl Acad Sci U S A 2020;117:6103-13. [PMID: 32123069 DOI: 10.1073/pnas.1912146117] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
480 Ning BF, Ding J, Liu J, Yin C, Xu WP, Cong WM, Zhang Q, Chen F, Han T, Deng X. Hepatocyte nuclear factor 4α-nuclear factor-κB feedback circuit modulates liver cancer progression. Hepatology. 2014;60:1607-1619. [PMID: 24752868 DOI: 10.1002/hep.27177] [Cited by in Crossref: 59] [Cited by in F6Publishing: 64] [Article Influence: 7.4] [Reference Citation Analysis]
481 Becker D, Sfakianakis I, Krupp M, Staib F, Gerhold-Ay A, Victor A, Binder H, Blettner M, Maass T, Thorgeirsson S, Galle PR, Teufel A. Genetic signatures shared in embryonic liver development and liver cancer define prognostically relevant subgroups in HCC. Mol Cancer 2012;11:55. [PMID: 22891627 DOI: 10.1186/1476-4598-11-55] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 2.8] [Reference Citation Analysis]
482 Chen WS. Advances in the relationship between microRNA and mechanism of human primary hepatocellular carcinoma. Shijie Huaren Xiaohua Zazhi 2009; 17(12): 1218-1223 [DOI: 10.11569/wcjd.v17.i12.1218] [Reference Citation Analysis]
483 Shimizu Y, Peltzer N, Sevko A, Lafont E, Sarr A, Draberova H, Walczak H. The Linear ubiquitin chain assembly complex acts as a liver tumor suppressor and inhibits hepatocyte apoptosis and hepatitis. Hepatology 2017;65:1963-78. [PMID: 28120397 DOI: 10.1002/hep.29074] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
484 de Lope CR, Tremosini S, Forner A, Reig M, Bruix J. Management of HCC. Journal of Hepatology 2012;56:S75-87. [DOI: 10.1016/s0168-8278(12)60009-9] [Cited by in Crossref: 363] [Cited by in F6Publishing: 201] [Article Influence: 36.3] [Reference Citation Analysis]
485 Wu Y, Liu Z, Xu X. Molecular subtyping of hepatocellular carcinoma: A step toward precision medicine. Cancer Commun (Lond) 2020;40:681-93. [PMID: 33290597 DOI: 10.1002/cac2.12115] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
486 Song BN, Chu IS. A gene expression signature of FOXM1 predicts the prognosis of hepatocellular carcinoma. Exp Mol Med 2018;50:e418. [PMID: 29303511 DOI: 10.1038/emm.2017.159] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
487 Kumar M, Zhao X, Wang XW. Molecular carcinogenesis of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: one step closer to personalized medicine? Cell Biosci. 2011;1:5. [PMID: 21711594 DOI: 10.1186/2045-3701-1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
488 Llovet JM, Villanueva A, Lachenmayer A, Finn RS. Advances in targeted therapies for hepatocellular carcinoma in the genomic era. Nat Rev Clin Oncol 2015;12:408-24. [PMID: 26054909 DOI: 10.1038/nrclinonc.2015.103] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
489 Kelley RK, Meyer T, Rimassa L, Merle P, Park JW, Yau T, Chan SL, Blanc JF, Tam VC, Tran A, Dadduzio V, Markby DW, Kaldate R, Cheng AL, El-Khoueiry AB, Abou-Alfa GK. Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma. Clin Cancer Res 2020;26:4795-804. [PMID: 32636319 DOI: 10.1158/1078-0432.CCR-19-3884] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
490 Huang Y, Cheng X, Sun P, Li T, Song Z, Zheng Q. Supplementary Sorafenib Therapies for Hepatocellular Carcinoma-A Systematic Review and Meta-Analysis: Supplementary Sorafenib for Liver Cancer. J Clin Gastroenterol 2019;53:486-94. [PMID: 30939505 DOI: 10.1097/MCG.0000000000001175] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
491 Blum HE. Treatment of hepatocellular carcinoma. Best Practice & Research Clinical Gastroenterology 2005;19:129-45. [DOI: 10.1016/j.bpg.2004.11.008] [Cited by in Crossref: 34] [Cited by in F6Publishing: 23] [Article Influence: 2.0] [Reference Citation Analysis]
492 Tang ZY. Hepatocellular carcinoma surgery--review of the past and prospects for the 21st century. J Surg Oncol. 2005;91:95-96. [PMID: 16028278 DOI: 10.1002/jso.20291] [Cited by in Crossref: 48] [Cited by in F6Publishing: 51] [Article Influence: 2.8] [Reference Citation Analysis]
493 Li J, Zhu YH, Huang P, Zhang B, Sun J, Guan XY. ITPKA expression is a novel prognostic factor in hepatocellular carcinoma. Diagn Pathol 2015;10:136. [PMID: 26249031 DOI: 10.1186/s13000-015-0374-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
494 Thompson SM, Callstrom MR, Jondal DE, Butters KA, Knudsen BE, Anderson JL, Lien KR, Sutor SL, Lee JS, Thorgeirsson SS, Grande JP, Roberts LR, Woodrum DA. Heat Stress-Induced PI3K/mTORC2-Dependent AKT Signaling Is a Central Mediator of Hepatocellular Carcinoma Survival to Thermal Ablation Induced Heat Stress. PLoS One 2016;11:e0162634. [PMID: 27611696 DOI: 10.1371/journal.pone.0162634] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
495 Nault JC, Cheng AL, Sangro B, Llovet JM. Milestones in the pathogenesis and management of primary liver cancer. J Hepatol 2020;72:209-14. [PMID: 31954486 DOI: 10.1016/j.jhep.2019.11.006] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 13.0] [Reference Citation Analysis]
496 LeGrand J, Park ES, Wang H, Gupta S, Owens JD Jr, Nelson PJ, DuBois W, Bair T, Janz S, Mushinski JF. Global gene expression profiling in mouse plasma cell tumor precursor and bystander cells reveals potential intervention targets for plasma cell neoplasia. Blood 2012;119:1018-28. [PMID: 22147894 DOI: 10.1182/blood-2011-06-363887] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
497 Hoffman D, Mehta N. Recurrence of hepatocellular carcinoma following liver transplantation. Expert Rev Gastroenterol Hepatol 2021;15:91-102. [PMID: 32933351 DOI: 10.1080/17474124.2021.1823213] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
498 Ahn SM, Haq F, Park I, Nault JC, Zucman-Rossi J, Yu E. The clinical implications of G1-G6 transcriptomic signature and 5-gene score in Korean patients with hepatocellular carcinoma. BMC Cancer 2018;18:571. [PMID: 29776391 DOI: 10.1186/s12885-018-4192-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
499 Candia J, Bayarsaikhan E, Tandon M, Budhu A, Forgues M, Tovuu LO, Tudev U, Lack J, Chao A, Chinburen J, Wang XW. The genomic landscape of Mongolian hepatocellular carcinoma. Nat Commun 2020;11:4383. [PMID: 32873799 DOI: 10.1038/s41467-020-18186-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
500 Cancer Genome Atlas Research Network. Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma. Cell. 2017;169:1327-1341.e23. [PMID: 28622513 DOI: 10.1016/j.cell.2017.05.046] [Cited by in Crossref: 846] [Cited by in F6Publishing: 791] [Article Influence: 169.2] [Reference Citation Analysis]
501 Yim SY, Lee JS. An Overview of the Genomic Characterization of Hepatocellular Carcinoma. J Hepatocell Carcinoma 2021;8:1077-88. [PMID: 34522690 DOI: 10.2147/JHC.S270533] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
502 Michielsen PP, Francque SM, van Dongen JL. Viral hepatitis and hepatocellular carcinoma. World J Surg Oncol. 2005;3:27. [PMID: 15907199 DOI: 10.1186/1477-7819-3-27] [Cited by in Crossref: 85] [Cited by in F6Publishing: 82] [Article Influence: 5.0] [Reference Citation Analysis]
503 Wang B, Xu X, Yang Z, Zhang L, Liu Y, Ma A, Xu G, Tang M, Jing T, Wu L, Liu Y. POH1 contributes to hyperactivation of TGF-β signaling and facilitates hepatocellular carcinoma metastasis through deubiquitinating TGF-β receptors and caveolin-1. EBioMedicine 2019;41:320-32. [PMID: 30745168 DOI: 10.1016/j.ebiom.2019.01.058] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
504 Kaposi-Novak P, Lee JS, Gòmez-Quiroz L, Coulouarn C, Factor VM, Thorgeirsson SS. Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J Clin Invest. 2006;116:1582-1595. [PMID: 16710476 DOI: 10.1172/jci27236] [Cited by in Crossref: 268] [Cited by in F6Publishing: 164] [Article Influence: 16.8] [Reference Citation Analysis]
505 Muñoz-Gámez JA, López Viota J, Barrientos A, Carazo Á, Sanjuán-Nuñez L, Quiles-Perez R, Muñoz-de-Rueda P, Delgado Á, Ruiz-Extremera Á, Salmerón J. Synergistic cytotoxicity of the poly (ADP-ribose) polymerase inhibitor ABT-888 and temozolomide in dual-drug targeted magnetic nanoparticles. Liver Int 2015;35:1430-41. [PMID: 24821649 DOI: 10.1111/liv.12586] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
506 Kim WJ, Kim SK, Jeong P, Yun SJ, Cho IC, Kim IY, Moon SK, Um HD, Choi YH. A four-gene signature predicts disease progression in muscle invasive bladder cancer. Mol Med 2011;17:478-85. [PMID: 21308147 DOI: 10.2119/molmed.2010.00274] [Cited by in Crossref: 43] [Cited by in F6Publishing: 44] [Article Influence: 3.9] [Reference Citation Analysis]
507 Lai JP, Sandhu DS, Yu C, Han T, Moser CD, Jackson KK, Guerrero RB, Aderca I, Isomoto H, Garrity-Park MM, Zou H, Shire AM, Nagorney DM, Sanderson SO, Adjei AA, Lee JS, Thorgeirsson SS, Roberts LR. Sulfatase 2 up-regulates glypican 3, promotes fibroblast growth factor signaling, and decreases survival in hepatocellular carcinoma. Hepatology 2008;47:1211-22. [PMID: 18318435 DOI: 10.1002/hep.22202] [Cited by in Crossref: 130] [Cited by in F6Publishing: 132] [Article Influence: 9.3] [Reference Citation Analysis]
508 Jian Z, Sun J, Chen W, Jin H, Zheng J, Wu Y. Involvement of discoidin domain 1 receptor in recurrence of hepatocellular carcinoma by genome-wide analysis. Med Oncol 2012;29:3077-82. [DOI: 10.1007/s12032-012-0277-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
509 Quintavalle C, Hindupur SK, Quagliata L, Pallante P, Nigro C, Condorelli G, Andersen JB, Tagscherer KE, Roth W, Beguinot F, Heim MH, Ng CKY, Piscuoglio S, Matter MS. Phosphoprotein enriched in diabetes (PED/PEA15) promotes migration in hepatocellular carcinoma and confers resistance to sorafenib. Cell Death Dis 2017;8:e3138. [PMID: 29072691 DOI: 10.1038/cddis.2017.512] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
510 Dos Santos ML, França A, Lima Filho ACM, Florentino RM, Diniz PH, Oliveira Lemos F, Gonçalves CAX, Coelho VL, Lima CX, Foureaux G, Nathanson MH, Vidigal PVT, Leite MF. Inositol 1,4,5-trisphosphate receptor type 3 is involved in resistance to apoptosis and maintenance of human hepatocellular carcinoma. Oncol Lett 2022;23:32. [PMID: 34966448 DOI: 10.3892/ol.2021.13150] [Reference Citation Analysis]
511 Lee JS, Heo J, Libbrecht L, Chu IS, Kaposi-Novak P, Calvisi DF, Mikaelyan A, Roberts LR, Demetris AJ, Sun Z, Nevens F, Roskams T, Thorgeirsson SS. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med. 2006;12:410-416. [PMID: 16532004 DOI: 10.1038/nm1377] [Cited by in Crossref: 677] [Cited by in F6Publishing: 641] [Article Influence: 42.3] [Reference Citation Analysis]
512 Marquardt JU, Galle PR, Teufel A. Molecular diagnosis and therapy of hepatocellular carcinoma (HCC): an emerging field for advanced technologies. J Hepatol. 2012;56:267-275. [PMID: 21782758 DOI: 10.1016/j.jhep.2011.07.007] [Cited by in Crossref: 117] [Cited by in F6Publishing: 114] [Article Influence: 10.6] [Reference Citation Analysis]
513 Hoshida Y, Toffanin S, Lachenmayer A, Villanueva A, Minguez B, Llovet JM. Molecular classification and novel targets in hepatocellular carcinoma: recent advancements. Semin Liver Dis 2010;30:35-51. [PMID: 20175032 DOI: 10.1055/s-0030-1247131] [Cited by in Crossref: 212] [Cited by in F6Publishing: 211] [Article Influence: 17.7] [Reference Citation Analysis]
514 Walther Z, Jain D. Molecular pathology of hepatic neoplasms: classification and clinical significance. Patholog Res Int. 2011;2011:403929. [PMID: 21559202 DOI: 10.4061/2011/403929] [Cited by in Crossref: 19] [Cited by in F6Publishing: 26] [Article Influence: 1.7] [Reference Citation Analysis]
515 Llovet JM, Zucman-Rossi J, Pikarsky E, Sangro B, Schwartz M, Sherman M, Gores G. Hepatocellular carcinoma. Nat Rev Dis Primers. 2016;2:16018. [PMID: 27158749 DOI: 10.1038/nrdp.2016.18] [Cited by in Crossref: 941] [Cited by in F6Publishing: 982] [Article Influence: 156.8] [Reference Citation Analysis]
516 Tsuchiya M, Parker JS, Kono H, Matsuda M, Fujii H, Rusyn I. Gene expression in nontumoral liver tissue and recurrence-free survival in hepatitis C virus-positive hepatocellular carcinoma. Mol Cancer. 2010;9:74. [PMID: 20380719 DOI: 10.1186/1476-4598-9-74] [Cited by in Crossref: 53] [Cited by in F6Publishing: 51] [Article Influence: 4.4] [Reference Citation Analysis]
517 Dang H, Steinway SN, Ding W, Rountree CB. Induction of tumor initiation is dependent on CD44s in c-Met⁺ hepatocellular carcinoma. BMC Cancer 2015;15:161. [PMID: 25886575 DOI: 10.1186/s12885-015-1166-4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
518 Llovet JM, Zucman-rossi J, Pikarsky E, Sangro B, Schwartz M, Sherman M, Gores G. Hepatocellular carcinoma. Nat Rev Dis Primers 2016;2. [DOI: 10.1038/nrdp.2016.18] [78495111110.1038/nrdp.2016.18','', '1948-5182')">Reference Citation Analysis]
519 Cavard C, Colnot S, Audard V, Benhamouche S, Finzi L, Torre C, Grimber G, Godard C, Terris B, Perret C. Wnt/beta-catenin pathway in hepatocellular carcinoma pathogenesis and liver physiology. Future Oncol. 2008;4:647-660. [PMID: 18922122 DOI: 10.2217/14796694.4.5.647] [Cited by in Crossref: 56] [Cited by in F6Publishing: 51] [Article Influence: 4.0] [Reference Citation Analysis]
520 Bell M, Turkbey EB, Escorcia FE. Radiomics, Radiogenomics, and Next-Generation Molecular Imaging to Augment Diagnosis of Hepatocellular Carcinoma. Cancer J. 2020;26:108-115. [PMID: 32205534 DOI: 10.1097/ppo.0000000000000435] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
521 Broelsch CE, Frilling A, Malago M. Should we expand the criteria for liver transplantation for hepatocellular carcinoma--yes, of course! J Hepatol. 2005;43:569-573. [PMID: 16120470 DOI: 10.1016/j.jhep.2005.07.016] [Cited by in Crossref: 48] [Cited by in F6Publishing: 41] [Article Influence: 2.8] [Reference Citation Analysis]
522 Rhee H, Kim H, Park YN. Clinico-Radio-Pathological and Molecular Features of Hepatocellular Carcinomas with Keratin 19 Expression. Liver Cancer 2020;9:663-81. [PMID: 33442539 DOI: 10.1159/000510522] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
523 N/A. N/A. Shijie Huaren Xiaohua Zazhi 2004; 12(10): 2395-2400 [DOI: 10.11569/wcjd.v12.i10.2395] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
524 Zimonjic DB, Zhou X, Lee JS, Ullmannova-Benson V, Tripathi V, Thorgeirsson SS, Popescu NC. Acquired genetic and functional alterations associated with transforming growth factor beta type I resistance in Hep3B human hepatocellular carcinoma cell line. J Cell Mol Med 2009;13:3985-92. [PMID: 19426152 DOI: 10.1111/j.1582-4934.2009.00769.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
525 Sohn BH, Shim JJ, Kim SB, Jang KY, Kim SM, Kim JH, Hwang JE, Jang HJ, Lee HS, Kim SC, Jeong W, Kim SS, Park ES, Heo J, Kim YJ, Kim DG, Leem SH, Kaseb A, Hassan MM, Cha M, Chu IS, Johnson RL, Park YY, Lee JS. Inactivation of Hippo Pathway Is Significantly Associated with Poor Prognosis in Hepatocellular Carcinoma. Clin Cancer Res 2016;22:1256-64. [PMID: 26459179 DOI: 10.1158/1078-0432.CCR-15-1447] [Cited by in Crossref: 60] [Cited by in F6Publishing: 43] [Article Influence: 8.6] [Reference Citation Analysis]
526 Lee YT, Sun N, Kim M, Wang JJ, Tran BV, Zhang RY, Qi D, Zhang C, Chen PJ, Sadeghi S, Finn RS, Saab S, Han SB, Busuttil RW, Pei R, Zhu Y, Tseng HR, You S, Yang JD, Agopian VG. Circulating Tumor Cell-Based Messenger RNA Scoring System for Prognostication of Hepatocellular Carcinoma: Translating Tissue-Based Messenger RNA Profiling Into a Noninvasive Setting. Liver Transpl 2021. [PMID: 34664394 DOI: 10.1002/lt.26337] [Reference Citation Analysis]
527 Schröder PC, Segura V, Riezu JI, Sangro B, Mato JM, Prieto J, Santamaría E, Corrales FJ. A signature of six genes highlights defects on cell growth and specific metabolic pathways in murine and human hepatocellular carcinoma. Funct Integr Genomics 2011;11:419-29. [PMID: 21562899 DOI: 10.1007/s10142-011-0230-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
528 Dalwadi DA, Torrens L, Abril-Fornaguera J, Pinyol R, Willoughby C, Posey J, Llovet JM, Lanciault C, Russell DW, Grompe M, Naugler WE. Liver Injury Increases the Incidence of HCC following AAV Gene Therapy in Mice. Mol Ther 2021;29:680-90. [PMID: 33554867 DOI: 10.1016/j.ymthe.2020.10.018] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
529 Zhao C, Zhou Y, Ma H, Wang J, Guo H, Liu H. A four-hypoxia-genes-based prognostic signature for oral squamous cell carcinoma. BMC Oral Health 2021;21:232. [PMID: 33941139 DOI: 10.1186/s12903-021-01587-z] [Reference Citation Analysis]
530 Lee JS, Chu IS, Mikaelyan A, Calvisi DF, Heo J, Reddy JK, Thorgeirsson SS. Application of comparative functional genomics to identify best-fit mouse models to study human cancer. Nat Genet. 2004;36:1306-1311. [PMID: 15565109 DOI: 10.1038/ng1481] [Cited by in Crossref: 324] [Cited by in F6Publishing: 317] [Article Influence: 18.0] [Reference Citation Analysis]
531 Lee G, Jeong YS, Kim DW, Kwak MJ, Koh J, Joo EW, Lee JS, Kah S, Sim YE, Yim SY. Clinical significance of APOB inactivation in hepatocellular carcinoma. Exp Mol Med 2018;50:1-12. [PMID: 30429453 DOI: 10.1038/s12276-018-0174-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
532 Carr BI, Pancoska P, Branch RA. Tumor and liver determinants of prognosis in unresectable hepatocellular carcinoma: a large case cohort study. Hepatol Int. 2010;4:396-405. [PMID: 20305756 DOI: 10.1007/s12072-009-9157-7] [Cited by in Crossref: 31] [Cited by in F6Publishing: 23] [Article Influence: 2.4] [Reference Citation Analysis]
533 Evert M, Frau M, Tomasi ML, Latte G, Simile MM, Seddaiu MA, Zimmermann A, Ladu S, Staniscia T, Brozzetti S, Solinas G, Dombrowski F, Feo F, Pascale RM, Calvisi DF. Deregulation of DNA-dependent protein kinase catalytic subunit contributes to human hepatocarcinogenesis development and has a putative prognostic value. Br J Cancer 2013;109:2654-64. [PMID: 24136149 DOI: 10.1038/bjc.2013.606] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 3.6] [Reference Citation Analysis]
534 Ma Y, Li K, Li S, Liang B, Liu Q, Mo Z. Prognostic value of ubiquitin-conjugating enzyme E2 S overexpression in hepatocellular carcinoma. Int J Biol Macromol 2018;119:225-31. [PMID: 30041036 DOI: 10.1016/j.ijbiomac.2018.07.136] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
535 Schulien I, Hasselblatt P. Diethylnitrosamine-induced liver tumorigenesis in mice. Methods Cell Biol 2021;163:137-52. [PMID: 33785162 DOI: 10.1016/bs.mcb.2020.08.006] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
536 Ozdemir B, Abd-Almageed W, Roessler S, Wang XW. iSubgraph: integrative genomics for subgroup discovery in hepatocellular carcinoma using graph mining and mixture models. PLoS One 2013;8:e78624. [PMID: 24223834 DOI: 10.1371/journal.pone.0078624] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
537 Villanueva A, Minguez B, Forner A, Reig M, Llovet JM. Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy. Annu Rev Med 2010;61:317-28. [PMID: 20059340 DOI: 10.1146/annurev.med.080608.100623] [Cited by in Crossref: 160] [Cited by in F6Publishing: 151] [Article Influence: 13.3] [Reference Citation Analysis]
538 Harding JJ, Khalil DN, Abou-Alfa GK. Biomarkers: What Role Do They Play (If Any) for Diagnosis, Prognosis and Tumor Response Prediction for Hepatocellular Carcinoma? Dig Dis Sci 2019;64:918-27. [PMID: 30838478 DOI: 10.1007/s10620-019-05517-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
539 Ji J, Eggert T, Budhu A, Forgues M, Takai A, Dang H, Ye Q, Lee JS, Kim JH, Greten TF, Wang XW. Hepatic stellate cell and monocyte interaction contributes to poor prognosis in hepatocellular carcinoma. Hepatology 2015;62:481-95. [PMID: 25833323 DOI: 10.1002/hep.27822] [Cited by in Crossref: 79] [Cited by in F6Publishing: 76] [Article Influence: 11.3] [Reference Citation Analysis]
540 Iavarone M, Colombo M. HBV-related HCC, clinical issues and therapy. Dig Liver Dis. 2011;43 Suppl 1:S32-S39. [PMID: 21195370 DOI: 10.1016/S1590-8658(10)60690-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
541 Park YY, Park ES, Kim SB, Kim SC, Sohn BH, Chu IS, Jeong W, Mills GB, Byers LA, Lee JS. Development and validation of a prognostic gene-expression signature for lung adenocarcinoma. PLoS One 2012;7:e44225. [PMID: 22970185 DOI: 10.1371/journal.pone.0044225] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 2.4] [Reference Citation Analysis]
542 Srivastava S, Wong KF, Ong CW, Huak CY, Yeoh KG, Teh M, Luk JM, Salto-Tellez M. A morpho-molecular prognostic model for hepatocellular carcinoma. Br J Cancer. 2012;107:334-339. [PMID: 22713659 DOI: 10.1038/bjc.2012.230] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
543 Katoh H, Ojima H, Kokubu A, Saito S, Kondo T, Kosuge T, Hosoda F, Imoto I, Inazawa J, Hirohashi S. Genetically distinct and clinically relevant classification of hepatocellular carcinoma: putative therapeutic targets. Gastroenterology. 2007;133:1475-1486. [PMID: 17983802 DOI: 10.1053/j.gastro.2007.08.038] [Cited by in Crossref: 64] [Cited by in F6Publishing: 53] [Article Influence: 4.3] [Reference Citation Analysis]
544 Woo HG, Park ES, Thorgeirsson SS, Kim YJ. Exploring genomic profiles of hepatocellular carcinoma. Mol Carcinog 2011;50:235-43. [PMID: 21465573 DOI: 10.1002/mc.20691] [Cited by in Crossref: 50] [Cited by in F6Publishing: 46] [Article Influence: 4.5] [Reference Citation Analysis]
545 Breuhahn K, Gores G, Schirmacher P. Strategies for hepatocellular carcinoma therapy and diagnostics: lessons learned from high throughput and profiling approaches. Hepatology. 2011;53:2112-2121. [PMID: 21433041 DOI: 10.1002/hep.24313] [Cited by in Crossref: 45] [Cited by in F6Publishing: 40] [Article Influence: 4.1] [Reference Citation Analysis]
546 Li Q, Zhang N, Jia Z, Le X, Dai B, Wei D, Huang S, Tan D, Xie K. Critical role and regulation of transcription factor FoxM1 in human gastric cancer angiogenesis and progression. Cancer Res. 2009;69:3501-3509. [PMID: 19351851 DOI: 10.1158/0008-5472.can-08-3045] [Cited by in Crossref: 142] [Cited by in F6Publishing: 105] [Article Influence: 10.9] [Reference Citation Analysis]
547 Kelley RK, Venook AP. Novel Therapeutics in Hepatocellular Carcinoma: How Can We Make Progress? American Society of Clinical Oncology Educational Book 2013. [DOI: 10.14694/edbook_am.2013.33.e137] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
548 Villanueva A, Hoshida Y, Battiston C, Tovar V, Sia D, Alsinet C, Cornella H, Liberzon A, Kobayashi M, Kumada H, Thung SN, Bruix J, Newell P, April C, Fan JB, Roayaie S, Mazzaferro V, Schwartz ME, Llovet JM. Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. Gastroenterology 2011;140:1501-12.e2. [PMID: 21320499 DOI: 10.1053/j.gastro.2011.02.006] [Cited by in Crossref: 254] [Cited by in F6Publishing: 248] [Article Influence: 23.1] [Reference Citation Analysis]
549 Sohn BH, Hwang JE, Jang HJ, Lee HS, Oh SC, Shim JJ, Lee KW, Kim EH, Yim SY, Lee SH, Cheong JH, Jeong W, Cho JY, Kim J, Chae J, Lee J, Kang WK, Kim S, Noh SH, Ajani JA, Lee JS. Clinical significance of four molecular subtypes of gastric cancer Identified by The Cancer Genome Atlas project. Clin Cancer Res. 2017;. [PMID: 28747339 DOI: 10.1158/1078-0432.ccr-16-2211] [Cited by in Crossref: 147] [Cited by in F6Publishing: 98] [Article Influence: 29.4] [Reference Citation Analysis]
550 Spano D, Russo R, Di Maso V, Rosso N, Terracciano LM, Roncalli M, Tornillo L, Capasso M, Tiribelli C, Iolascon A. Galectin-1 and its involvement in hepatocellular carcinoma aggressiveness. Mol Med 2010;16:102-15. [PMID: 20200618 DOI: 10.2119/molmed.2009.00119] [Cited by in Crossref: 51] [Cited by in F6Publishing: 54] [Article Influence: 3.9] [Reference Citation Analysis]
551 Yim SY, Lee JS. Genomic Perspective on Mouse Liver Cancer Models. Cancers (Basel) 2019;11:E1648. [PMID: 31731480 DOI: 10.3390/cancers11111648] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
552 Li L, Lu N, Dai Q, Wei L, Zhao Q, Li Z, He Q, Dai Y, Guo Q. GL-V9, a newly synthetic flavonoid derivative, induces mitochondrial-mediated apoptosis and G2/M cell cycle arrest in human hepatocellular carcinoma HepG2 cells. Eur J Pharmacol 2011;670:13-21. [PMID: 21944925 DOI: 10.1016/j.ejphar.2011.08.054] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.1] [Reference Citation Analysis]
553 Befeler AS, Hayashi PH, Di Bisceglie AM. Liver transplantation for hepatocellular carcinoma. Gastroenterology. 2005;128:1752-1764. [PMID: 15887162 DOI: 10.1053/j.gastro.2005.03.033] [Cited by in Crossref: 93] [Cited by in F6Publishing: 86] [Article Influence: 5.5] [Reference Citation Analysis]
554 Dai XM, Yang SL, Zheng XM, Chen GG, Chen J, Zhang T. CD133 expression and α-fetoprotein levels define novel prognostic subtypes of HBV-associated hepatocellular carcinoma: A long-term follow-up analysis. Oncol Lett 2018;15:2985-91. [PMID: 29435028 DOI: 10.3892/ol.2017.7704] [Cited by in Crossref: 2] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
555 Rebouissou S, Nault JC. Advances in molecular classification and precision oncology in hepatocellular carcinoma. J Hepatol 2020;72:215-29. [PMID: 31954487 DOI: 10.1016/j.jhep.2019.08.017] [Cited by in Crossref: 65] [Cited by in F6Publishing: 83] [Article Influence: 65.0] [Reference Citation Analysis]
556 Chen CP, Haas-kogan D. Neoplasms of the hepatobiliary system: clinical presentation, molecular pathways and diagnostics. Expert Review of Molecular Diagnostics 2014;10:883-95. [DOI: 10.1586/erm.10.76] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
557 Yim SH, Chung YJ. An overview of biomarkers and molecular signatures in HCC. Cancers (Basel). 2010;2:809-823. [PMID: 24281095 DOI: 10.3390/cancers2020809] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
558 Silva MF, Wigg AJ. Current controversies surrounding liver transplantation for hepatocellular carcinoma. J Gastroenterol Hepatol. 2010;25:1217-1226. [PMID: 20594247 DOI: 10.1111/j.1440-1746.2010.06335.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
559 Kwon JH, Lee N, Park JY, Yu YS, Kim JP, Shin JH, Kim DS, Joh JW, Kim DS, Choi KY, Kang KJ, Kim G, Moon YH, Wang HJ. Actionable gene expression-based patient stratification for molecular targeted therapy in hepatocellular carcinoma. PLoS One 2013;8:e64260. [PMID: 23785399 DOI: 10.1371/journal.pone.0064260] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
560 Calvisi DF, Simile MM, Ladu S, Frau M, Evert M, Tomasi ML, Demartis MI, Daino L, Seddaiu MA, Brozzetti S, Feo F, Pascale RM. Activation of v-Myb avian myeloblastosis viral oncogene homolog-like2 (MYBL2)-LIN9 complex contributes to human hepatocarcinogenesis and identifies a subset of hepatocellular carcinoma with mutant p53. Hepatology 2011;53:1226-36. [DOI: 10.1002/hep.24174] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 3.5] [Reference Citation Analysis]
561 Jiang Y, Sun A, Zhao Y, Ying W, Sun H, Yang X, Xing B, Sun W, Ren L, Hu B, Li C, Zhang L, Qin G, Zhang M, Chen N, Zhang M, Huang Y, Zhou J, Zhao Y, Liu M, Zhu X, Qiu Y, Sun Y, Huang C, Yan M, Wang M, Liu W, Tian F, Xu H, Zhou J, Wu Z, Shi T, Zhu W, Qin J, Xie L, Fan J, Qian X, He F; Chinese Human Proteome Project (CNHPP) Consortium. Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma. Nature. 2019;567:257-261. [PMID: 30814741 DOI: 10.1038/s41586-019-0987-8] [Cited by in Crossref: 209] [Cited by in F6Publishing: 213] [Article Influence: 69.7] [Reference Citation Analysis]
562 Derambure C, Coulouarn C, Caillot F, Daveau R, Hiron M, Scotte M, François A, Duclos C, Goria O, Gueudin M, Cavard C, Terris B, Daveau M, Salier JP. Genome-wide differences in hepatitis C- vs alcoholism-associated hepatocellular carcinoma. World J Gastroenterol 2008; 14(11): 1749-1758 [PMID: 18350606 DOI: 10.3748/wjg.14.1749] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
563 Mou L, Tian X, Zhou B, Zhan Y, Chen J, Lu Y, Deng J, Deng Y, Wu Z, Li Q, Song Y, Zhang H, Chen J, Tian K, Ni Y, Pu Z. Improving Outcomes of Tyrosine Kinase Inhibitors in Hepatocellular Carcinoma: New Data and Ongoing Trials. Front Oncol 2021;11:752725. [PMID: 34707994 DOI: 10.3389/fonc.2021.752725] [Reference Citation Analysis]
564 Andrisani OM, Studach L, Merle P. Gene signatures in hepatocellular carcinoma (HCC). Semin Cancer Biol 2011;21:4-9. [PMID: 20851183 DOI: 10.1016/j.semcancer.2010.09.002] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 2.5] [Reference Citation Analysis]
565 Furuta K, Sato S, Yamauchi T, Ozawa T, Harada M, Kakumu S. Intrahepatic gene expression profiles in chronic hepatitis B and autoimmune liver disease. J Gastroenterol. 2008;43:866-874. [PMID: 19012040 DOI: 10.1007/s00535-008-2237-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
566 Itzel T, Spang R, Maass T, Munker S, Roessler S, Ebert MP, Schlitt HJ, Herr W, Evert M, Teufel A. Random gene sets in predicting survival of patients with hepatocellular carcinoma. J Mol Med (Berl) 2019;97:879-88. [PMID: 31001651 DOI: 10.1007/s00109-019-01764-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
567 Xue F, Higgs BW, Huang J, Morehouse C, Zhu W, Yao X, Brohawn P, Xiao Z, Sebastian Y, Liu Z, Xia Y, Shen D, Kuziora M, Dong Z, Han H, Gu Y, Gu J, Xia Q, Yao Y. HERC5 is a prognostic biomarker for post-liver transplant recurrent human hepatocellular carcinoma. J Transl Med 2015;13:379. [PMID: 26653219 DOI: 10.1186/s12967-015-0743-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
568 Pomyen Y, Budhu A, Chaisaingmongkol J, Forgues M, Dang H, Ruchirawat M, Mahidol C, Wang XW; TIGER-LC Consortium. Tumor metabolism and associated serum metabolites define prognostic subtypes of Asian hepatocellular carcinoma. Sci Rep 2021;11:12097. [PMID: 34103600 DOI: 10.1038/s41598-021-91560-1] [Reference Citation Analysis]
569 Bagante F, Spolverato G, Ruzzenente A, Luchini C, Tsilimigras DI, Campagnaro T, Conci S, Corbo V, Scarpa A, Guglielmi A, Pawlik TM. Artificial neural networks for multi-omics classifications of hepato-pancreato-biliary cancers: towards the clinical application of genetic data. Eur J Cancer 2021;148:348-58. [PMID: 33774439 DOI: 10.1016/j.ejca.2021.01.049] [Reference Citation Analysis]
570 Zhu P, Piao Y, Dong X, Jin Z. Forkhead box J1 expression is upregulated and correlated with prognosis in patients with clear cell renal cell carcinoma. Oncol Lett 2015;10:1487-94. [PMID: 26622696 DOI: 10.3892/ol.2015.3376] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
571 Freeman RB. MELD: the holy grail of organ allocation? J Hepatol 2005;42:16-20. [PMID: 15629501 DOI: 10.1016/j.jhep.2004.11.002] [Cited by in Crossref: 55] [Cited by in F6Publishing: 52] [Article Influence: 3.2] [Reference Citation Analysis]
572 Behnke M, Reimers M, Fisher R. The expression of embryonic liver development genes in hepatitis C induced cirrhosis and hepatocellular carcinoma. Cancers (Basel) 2012;4:945-68. [PMID: 23667740 DOI: 10.3390/cancers4030945] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
573 Xie XW, Wang XY, Liao WJ, Fei R, Cong X, Chen Q, Wei L, Chen HS, Wang Y. Effect of Upregulated DNA Replication and Sister Chromatid Cohesion 1 Expression on Proliferation and Prognosis in Hepatocellular Carcinoma. Chin Med J (Engl) 2018;131:2827-35. [PMID: 30511685 DOI: 10.4103/0366-6999.246076] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
574 Dhanasekaran R, Venkatesh SK, Torbenson MS, Roberts LR. Clinical implications of basic research in hepatocellular carcinoma. J Hepatol 2016;64:736-45. [PMID: 26450813 DOI: 10.1016/j.jhep.2015.09.008] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 3.7] [Reference Citation Analysis]
575 Coulouarn C, Factor VM, Andersen JB, Durkin ME, Thorgeirsson SS. Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene. 2009;28:3526-3536. [PMID: 19617899 DOI: 10.1038/onc.2009.211] [Cited by in Crossref: 484] [Cited by in F6Publishing: 470] [Article Influence: 37.2] [Reference Citation Analysis]
576 Hao K, Lamb J, Zhang C, Xie T, Wang K, Zhang B, Chudin E, Lee NP, Mao M, Zhong H, Greenawalt D, Ferguson MD, Ng IO, Sham PC, Poon RT, Molony C, Schadt EE, Dai H, Luk JM. Clinicopathologic and gene expression parameters predict liver cancer prognosis. BMC Cancer 2011;11:481. [PMID: 22070665 DOI: 10.1186/1471-2407-11-481] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
577 Hayashi T, Shibata M, Oe S, Miyagawa K, Honma Y, Harada M. C-reactive protein can predict dose intensity, time to treatment failure and overall survival in HCC treated with lenvatinib. PLoS One 2020;15:e0244370. [PMID: 33351844 DOI: 10.1371/journal.pone.0244370] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
578 Qian Y, Daza J, Itzel T, Betge J, Zhan T, Marmé F, Teufel A. Prognostic Cancer Gene Expression Signatures: Current Status and Challenges. Cells 2021;10:648. [PMID: 33804045 DOI: 10.3390/cells10030648] [Reference Citation Analysis]
579 Makowska Z, Boldanova T, Adametz D, Quagliata L, Vogt JE, Dill MT, Matter MS, Roth V, Terracciano L, Heim MH. Gene expression analysis of biopsy samples reveals critical limitations of transcriptome-based molecular classifications of hepatocellular carcinoma. J Pathol Clin Res 2016;2:80-92. [PMID: 27499918 DOI: 10.1002/cjp2.37] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 6.5] [Reference Citation Analysis]
580 Kim SM, Leem SH, Chu IS, Park YY, Kim SC, Kim SB, Park ES, Lim JY, Heo J, Kim YJ. Sixty-five gene-based risk score classifier predicts overall survival in hepatocellular carcinoma. Hepatology. 2012;55:1443-1452. [PMID: 22105560 DOI: 10.1002/hep.24813] [Cited by in Crossref: 79] [Cited by in F6Publishing: 73] [Article Influence: 7.9] [Reference Citation Analysis]